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Backgrond  
The principle of photodynamic therapy (PDT) is based on the generation of reactive 
oxygen species, notably singlet oxygen, within cells and tissues. This is achieved by the 
administration of a photosensitiser, or a photosensitiser precursor, and subsequent 
illumination with (visible) light of an appropriate wavelength. The photosensitiser absorbs the 
energy of the photons and transfers it to molecular oxygen in the tissue. This photochemical 
reaction results in the formation of reactive oxygen species that cause damage to critical 
cellular and tissue structures. The characteristics of the photosensitiser determine their 
spatial distribution within cells and tissues which has a strong influence on the response to 
therapy. For this reason it is important to consider the study of specific photosensitisers and 
recognise the importance of their specific field of application. PDT has been used to treat 
various (pre-) malignant and non malignant conditions that range from skin cancer and 
psoriasis to age-related macular degeneration (AMD) and prostate cancer. In each case the 
specifics of the disease and photosensitiser are critical parameters for the successful 
application of the therapy.  
 
Historical development of Photodynamic Therapy 
PDT is now recognised as the treatment of choice for a small number of important 
diseases such as non-melanoma skin cancer and AMD. As described briefly below it is 
under investigation for numerous other conditions. The potential for PDT, based on the use 
of porphyrin photosensitisers was first recognised at the end of the 19th century 1-4. Patients 
suffering from skin photosensitivity were found to excrete Haematoporphyrin (HP) via their 
urine 1. Haematoporphyrin (Hp) is a complex mixture of different porphyrins and their 
aggregates. Lipson showed that photodetection of tumours was enhanced using a derivative 
of haematoporphyrin; HpD 5. Clinical treatments using HpD were introduced in 1976 by 
Dougherty et al. 6. Due to the complex nature of HpD, the results with HpD-PDT were 
variable and the active fraction was enriched to yield dihaematoporphyrin ether or Photofrin® 
(PII) 7. At present PII-PDT is approved by the FDA for the ablation of precancerous lesions 
(high-grade dysplasia) in Barrett’s oesophagus, tumours located in the bronchi and palliative 
treatment of advanced cancers of the oesophagus. The prolonged skin photosensitisation 
after administration of HpD and PII, which can last for several weeks, stimulated 
investigators to design other photosensitisers.  
Since then many different photosensitisers have been studied and the most common 
known and (pre) clinically successful photosensitisers are BPD-MA (benzoporphyrin 
derivative monoacid ring A), mTHPC (meso-tetra-hydroxyphenyl-chlorin) and ALA (5-
aminolevulinic acid) or other precursors of PpIX (protoporphyrin IX). BPD-MA is a vascular 
photosensitiser that is primarily used to treat abnormal blood vessels. BPD-MA PDT is 
approved by the FDA for the treatment of subfoveal choroidal neovascularisation (CNV) 
caused by age-related macular degeneration (AMD) 8, pathological myopia (a form of 
nearsightedness) and presumed ocular histoplasmosis (a fungal infection of the eye). Light 
General Introduction 
 9 
treatment is typically started shortly after administration of the photosensitiser. This process 
is repeated every three months for as long is needed to prevent regrowth of the abnormal 
vessels (usually 6 or 7 times over 2-3 years). The skin photosensitisation associated with 
this photosensitiser is much shorter compared to PII and patients should stay away from 
direct sunlight and bright indoor light for 5 days. mTHPC is an other photosensitiser that is 
highly lipophylic and very potent 9. mTHPC mediated PDT is approved by the EU and the 
FDA for the palliative treatment of head and neck cancer and is under investigation for the 
treatment of various other diseases. In general, pharmacokinetic studies show high plasma 
levels in the first hours and a retained fraction in (malignant) tissues days after systemic 
administration. A drug light interval of 4 days is therefore not uncommon and patients are 
photosensitive for approximately 15 days. Different clinical trials are ongoing investigating 
the utility of novel photosensitisers like HPPH (2-[1-hexyloxyethyl]-2-devinyl 
pyropheophorbide-a) and Npe6 (mono-L-aspartyl chlorine e6). Also the use of 
photosensitisers bound to carriers like monoclonal antibodies or tumour specific cell surface 
receptors for selective delivery to tumour is under investigation.  
A different approach to administering a photosensitiser is to administer a precursor. The 
photosensitiser protoporphyrin IX (PpIX) is one of the intermediate products of the haem 
synthesis pathway that takes place in every cell containing mitochondria. Exogenous 
administration of 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) leads to the 
accumulation of PpIX as described in detail below. Kennedy et al. 10 were the first to 
recognise that ALA induced PpIX can be used for PDT to treat basal cell carcinomas (BCC). 
ALA can also be used for the diagnosis of cancerous lesions. At present ALA-PDT is in 
clinical trials worldwide to treat a variety of cancers and other disorders. In London a large 
phase III clinical trial is running investigating ALA-PDT for the treatment of Barrett’s 
oesophagus. Studies are performed investigating the applicability of ALA-PDT for the 
treatment of bladder, brain and prostate tumours. The use of ALA derivatives or esterified 
ALA for PDT was first suggested by Kloek et al. 11 in 1996. At present methyl 
aminolevulinate (MAL) is clinically the most successful derivative of ALA and recently also 
hexyl aminolevulinate (HAL) has gained increasing interest 12. MAL mediated PDT is 
indicated, in most European countries, for the treatment of nodular and superficial BCC. 
ALA-PDT is approved by the FDA to treat actinic keratosis and the treatment of choice for 
superficial non-melanoma skin cancer 13. The optimisation of ALA-PDT and its mechanism 
of action are the subject of this thesis.  
 
Principles of PDT using porphyrin pre-cursors 
Photochemical reaction  
The cytotoxic effect of photodynamic therapy is the result of the photochemical reaction 
that is initiated by the absorption of light of the appropriate wavelength by the 
photosensitiser (Figure 1). As a result the photosensitiser is excited from the ground state to 
the excited state (S1, S2 etc). This state is unstable and will release the absorbed energy via 
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one of the two possible routes. It can decay back to its ground state by means of 
fluorescence emission. Or it undergoes intersystem crossover to its excited triplet state (T1) 
and becomes photodynamically active. This triplet state is relatively long lived and hence 
exchanges the energy through collisions with molecules in its environment. Two specific 
types of reactions are described 14. The type I reaction involves the collisions with substrate 
or solvents, forming radicals and radical ions, which after interaction with oxygen can 
produce oxygenated products. The type II reaction involves the collisions with oxygen, 
forming the highly reactive singlet oxygen. Although type I reactions can occur under certain 
conditions it is generally thought that the PDT induced damage is predominantly caused by 
type II reactions.  
Three parameters are critically important for the formation of singlet oxygen; the 
photosensitiser, light and oxygen. Singlet oxygen is a highly reactive oxygen species (ROS) 
with a short lifetime (< 200 ns) and a short diffusion range 15. For these reasons the primary 
target of PDT is determined by the distribution of the photosensitiser in cells and in tissues.  
Figure 1: Energy level scheme of the photodynamic reaction. 
 
Haem synthesis and protoporphyrin IX 
As described above exogenous administration of 5-aminolevulinic acid (ALA) leads to the 
accumulation of the photosensitiser protoporphyrin IX (PpIX) which is the penultimate 
molecule of the haem synthesis pathway. Haem is synthesised from succinyl CoA and 
glycine via a series of enzymatic reactions that takes place in and around the mitochondria 
of almost every living cell (Figure 2). Under normal circumstances the accumulation of 
photosensitive intermediates like PpIX is avoided by two mechanisms involving the first 
reaction in this pathway. The condensation of glycine and succinyl CoA to form ALA is rate-
limited and feedback controlled by haem.  
Exogenous administration of ALA bypasses the feedback inhibition and overloads the 
cycle. The second step in the pathway is now rate-limiting but also the last step, the 
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chelation of iron to PpIX to form haem, is relatively slow. As a result of this several 
photosensitive porphyrins are temporary accumulated of which PpIX is the predominate one. 
This can also be achieved by the administration of ALA derivatives or esterified ALA like 
methyl aminolevulinate (MAL) or hexyl aminolevulinate (HAL). A different approach is the 
administration of iron chelators like desferrioxamine (DFO) and CP94 in combination with 
ALA 16.  
 
Figure 2: Schematic overview of the haem biosynthetic pathway based on Peng et al. 17. Thick 
arrows indicate the principal biosynthetic route. The dashed arrow indicates the haem feedback control. 
The porphyrins are fluorescent compounds of which PpIX is the most potent. 
 
Administration routes and distribution in tissue 
ALA can be administered either systemically or topically depending on the host and target 
tissue. The most common administration route to treat human skin diseases is the topical 
application of ALA in a cream using 20% w/w ALA for 3-6 hours. Also in pre-clinical studies 
topical ALA administration is common using creams containing a dosage of 2 to 40% w/w 
ALA and application times ranging from 1 to 24 hours. MAL and other ALA-esters are mainly 
used for topical applications in creams using concentrations between 2 and 16%. 
The penetration of a topically applied drug through skin dependents on its biochemical 
and biophysical characteristics. Also the vehicle in which it is dissolved and the condition of 
the skin is of influence and should be considered. ALA is highly hydrophylic and has a 
positive charge. To improve the penetration into the deeper regions of the skin lesions the 
use of penetration enhancers in the vehicle or prior to application of ALA has been 
investigated. Tape-stripping the stratum corneum has been shown to increase the ALA 
penetration through normal skin 18. Ionthophoresis can be used to shorten the ALA 
application time. MAL and other ALA-esters are more lipophilic than ALA and this may 
enhance the cellular uptake. In-vitro studies have shown that cells accumulate more PpIX 
after ALA-ester compared to ALA administration. In vivo experiments show that MAL and 
ALA result in similar PpIX fluorescence intensities in the applied areas 19. That study also 
showed a significant difference in the distribution of PpIX after topical application of MAL or 
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ALA. PpIX fluorescence is observed in areas remote from the application site after ALA and 
not after MAL application suggesting that ALA but not MAL is systemically distributed after 
topical application.  
Systemic administration of ALA is only used when the target tissue can not be reached 
via topical application or intravesical instillation. As might be expected the toxicity of ALA is 
more important after systemic than after topical administration. In clinical PDT studies, 
treating oral cancer, Barrett’s oesophagus or gastrointestinal cancer, ALA is dissolved in 
orange juice and administered orally using doses up to 60 mg kg-1 body weight 20,21. 
Adverse effects reported 21,22 for these doses include mild nausea, vomiting, transient 
abnormalities of liver function and decreased blood pressure or non-specific photosensitivity. 
Lower ALA doses like 5-20 mg kg-1 body weight have been used for diagnostic purposes. In 
pre-clinical models also other systemic administration routes like intravenous and 
intraperitoneal injections have been investigated. Usually the ALA doses administered in 
pre-clinical studies are higher compared to clinical studies; a dose of 100-200 mg kg-1 body 
weight is common.  
 
Distribution of PpIX in tissues and cells 
Although the haem pathway is present in all cells containing mitochondria some tissues 
accumulate more PpIX than others 23. In general high accumulation of PpIX is found in 
tissues deriving from ecto- and endoderm like epidermis, oral mucosa, endometrium, 
urothelium or glands. In contrast tissues of mesodermal origin like muscle, connective 
tissue, cartilage and blood cells show low PpIX accumulation. 
In vitro studies have shown that cells take up ALA via active transport using ß-amino acid 
and GABA carriers whereas MAL is taken up by passive transport 24. Several subcellular 
localisation studies have shown that PpIX fluorescence is pre-dominantly observed in the 
mitochondia 25,26.  
 
Light / Illumination  
Light is one of the three critically important parameters for PDT. The distribution and 
penetration depth of light in tissue depends on the wavelength used and the optical 
properties of the tissue (Figure 3). These optical properties depend on the type of scatterers 
and absorbers and their spatial distribution in tissue. In general photons are scattered due to 
local change of refractive index or by small particles in tissue. Examples of scatterers in 
tissue are cell membranes or membrane aggregates, collagen fibres and nuclei. Typical 
absorbers in tissue are water, lipids and blood (haemoglobine, both oxy-and de-
oxygenated).  
The optimal wavelength to use for PDT or for monitoring PDT (see below) depends on 
the absorption characteristics of the photosensitiser, the tissue optical properties and the 
intended sampling or treatment depth. The absorption spectrum of PpIX shows a high peak 
in the blue region of the spectrum with a few smaller peaks between 500 and 635 nm. For 
PDT using PpIX either blue light is used to treat superficial conditions like actinic keratosis or 
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the deeper penetrating red light (610-640 nm) is used to treat superficial BCC and other skin 
lesions. 
Figure 3: An estimate of the penetration depth of light in healthy human skin. Here penetration depth 
is defined as the depth that is reached by 37% of the light 27. 
 
PpIX Fluorescence  
The fluorescence emission spectrum of PpIX shows peaks around 635 and 705 nm that 
can be used for fluorescence detection. To collect the PpIX fluorescence from tissue the 
contribution of chromophores naturally present should be considered. This autofluorescence 
typically comes from proteins like collagen, flavins and NADH. Furthermore it has been 
shown that the derivatives of chlorophyll, pheophorbides, show an emission peak around 
670-675 nm. In experimental models the contribution of pheophorbides to the fluorescence 
signal can be minimised by feeding the animals chlorophyll free food 2 weeks prior to the 
experiment. The specific contribution of these chromophores to the autofluorescence 
spectrum varies between tissue types and individuals. Figure 4 shows a typical example of 
an autofluorescence spectrum and a PpIX fluorescence spectrum collected from mouse skin 
using 514 nm excitation light.  
Figure 4: An example of a PpIX and autofluorescence spectrum collected from hairless mouse skin 
using 514 nm excitation light. 
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Monitoring PDT induced damage  
In order to optimise therapy it is necessary to measure PDT response. PDT induced 
damage is usually scored after treatment using different methods depending on the model 
used. For in-vitro studies it could be the clonogenic assay or a histochemical assay in which 
a stain is used to determine the vitality of the nucleus (propidium iodide) or the mitochondria 
(MTT assay). In pre-clinical models there are a variety of different methods ranging from 
determination of the tumour growth delay or cure to visually observed necrosis of tissue to 
histologically scored damage in tissues.  
In general the response to PDT can be highly variable. This is probably due to the 
complexity of the photodynamic action, which affects the availability of the three important 
parameters (light, oxygen and photosensitiser) and vice versa. Oxygen might be depleted 
locally as the demand for oxygen for the formation of singlet oxygen might be higher than 
the diffusion rate. The diffusion rate may be hampered by the vascular responses to PDT 
(see below). Vascular effects in themselves change the tissue optical properties resulting in 
a modified light distribution within tissue. And last but not least the availability of PpIX 
decreases as it undergoes self-sensitised photobleaching mediated by the production of the 
highly reactive singlet oxygen 28,29. All these different reactions take place during PDT, are 
difficult to control or predict, and have a significant impact on the response to PDT. Several 
studies have shown a good correlation between the formation of singlet oxygen, PDT 
induced damage and PpIX photobleaching during PDT 30,31. The intrinsic mechanism of 
photobleaching has been shown to be photosensitiser specific. PpIX undergoes self-
sensitised photobleaching resulting in the formation of various photoproducts, in particular 
the chlorin photoprotoporphyrin. This photoproduct fluoresces around 675 nm and in turn is 
also photobleached. The influence of the variation in fluorescence intensity of the 
photoproduct is significant and should be considered while measuring PpIX fluorescence 
photobleaching rates. Also the changes in tissue optical properties and the possible 
photobleaching of autofluorescence should be considered. 
 
Techniques to measure PpIX fluorescence 
PpIX fluorescence can be determined non-invasively in superficial tissues like skin or 
oesophagus using techniques such as fluorescence imaging or spectral analysis. 
Fluorescence imaging is generally used to investigate the spatial distribution of PpIX within 
tissue. The fluorescence emission is collected using a small band pass filter around the 
emission peak. The contribution of autofluorescence can be accounted for by collecting an 
autofluorescence image prior to administration of the PpIX precursor and subtracting this 
from the subsequent fluorescence images.  
Fluorescence spectral analysis is a different and more accurate technique to determine 
the PpIX fluorescence. Changes in tissue optical properties at the emission wavelengths can 
be corrected for by dividing the fluorescence emission spectrum by the reflectance  
spectrum 32. The contribution of photoproducts and possible changes in autofluorescence 
can be accounted for by the use of single value decomposition (SVD) 33,34. The basis 
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spectra of auto-, PpIX- and photoproduct fluorescence are used to fit their contribution to the 
measured fluorescence emission spectrum to determine the actual PpIX fluorescence 
intensity.  
 
Mechanism of action 
As described above PDT induced damage is mainly the result of the formation of the 
highly reactive singlet oxygen that has a short lifetime and diffusion range. The tissue and 
cellular localisation of the photosensitiser therefore determines the primary target of PDT 
that is critically important for the mechanism of action. In the literature many different 
responses to PDT are reported that can be divided into three categories; cellular, vascular 
and immunological responses. The mechanism of action of tissues to PDT resulting in the 
overall response is a combination of these responses depending on the tissue oxygen 
availability, the photosensitiser and the illumination scheme used.  
 
Cellular response 
Cells either survive or die from the PDT induced damage and many different processes 
are involved in this. In general three modes of cell death after PDT are described in the 
literature; necrosis, apoptosis and recently also autophagy. Necrosis is a disorderly cell 
death that usually results from acute tissue injury. It involves cell swelling, chromatin 
digestion, disruption of plasma and organelle membranes, and cell lysis. The disruption of 
the plasma membrane may release harmful proteins and chemicals that damage neighbour 
cells and provokes an inflammatory response. Damage to the plasma membrane and 
lysosome membranes generally leads to necrosis. PDT using a photosensitiser that 
localises in these membranes will therefore result in a necrotic response after PDT.  
Apoptosis is a type of programmed cell death that involves a series of biochemical 
events. It involves blebbing, shrinkage, nuclear fragmentation, chromatin condensation, and 
DNA fragmentation. In the final stage of apoptosis phagocytes remove the dying cells 
without eliciting an inflammatory response. Many pathways and signals can lead to 
apoptosis. Extra-cellular factors like hormones, growth factors or cytokines can initiate 
apoptosis. It could also be induced intra-cellularly in response to stress. Damage to the 
mitochondria may lead to the release of intra-cellular apoptotic signals in the cell. 
Endogenously accumulated PpIX is localised in the mitochondria and subsequent 
illumination causes mitochondrial damage. The whole apoptotic cell death process requires 
energy and a functional cell machinery but sometimes the overall damage caused by PDT is 
so severe that the cell can not complete the chain of reactions involved in apoptosis and it 
turns into a necrotic cell death.  
The role of autophagy in PDT induced cell death or survival is relatively unknown. 
Autophagy is a process by which cells undergo partial autodigestion through the lysosomes 
in an attempt to prolong survival. Recently it has been considered as a secondary type of 
programmed cell death although there is no proof yet that cell death is really caused by 
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autophagy and not the result of an unsuccessful attempt to prevent it. PDT resulting in ER 
stress using CPO (a porphycyne photosensitiser) has been shown to induce both apoptosis 
and autophagy 35.  
 
Vascular response 
PDT induced damage has been shown to lead to different vascular responses like 
vasoconstriction or dilatation, adhesion of trombocytes and leucocytes and leakage of tissue 
fluid and macromolecules 36. Changes in vessel diameter and platelet aggregation are 
generally responses that occur (early) during PDT and these responses may be reversible. 
Leakage of vessels causing the formation of oedema is generally observed immediately 
after PDT. These reactions could be a direct response to endothelial cell causing them to 
retract and expose the sub-endothelial matrix. Thrombocytes adhere to the matrix and 
become activated. They release vasoactive eicosanoids like thromboxane leading to 
(temporary) constriction of primarily arterioles 37,38. Neo vessels and especially tumour 
vessels are usually more sensitive to PDT induced damage than normal vessels. This 
phenomenon is used in the approach to treat age related macular degeneration utilising a 
photosensitiser that localises in the vascular endothelium. It has been postulated that the 
vascular response, causing indirect damage by the deprivation of oxygen and nutrients, is 
necessary, in addition to the direct cellular damage, to achieve complete tumour destruction 
39
. Temporary vascular occlusion and the subsequent re-perfusion also results in 
ischemia/re-perfusion injury (I/R injury). The absence of oxygen and nutrients from blood 
creates a condition in which the restoration of circulation results in inflammation and 
oxidative damage through the induction of oxidative stress. Vascular responses could, 
however, also lead to less effective PDT treatments. As mentioned before oxygen is one of 
the three crucially important parameters for PDT induced damage. Without the availability of 
oxygen, as a result of vascular damage, singlet oxygen can not be formed and PDT damage 
is not induced.  
 
Immune response 
Besides the cellular and vascular response PDT is also known to activate the immune 
system via various routes. Cellular necrosis involves the release of the intracellular content 
including cytokines that usually regulate the inflammatory and immunological responses. It is 
likely that neutrophils invade the treatment area to remove the necrotic cell debris. 
Secondary to that, the expression of pro-inflammatory cytokines like IL-6 and 10 was shown 
to be induced by (Photofrin-mediated) PDT 39. Furthermore, as a result of the endothelial cell 
damage, inflammation cells are able to invade the tissue. In Photofrin mediated PDT it is 
shown that acute inflammatory cells adhere to the vessel walls within 5 minutes after the 
start of PDT. This results in a rapid and massive accumulation of neutrophils in the treated 
area 40. Besides the acute inflammatory reaction also other immune effector cells like 
lymphocytes and monocytes/macrophages are recruited to the treated area. Recently it has 
been shown that pro-inflammatory mediators activate antigen presenting cells (APCs) that 
stimulate cytokine secretion and effector T-cell proliferation 41. It is suggested that PDT and 
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the subsequent immunological reaction can be used for in situ vaccination inducing a 
systemic antitumor response 42. Studies using pre-clinical animal models that are deprived 
of neutrophils show a decreased effectiveness of the PDT treatment. This indicates that 
neutrophils have a more active role than just phagocytosis of cell debris 43.  
 
Response to ALA-PDT 
ALA mediated PDT induces most of the responses mentioned above. Many in-vitro 
studies have reported apoptotic cell death after ALA-PDT although there are also studies 
that report necrotic cell death. The release of cytochrome-c into the cytoplasma in response 
to mitochondrial damage seems to be the first step, initiating the activation of the different 
caspase proteins that leads to apoptotic cell death 44. In-vivo studies show a combination of 
apoptotic and necrotic cell death in tissue after ALA-PDT. Apoptosis is considered an early 
event while it occurs within the first hours after PDT preceding the appearance of necrosis. 
Vascular damage like vasoconstriction and vascular leakage is also observed using either 
topical or systemic administration of ALA 45,46. Also I/R injury seems to play a role since the 
use of known inhibitors of I/R injury diminish the effect of ALA-PDT in the normal rat colon 47. 
The role of neutrophils or the immune system in ALA-PDT is unknown.  
 
Optimisation of ALA-PDT 
The initial clinical complete response rate of sBCC to ALA mediated PDT is high, 
complete response rates (CR) above 90% are reported. However the long term response is 
concerningly low: CR below 30% have been reported. Also the responses of nodular BCC or 
other lesions are not optimal. This prompted investigators to search for approaches to 
improve the response to ALA-PDT. The standard treatment involves the application of ALA 
for 4 hours and the subsequent light treatment. A number of factors limit the response to 
ALA-PDT. First of all the availability of ALA to cells in deeper regions of the skin lesions is 
limited by the penetration depth of topically applied ALA. The PpIX accumulation is further 
limited by the capacity of the haem synthesis pathway. The actual PDT response is limited 
by the availability of oxygen and the distribution of light. 
Different methods have been used in an attempt to improve the response to PDT. As 
described above, the uptake of ALA and/or the accumulation of PpIX can be improved by 
the use of ionthophoresis, ALA derivatives, penetration enhancers or iron chelators. A 
different approach to improve the PDT response is to change the illumination parameters. 
The availability of oxygen for PDT can be increased by the use of a lower fluence rate for 
illumination as this lowers the demand for oxygen for the photodynamic action. Illumination 
with a lower fluence rate has shown to result in more PDT induced damage in normal 
hairless mouse skin 31. Light fractionation using one or more short dark intervals may 
improve the response due to two mechanisms. The availability of oxygen could be increased 
since oxygen re-diffuses the treated area during the dark interval 48. The second mechanism 
is the inflicted I/R injury caused by (repetitive) light-on/light-off intervals. This type of light 
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fractionation has shown to increase the PDT induced damage as determined by the size of 
the necrotic area in normal colon 49. 
Light fractionation using a long dark interval between the two light fractions, i.e., a two-
fold illumination scheme, is the approach described in this thesis. The design of this type of 
light fractionation was inspired by a clinical observation of Star 50 who noted the return of 
PpIX fluorescence in time after treatment in a lesion that showed complete photobleaching 
during treatment. This increase in PpIX fluorescence in time after PDT has also been 
reported by other investigators 51,52. The rationale behind light fractionation using a dark 
interval of more than one hour was to also utilise this PpIX for PDT. Our first studies using 
this type of light fractionation were promising 46,53.  
 
Outline of the thesis: 
Light fractionated ALA-PDT is the subject of this thesis. First the influence of the different 
illumination parameters on the response to PDT is investigated. Second the mechanism 
behind the increased effectiveness of light fractionated ALA-PDT is studied.  
 
The first three chapters are focussed on the optimisation of light fractionated ALA-PDT. In 
Chapter 2 the effect of different illumination schemes is investigated using the growth delay 
of the rat rhabdomyosarcoma after PDT. The following variables are studied; the influence of 
drug-light interval, low fluence rate illumination, short term light fractionation using dark 
intervals of only seconds or minutes and long term light fractionation using a dark interval of 
75 minutes. Rhabdomyosarcoma is transplanted on the thigh of the rat and transdermally 
illuminated after intra-venous injection of ALA. The tumour volume is monitored daily after 
PDT to determine the delay in growth.  
In earlier studies it was shown that light parameters like fluence and fluence rate have a 
large influence on the effectiveness of PDT. The influence of these parameters for light 
fractionated ALA-PDT was investigated in Chapters 3 and 4. For these studies the hairless 
mouse model was used and ALA was topically applied, while this is more representative of 
clinical ALA-PDT than using a solid tumour model and systemic ALA. The fluences of the 
first and second fraction were varied as well as the fluence rate and the duration of the dark 
interval. The PpIX fluorescence and photobleaching kinetics were measured before-, during 
and after PDT and the effectiveness of the treatment was determined by scoring the skin 
damage visually. 
 
The mechanism behind the increased effectiveness of light fractionated ALA-PDT is the 
focus of the following chapters. Neutrophils are crucially important for the effectiveness of 
Photofrin-mediated PDT therefore their role in the response to ALA-PDT is investigated in 
Chapter 5. The rat rhabdomyosarcoma solid tumour model is used again while in this model 
both the increased effectiveness of light fractionated ALA-PDT and the role of neutrophils in 
General Introduction 
 19 
PII-PDT are shown before. The PpIX fluorescence kinetics pre and post PDT are also 
investigated in correlation with the delivered fluence. 
The source of the increase in PpIX fluorescence observed in time after PDT is 
investigated in Chapter 6. The increase in PpIX fluorescence is either the result of re-
distribution or local re-synthesis. In the skin-fold observation chamber the increase in PpIX 
fluorescence after PDT was determined as a function of the distance from the vasculature. 
In a separate group the temperature dependence of the increase in PpIX fluorescence after 
PDT was determined by cooling the tissue for one hour after PDT to 10-12°C, a temperature 
at which the accumulation of PpIX is inhibited. The increase in PpIX fluorescence after PDT 
followed by cooling is compared with that measured without cooling. 
The effect of light fractionated PDT is studied using MAL in Chaper 7. This study is 
performed on the hairless mouse model using the most effective light fractionation scheme 
determined for ALA. The visual skin damage observed in time after PDT was compared with 
the results obtained earlier ALA. The PpIX fluorescence and photobleaching kinetics were 
monitored and compared after both topical MAL and ALA administration. The difference in 
response to MAL and ALA-PDT is investigated in Chapter 8. In this study the spatial 
distribution of PpIX fluorescence is investigated in normal mouse skin after 4 hours of topical 
application of either MAL or ALA using fluorescence microscopy. This is correlated with the 
PDT response histologically observed at 2.5, 24 and 48 hours after PDT. 
The hypothesis that the increased effectiveness of light fractionated ALA-PDT is the 
result of a cellular mechanism in which the sub-lethally damaged cells are more vulnerable 
to a second light fraction is investigated in Chapter 9. In collaboration with the Centro de 
Investigaciones sobre Porfirinas y Porfirias (CIPYP) of the University of Buenos Aires in 
Argentina cell survival is investigated after a standard and a light fractionated treatment 
scheme in-vitro using different cell lines. 
 
In the general discussion, Chapter 10, the results of these studies are discussed in the 
context of the current concepts in the literature and future perspectives are presented.  
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Abstract 
We have studied different single and fractionated illumination schemes after systemic 
administration of 5-aminolevulinic acid (ALA) in order to improve the response of nodular 
tumours to ALA-mediated photodynamic therapy (ALA-PDT). Tumours transplanted on the 
thigh of female WAG/Rij rats were transdermally illuminated with red light (633 nm) after 
systemic ALA administration (200 mg kg-1). The effectiveness of each treatment scheme 
was determined from the tumour volume doubling time. A single illumination (100 J cm-2 at 
100 mW cm-2, 2.5 h after ALA administration) yielded a doubling time of 6.6 ± 1.2 days. This 
was significantly different from the untreated control (doubling time 1.7 ± 0.1 days). The only 
treatment scheme that yielded a significant improvement compared to all other schemes 
studied was illumination at both 1h and 2.5 h after ALA-administration (both 100 J cm-2 at 
100 mW cm-2), and resulted in a tumour volume doubling time of 18.9 ± 2.9 days. A possible 
mechanism to explain this phenomenon is that the protoporphyrin IX formed after 
administration of ALA is photodegraded by the first illumination. In the 75 minute interval 
new porphyrin is formed enhancing the effect of the second illumination. 
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Introduction 
Photodynamic therapy (PDT) using 5-aminolevulinic-acid (ALA) induced protoporphyrin 
IX (PpIX) as a photosensitiser is widely used as an experimental therapy, especially for 
cutaneous cancer. A complete initial response rate (CR) of more than 90% has been 
reported for treatment of human superficial basal cell carcinoma (BCC) with topically applied 
ALA-PDT 1-3. However for nodular BCC a much lower CR, of 50% is obtained 2,4. An 
explanation for this lower efficacy might be that topically applied ALA does not penetrate to 
the deep layers of tumour 5,6. Oral or systemic administration of ALA may improve the 
biodistribution of PpIX 5,7. However, also after systemic ALA-PDT only superficial necrosis 
was found in patients treated for dysplasia of the mouth 8 or the oesophagus 9. These 
clinical reports show the need for improvement of topical and systemic ALA-PDT. A number 
of animal studies have demonstrated that the response to PDT after systemic ALA 
administration can be improved by modifying the illumination scheme, for example by 
reducing the fluence rate, to improve oxygenation 10-12. Another option is the use of light 
fractionation with either a short 10,11,13 or a long-term interval 14. The short term light 
fractionation scheme (with one or more interruptions of seconds or minutes) may allow 
reoxygenation during the dark period. Theoretically, this will lead to more singlet oxygen 
formation 10. We define a long-term light fractionation scheme as an illumination scheme 
with two light fractions separated by an interval of 1 hour or longer. After the first light 
fraction PpIX is partially or completely photobleached and in time post treatment new PpIX is 
formed which can be used for a second illumination 14,15. Van der Veen et al. 14 reported 
complete necrosis of 4 out of 6 tumours in a rat skinfold observation chamber model using a 
long term light fractionation scheme (with an interval of 75 min) after a single ALA 
administration. No necrosis was observed after a single illumination. These studies show 
that improvement of ALA-PDT using different illumination schemes is possible. Our interest 
in the present paper is to improve systemic ALA PDT of nodular tumours. We therefore 
studied the effectiveness of different illumination schemes published by our own group 12,14 
and others 11,13 by measuring the tumour volume doubling time of a transplantable rat 
rhabdomyosarcoma after transdermal illumination. 
 
Materials and Methods 
5-Aminolevulinic acid hydrochloride (ALA, Finetech, Haifa, Israel) was dissolved in a 
0.9% NaCl infusion solution (90 mg ml-1). A freshly prepared ALA solution was administered 
i.v., to a dose of 200 mg kg-1 body weight under ether anaesthesia. After administration the 
animals were kept under subdued light conditions. 
Rat rhabdomyosarcoma (Rh), originally derived from an isologous undifferentiated 
rhabdomyosarcoma, was maintained by subcutaneously transplanting small pieces of 
tumour (∼ 1 mm³) on the thigh of female WAG/Rij rats (12 - 13 weeks old). The tumour 
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growth was monitored daily by measuring the three orthogonal diameters using callipers and 
the tumour volume was estimated by the formula for an ellipsoid, V=(pi/6)∗D1∗D2∗D3. 
Tumours were randomly assigned to control and treatment groups when their volume 
reached 50 mm³. 
PDT was carried out under general anaesthesia using intra muscular Hypnorm, 0.5 ml  
kg-1 (Janssen Pharmaceutica, Tilburg, The Netherlands) and diazepam, 2.5 ml kg-1. Prior to 
the light treatment the skin overlying the tumour was shaved. The animals were placed on a 
temperature-controlled stage and covered with a black polythene mask. Tumours were 
transdermally illuminated with a 10 mm diameter plane parallel light beam (633 nm). 
Immediately after PDT the animals were housed under subdued light conditions at 28 °C for 
the first 24 hours. This was done to minimise the decrease in body temperature caused by 
the anaesthesia. Subsequently the animals were kept at room temperature. 
Ten groups of animals were treated according to various treatment schemes. Groups A, 
B and C served as controls and were treated either with anaesthesia only (n=6), light only 
(100 J cm-2 at 100 mW cm-2; n=3) or ALA only (200 mg kg-1 i.v.; n=3) respectively. Groups D 
to J, (n=6 in each), were treated according to different illumination schemes as shown in 
Figure 1. Each illumination was carried out at either 1 and/or at 2.5 hours post injection of 
ALA. These time points were based on a pharmacokinetic study performed on this animal 
model in which we found a maximal PpIX fluorescence of the tumour at 2.5 hours post 
injection. At one hour post ALA administration approximately one third of the maximal PpIX 
fluorescence was observed. 
In group D and E the tumours were illuminated with a single light fluence of 100 J cm-2 at 
a fluence rate of 100 mW cm-2 delivered at either 1 or 2.5 hours post ALA injection 
respectively. In the groups F to I the tumours were illuminated at 2.5 hours post injection of 
ALA. The tumours in group F received 100 J cm-2 at 25 mW cm-2 so that the treatment time 
 
 
 
Figure 1. Schematic diagram of the treatment schemes studied. 
D 
E 
F 
G 
I 
J 
H 
2.5 hours 
 
1 hour 
Improvement of systemic ALA-PDT 
 27 
was a factor of 4 longer than that of groups D and E. The short term light fractionation 
schemes were applied in group G and H. In group G 100 J cm-2 at 100 mW cm-2 was 
delivered with one interruption of 150 seconds after the first 5 J cm-2 13. In group H 100 J  
cm-2 at 100 mW cm-2 was delivered with multiple interruptions, turning the light off and on 
every 30 seconds 11. Groups I and J were both treated with a double light fluence of 200 J 
cm-2 at 100 mW cm-2 given either in one fraction (2.5 hours p.i. of ALA) or according to a 
long term light fractionation scheme of two equal fractions of 100 J cm-2 with an interruption 
of 75 minutes (treatment at 1 and 2.5 hours p.i. of ALA 14). 
The light distribution within the tumours treated in this study was studied in a separate 
series of experiments using two isotropic probes (500 µm, bulb diameter, Rare Earth 
Medical, West Yarmouth MA, USA). The isotropic probes were connected to a dosimetry 
device that enables real-time fluence (rate) measurements to be recorded. One probe was 
placed on top of the skin at the centre of the illuminated area. The second probe was 
implanted between the base of the tumour and the underlying muscle at the centre of the 
illuminated area. Insertion of the isotropic probe through the skin was performed at a site 
distant from the tumour (>1 cm) to reduce the effect of bleeding on the measurements. The 
fluence rate was measured continuously during illumination at 100 mW cm-2 to a fluence of 
100 J cm-2 in 5 tumours 2.5 hours after administration of ALA (scheme E). These data were 
used to estimate the mean optical attenuation coefficient of the combination of tumour and 
overlying skin. 
Tumour re-growth and macroscopic changes to the surrounding normal tissue were 
monitored every 1 or 2 days following therapy until the size of the tumour had reached 5 
times its treatment volume. The treatment volume of each tumour (approximately 50 mm3) 
was defined as 100% and the points in time (in days after treatment) at which the tumour 
reached certain fixed volumes; 50%, 200%, 500% etc, were linearly interpolated. The 
effectiveness of each treatment scheme was determined by comparison of the mean tumour 
volume doubling time of each group, defined as the number of days the tumour required to 
double its pre-treatment volume. The effect on the tumour growth post treatment was 
determined for each group (determined by the number of days the tumour required to grow 
from 200% to 500%). All results are presented as mean (± SEM). The relative effectiveness 
of each treatment scheme was statistically compared using the analysis of variance followed 
by a Student-Newman-Keuls test, as necessary. For all tests a P value of less than 0.05 was 
considered to be statistically significant. 
 
Results 
Normal tissue response to PDT  
Three types of macroscopic normal tissue response were observed: oedema of the thigh, 
discoloration of the skin overlying the tumour and crust formation. None of the total of 12 
animals in the three control groups showed any type of normal tissue damage. 
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The oedema was investigated by measuring the thickness of the leg adjacent to the 
tumour daily. All animals treated with ALA-PDT showed a mild to severe oedema of the leg 
which was found to be maximal on day 1 post treatment and cleared by day 4. Normally the 
leg has a thickness of approximately 7 mm but at day 1 post treatment the leg could 
measure up to be from 10.7 to 15.8 mm thick (Table 1). The oedema found for tumours 
treated at 1 hour post administration of ALA was significantly less compared to the other 
treatment schemes. The oedema found for tumours illuminated with 200 J cm-2 in one 
fraction (scheme I) was significantly greater compared to the rest of the treatment schemes. 
Almost all treatment schemes induced a bluish/black discoloration of the skin overlying 
the tumour after treatment, which cleared within a few days. The involved area was as large 
as the illuminated tumour under the skin that is smaller than the illuminated area. In some 
treatment schemes severe discolouration was accompanied by crust formation (Table 1). 
To investigate whether the oedema, discolouration and crust formation were influenced 
by the presence of an underlying tumour, a group of 4 animals without a tumour was 
illuminated according to the treatment scheme used in group J. The oedematous response 
was found to be the same for skin and muscle illuminated in the absence of tumour. The 
discolouration was found to be less marked being only pale blue for the group with no 
tumour compared to dark blue/black for the group with a tumour. The crust seemed to be 
macroscopically thinner and smaller in size and appeared only in 50% of the animals. 
 
Table 1. Normal tissue damage caused by the different treatment schemes used. 
Group Normal tissue damage 
 Oedema (mm) Crusts (n) 
D     10.7 ± 0.3 a) 2 
E     14.2 ± 0.9 - 
F     13.8 ± 0.3 4 
G     12.4 ± 0.2 2 
H     13.3 ± 0.7 2 
I     15.8 ± 0.3 b) 3 
J     12.7 ± 0.7 6 
a)
 significantly less oedema compared to the other groups 
b)
 significantly more oedema compared to the other groups 
 
To histologically determine the location of the oedema and the cause of the discoloration, 
a separate set of experiments were performed. Four extra animals were illuminated with 200 
J cm-2 given either in one fraction or according to a long term light fractionation scheme 
(groups I and J, respectively). The illuminated area was excised at day 1 post treatment for 
histology. Sections of the leg, including skin and soft tissues were stained with haemotoxylin 
and eosine after formalin fixation. The epidermis and the dermal adnexa showed necrosis 
after both illumination schemes. Severe oedema was found in the dermis and the muscle 
surrounding and underlying the tumour whereas the tumour showed little or no oedema. 
Enlarged blood vessels that were located around and at the border of the tumour were 
heavily damaged and there was evidence of haemorrhage. 
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Tumour volume measurements  
The error associated with the tumour volume measurements was estimated by comparing 
the measurements of two independent observers for 14 tumours treated in this study in a 
range of tumour volumes. The relative error decreased from 5.3 ± 0.9% for tumour volumes 
below 30 mm³, to 3.7 ± 1.3% for tumour volumes ranging from 30 to 60 mm³, to 3.5 ± 0.7% 
for tumour volumes ranging from 60 to 120 mm³, to 2.3 ± 0.5% for tumour volumes ranging 
from 120 to 240 mm³. 
 
Tumour response to PDT  
There was no significant difference in treatment volume for the tumours in different 
groups and the mean treatment volume was measured to be 50.3 ± 1.4 mm³ (n=54). The 
tumour volume doubling times measured for the three control groups (A-C) were not 
significantly different. These data were combined and used as a pooled control group for 
comparison with the remaining treatment schemes. The rhabdomyosarcoma was found to 
have a mean tumour volume doubling time of 1.7 ±  0.1 days (n=12).  
All of the PDT schemes investigated demonstrated a significantly longer tumour volume 
doubling time compared to control tumours, as shown in Figure 2. Tumours illuminated with 
a light fluence of 100 J cm-2 at 100 mW cm-2, 1 or 2.5 hours after ALA administration 
demonstrated a tumour volume doubling time of 5.0 ± 1.5 days and 6.6 ± 1.2 days 
respectively (group D and E). The use of a short term light fractionation scheme with a dark 
interval of 150 seconds, after the first 5 J cm-2 of the total 100 J cm-2 was delivered, showed 
a tumour volume doubling time of 7.5 ± 1.5 days. This was comparable to the tumour 
volume doubling time found for the other short term light fractionation scheme (30 seconds 
 
Figure 2. Relative tumour volume in time after ALA-PDT using different illumination schemes: control 
(-); scheme D: 1 hr 100 J cm-2 at 100 mW cm-2 (×); scheme E: 2.5 hrs 100 J cm-2 at 100 mW cm-2 (▲); 
scheme F: 2.5 hrs 100 J cm-2 at 25 mW cm-2 (); scheme G: 2.5 hrs 100 J cm-2 at 100 mW cm-2 using a 
short term light fractionation scheme with one dark interval of 150 seconds after 5 J cm-2 (); scheme H: 
2.5 hrs 100 J cm-2 at 100 mW cm-2 using a short term light fractionation scheme: 30 sec on/ 30 sec off 
(○); scheme I: 2.5 hrs 200 J cm-2 at 100 mW cm-2 () and scheme J: both 1 and 2.5 hrs 100 and 100 J 
cm-2 at 100 mW cm-2 (■). Data are shown as mean ± SEM. 
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light on/off, 7.5 ± 0.8 days). Although the mean tumour volume doubling time found for both 
short term light fractionation schemes is longer compared to illumination with a single 
fraction (group E), the increase was not found to be statistically significant. Also illumination 
with a 4 times lower fluence rate (group F) resulted in an increased mean tumour volume 
doubling time (8.8 ± 1.9 days) compared to group E which was again not statistically 
significant. Even increasing the fluence to 200 J cm-2 (group I) did not increase the mean 
tumour volume doubling time (8.6 ± 0.8 days) significantly, compared to group E. Only the 
use of a long term light fractionation scheme (100 J cm-2 at both 1 and 2.5 hours p.i. of ALA, 
group J) showed a significantly increased tumour volume doubling time compared to all the 
other illumination schemes: 18.9 ± 2.9 days. 
None of the investigated protocols resulted in a “cure” of the tumour and only in group J 
three out of six tumours were not palpable for 10 to 13 days before the tumour was again 
detectable. No statistically significant difference could be shown in the tumour growth post 
treatment defined as the time a tumour required to grow from 200 to 500%. The tumour 
volume increased by a factor of 2.5 in 2.58 ± 0.06 days. 
 
Tumour thickness 
As might be expected since the illumination was superficial, the tumour response to PDT 
seemed to be correlated to the thickness of the treated tumour. After observation of the 
growth curves of the individual tumours in the groups there seemed to be a threshold for the 
thickness. Tumours thinner than 4 mm responded significantly better to treatment with a 
total fluence dose of 100 J cm-2 compared to thick tumours. The mean tumour volume 
doubling time for thin tumours of groups D to H was 12.0 ± 2.2 days (n=5) compared to a 
mean tumour volume doubling time of 5.9 ± 2.2 days for thick tumours (n=25). For 
illuminations with a total light fluence of 200 J cm-2 delivered either in one fraction or 
according to a long term light fractionation scheme (groups I and J, respectively) this 
difference in volume doubling time between thin and thick tumours was not found. 
 
Light distribution 
No significant variation in the measured fluence rate was observed during irradiation in 
individual treatments. The fluence rate measured by the probe placed on top of the skin 
overlying the tumour was 184.4 ± 14 mW cm-2 (n=5) where the incident light fluence rate 
was 100 mW cm-2. The fluence rate measured by the probe placed at depth between the 
tumour base and the underlying muscle was 42.3 ± 3.2 mW cm-2 (n=5). Therefore the 
fluence rate at the base of the tumour was approximately 23% of the fluence rate measured 
at the top of the tumour. From these measurements a mean effective attenuation coefficient, 
µeff, was calculated to be 3.5 ± 1.2 cm-1. 
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Discussion 
In this study we have demonstrated a dramatic increase in tumour volume doubling time 
following systemic ALA PDT using a long-term light fractionation scheme (two light fractions 
separated by a dark interval of 75 minutes). In previous studies it has been shown that new 
PpIX is formed after complete photobleaching caused by the illumination 14,15. This newly 
formed PpIX can be utilised during a second illumination. Van der Veen et al. 14 showed in a 
skinfold chamber model that a long term light fractionation scheme resulted in 4 out of 6 
tumours with complete necrosis at day 7 post treatment compared to no necrosis for a single 
illumination scheme. In this long-term light fractionation scheme a double light fluence (200 J 
cm-2) was delivered 14 compared to the single illumination (100 J cm-2) which might be the 
explanation for the increased effect. However, when PpIX is completely photobleached, a 
longer illumination is not expected to be more effective. This is also demonstrated in the 
present study. Treating the tumour with a double light fluence (200 J cm-2) did not 
significantly increase tumour volume doubling time compared to 100 J cm-2 whereas 
treatment with the same total fluence according to a long term light fractionation scheme did 
(Figure 1). In fact, this scheme increased the tumour volume doubling time by a factor of 2.6. 
The substantially improved tumour response can only be explained by the use of the dark 
interval between two light fractions. As we have discussed the long interruption may allow 
time for the formation of new PpIX which can be used for a second illumination and result in 
extra cell death. The origin of this new PpIX fluorescence is as yet unknown. One possibility 
is that ALA is still present in the tissue and can be converted into PpIX by the surviving cells. 
The oedema formation was not increased using a long-term light fractionation scheme 
compared to a single illumination of 100 J cm-2. The discolouration was more pronounced 
compared to a single illumination and all the animals formed crust. From the histology it can 
be concluded that the discolouration was caused by haemorrhage of the blood vessels 
around and at the border of the tumour. This means that the discolouration and the 
accompanied crust formation caused by necrosis of epidermal, dermal and tumour tissue 
was actually a combined normal and tumour tissue response. The fact that we saw more 
crust after illumination with a long-term light fractionation scheme is then not surprising. 
In contrast, ALA PDT using a low fluence rate or a short-term light fractionation scheme 
did not significantly improve the tumour volume doubling time. These illumination schemes 
were designed to increase the amount of singlet oxygen formation during the treatment by 
reducing the demand rate for oxygen 10. Several authors have shown that this can enhance 
the PDT response in a variety of animal models. Robinson et al. 12 reported a higher 
damage score of normal hairless mouse skin after topical ALA-PDT with a low fluence rate. 
They observed that the difference in damage score between an illumination with a fluence 
rate of 150 and 50 mW cm-2 was rather small whereas the difference between these fluence 
rates and 5 mW cm-2 was considerable. Hua et al. 11 showed a 1.5 times longer volume 
doubling time for tumours illuminated with a 4 times lower fluence rate after systemic ALA 
administration. The volume doubling time was found to be further enhanced for tumours 
treated with a 30 seconds light on/off short term light fractionation scheme. Messmann et al. 
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obtained a greater area of necrosis of normal colon after illumination using several short-
term light fractionation schemes 13. Off course, it is difficult to compare these studies since 
the animal model used, the ALA doses and the illumination methods are all different. The 
fact that we could not show an improved tumour response using any of these schemes 
indicates that little or no extra tumour damage was obtained by the use of a low fluence rate 
or dark periods of several seconds or minutes for this tumour model. These results imply 
that improving the tumour response to ALA PDT is not simply a matter of interrupting the 
illumination for a few seconds or minutes and that tumour response may be different both for 
different sizes of tumour and for different tumour types. 
Fan et al. 8 investigated the short and long term light fractionation schemes in patients 
treated for mouth dysplasia with orally administered ALA. They were not able to show an 
improved tumour response using either of these treatment schemes compared to a single 
fraction illumination. It should be noted that the maximum ALA dose orally administered in 
patients is 60 mg kg -1 whereas experimental animals are given 200 mg kg -1 intra venously. 
In summary, no significant improved tumour response could be obtained using a low 
fluence rate or a short-term light fractionation scheme (dark interval of seconds or minutes) 
for the illumination of a solid rhabdomyosarcoma transplanted on the thigh of a rat. This 
could only be achieved by using a long-term light fractionation scheme with a dark period of 
75 minutes between two light treatments. 
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Abstract 
Light fractionation with dark periods of the order of hours has been shown to considerably 
increase the efficacy of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT). Recent 
investigations have suggested that this increase may be due to the resynthesis of 
protoporphyrin IX (PpIX) during the dark period following the first illumination that is then 
utilised in the second light fraction. Light parameters are known to influence the response to 
PDT using single light fractions. In the present study we have investigated the kinetics of 
PpIX fluorescence and PDT-induced damage during PDT in the normal skin of the SKH1 HR 
hairless mouse using different light fractionation schemes. ALA was topically applied for 4 
hour and PDT was performed using 514 nm light. The results show that the kinetics of PpIX 
fluorescence after a single light fraction, with light fluences of 5, 10 and 50 J cm-2 is 
dependent on the fluence delivered; the resynthesis of PpIX is progressively inhibited 
following fluences above 10 J cm-2.  
All investigated light fractionation schemes show an increased skin response to ALA-PDT 
compared to a single illumination with the same cumulative fluence delivered 4 or 6 h after 
the application of ALA. The fluence and fluence rate of the two light fractions are crucially 
important for the efficacy of the treatment. The most optimal fractionation scheme involves a 
first fraction of 5 J cm-2 delivered at 50 mW cm-2 followed by a second light fraction of 95 J 
cm-2 at 50 mW cm-2.  
The kinetics of PpIX fluorescence do not explain this significant increase in PDT 
response. Histological sections of the illuminated volume showed a trend toward increasing 
extent and depth of necrosis for the two-fold illumination scheme in which the first light 
fraction is 5 J cm-2, compared with a single illumination scheme.  
The influence of light parameters 
 37 
Introduction  
Photodynamic therapy (PDT) using topically applied 5-aminolevulinic acid (ALA) is an 
emerging treatment modality for a number of (pre-) malignant conditions. ALA is converted 
in situ via the haem biosynthetic pathway into the photosensitiser protoporphyrin IX (PpIX). 
An excess of exogenous ALA can lead to the accumulation of therapeutic levels of PpIX in 
various tissues. To date ALA-PDT has been primarily used for the treatment of 
nonmelanoma skin lesions, such as actinic keratoses (AK), basal cell carcinoma (BCC) and 
squamous cell carcinoma. It has recently received approval in the United States for the 
treatment of AK of the face or scalp. Since its introduction by Kennedy et al. 1 a number of 
studies have reported complete initial response rates +/- 85%, for superficial BCC 2,3. 
However, for nodular BCC, a much lower complete response rate of 50% is obtained 2-4. 
Improvement of PDT efficacy, particularly in nodular tumours, is necessary. Various options 
have been investigated, which include the use of penetration enhancers, iron chelators, 
varying the duration of ALA application and modifying the illumination scheme 5-8. The 
illumination can be modified in a number of ways: reducing the fluence rate has been shown 
to improve efficacy by reducing the demand for oxygen during illumination and increasing 
the total amount of singlet oxygen produced 9-11. Introducing short-term fractionation (with 
one or more interruptions of seconds or minutes) allows reoxygenation during the dark 
intervals and has essentially the same effect as reducing the fluence rate 10.  
We have recently reported another type of light fractionation that leads to increased PDT 
efficacy. Long-term light fractionation, in which two light fractions are delivered, separated by 
an interval of1 h or longer, has been shown to enhance PDT response in two different model 
systems 12-14. We showed that PpIX fluorescence, that had been photobleached during 
illumination, reappeared in the hours immediately after illumination and postulated that the 
increase in PDT efficacy was due to the utilisation of this additional PpIX during the second 
illumination. The optimum two-fold illumination scheme will be determined by the time 
interval between illuminations and the ‘dose’ delivered during each illumination. With these 
three parameters it is easy to design numerous complex treatment and control treatment 
schemes. In the first part of the study we extend our previous findings by (1) investigating, in 
detail, the kinetics of PpIX fluorescence after illumination; and (2) determining the 
relationship between the illumination parameters (fluence and fluence rate), the 
photobleaching of PpIX during illumination, and the PDT effect of two-fold illumination with a 
2 h dark interval. The results showed that the dose delivered in the first fraction is an 
important parameter that determines, at least in part, the response of tissue to a two-fold 
illumination. We continued this study with a second part in which we investigated the 
relationship between (3) the fluence delivered during and (4) the timing of the first fraction of 
a two-fold illumination scheme, the PDT response and the kinetics of PpIX fluorescence 
during treatment with a cumulative fluence of 100 J cm-2 and a 2 h dark interval. 
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Materials and Methods 
Animal model. The experimental protocol was approved by the ‘‘Committee on Animal 
Research’’ of the Erasmus University Rotterdam. Female inbred albino hairless mice (SKH1 
HR, Charles River, Someren, The Netherlands), aged between 8 and 10 weeks, are 
included in this study. Prior to treatment animals were fed on a diet free of chlorophyll (Hope 
Farms B.V., Woerden, The Netherlands) for a minimum of 2 weeks in order to remove the 
autofluorescence emission from mouse skin centered on 675 nm 15 attributed to 
pheophorbide-a a breakdown product of chlorophyll 16. This fluorescence emission overlaps 
with those of PpIX and its fluorescent photoproducts, and pheophorbide-a is itself a 
photosensitiser.  
ALA application. ALA (20%) (Medac, Hamburg, Germany) was dissolved in 3% 
carboxymethylcellulose in water. To prevent skin irritation each solution was prepared to 
approximately pH 4 by the addition of NaOH (2 M). ALA was applied topically to a 7 mm 
diameter area (the same diameter as that illuminated during treatment) on the dorsal skin of 
each animal and covered with a thin layer of gauze; a polythene dressing (Tegaderm, 3M, 
The Netherlands) was used to occlude the area for 4 h prior to treatment. Before the 
application of drug animals received low-dose analgesia (Hypnorm; fluanisol/fentanyl 
mixture, Janssen Pharmaceutics, BE and 0.05 mL Diazepam, Centrafarm B.V., Etten-Leur, 
The Netherlands) to alleviate possible anxiety caused by the dressing.  
PDT light delivery and fluorescence/reflectance spectroscopy. PDT light delivery and 
fluorescence spectroscopy were performed as described previously 15. The 514 nm output 
from an argon ion laser is delivered via a 400 µm fibre and imaged to a 7 mm diameter spot 
of homogeneous profile on the skin of the mouse using a microlens (QLT, Vancouver, BC, 
Canada). Scattered excitation light and fluorescence emission (550–792 nm) are collected 
from the whole of the illuminated area using and focused into either a 1 mm core optical 
fibre or 400 µm optical fibre coupled to a spectrograph (Acton Research, Acton, MA) with a 
charge-coupled device (CCD) camera (Princeton Instruments Inc., Princeton, NJ) or a 400 
µm optical fibre coupled to a fibre optic spectrometer (Ocean Optics, Eerbeek, Netherlands). 
A long pass filter, OG 570 (Melles Griot, Zevenaar, The Netherlands) is placed in the optical 
path to block scattered 514 nm excitation light. In addition, immediately prior to treatment 
and at regular intervals during illumination the 514 nm PDT illumination is interrupted for a 
short period of time to allow a reflectance spectrum to be acquired using the same 
spectrograph. The output from a filtered halogen-lamp, (0.15 mW cm-2, Stortz, Tutlingen, 
Germany), delivered by a second 400 µm fibre and microlens is imaged onto the 7 mm 
diameter treatment spot. A long pass filter (OG 530, Melles Griot) is used to minimise 
fluorescence excitation of the tissue during reflection measurements. Using this setup both 
fluorescence and reflectance measurements are acquired using the same source detector 
geometry. The kinetics of PpIX fluorescence prior to and following PDT were determined 
using the same excitation and detection system, except that low-intensity excitation (0.1 mW 
cm-2) was used in order to minimise photobleaching. A fluorescence image was also 
acquired prior to each period of illumination using a CCD camera with double-stage image 
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intensifier (ADIMEC, Eindhoven, The Netherlands or Lambert Instruments, Leutingwolde, 
Germany) to locate the area of interrogation and maintain a constant distance between the 
mouse skin and the head of the spectrometer. During illumination each mouse is placed on 
a temperature-controlled stage and anesthetised with a combination of 2% Ethrane (Abbott, 
Amstelveen, The Netherlands) oxygen and N2O. Fluorescence emission spectra (550–792 
nm) are acquired at intervals of 5 s during 514 nm illumination using an integration time of 
0.5 s or 1.5 s. Reflectance spectra were either acquired before and after illumination or 
every 30 s using an integration time of 0.5 s. During this procedure the PDT illumination is 
interrupted for 3 s. In total the PDT illumination is interrupted for 10% of the duration of the 
treatment.  
Data analysis. The spectral analysis of data acquired during illumination performed in this 
study is substantially different from that used in our two previously published studies 
involving PpIX photobleaching 15,17. This change is in light of the recent work of Foster and 
his co-workers 18-21. During illumination of a highly scattering medium such as tissue, 
changes in the measured fluorescence may be due to changes in the actual fluorescence 
intensity of the medium and/or to changes in its optical properties.  
To correct for such changes in tissue optical properties during illumination we use a 
method introduced by Wu et al. 22, in which the measured fluorescence emission is divided 
by the reflectance signal over the same range of wavelengths that the fluorescence is 
acquired. Since the source-detector geometry described above is identical for both 
fluorescence and reflectance measurements, the optical properties encountered by 
fluorescence and reflectance light are the same. Thus dividing the fluorescence emission by 
the reflectance corrects changes in optical properties of the tissue at the emission 
wavelengths. Since we have not acquired a reflectance spectrum for each of the 
fluorescence spectra obtained during illumination we have corrected all the fluorescence 
spectra acquired during each illumination period with a second-order polynomial 
interpolation of the reflectance spectra acquired at regular intervals during that illumination. 
In case the reflectance spectrum was acquired immediately before and after each light 
fraction, we have corrected all the fluorescence spectra acquired during each illumination 
period with a linear interpolation of these reflectance spectra. 
The fluorescence emission spectra, corrected for tissue optical properties, are analyzed 
as a linear combination of basis fluorescence spectra 18,19 using single value decomposition 
(SVD) algorithm. The three basis fluorescence spectra used in this analysis are the 
autofluorescence of normal mouse skin, PpIX and the hydroxyaldehyde chlorin photoproduct 
of PpIX. We also investigated the use of other basis fluorescence spectra, in particular that 
of a blueshifted water-soluble porphyrin with a peak emission in the wavelength range 600–
620 nm. In all cases however, this resulted in a reduction in the goodness-of-fit and we were 
unable to find evidence for any such an emission under the illumination conditions 
investigated.  
An average autofluorescence spectrum was determined from the average of 20 
autofluorescence spectra from 20 animals, before the application of ALA. Similarly an 
average PpIX fluorescence spectrum was determined from the average of 20 fluorescence 
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spectra acquired from 20 animals, 4 h after the application of ALA. The PpIX basis spectrum 
was determined by subtracting the average autofluorescence spectrum described above.  
In keeping with the analysis of Finlay and Foster 18 we accounted for differences in the 
autofluorescence between animals by constructing an individual autofluorescence basis 
spectrum for each animal. The initial spectrum acquired during each illumination was fit 
using an SVD as a combination of the average autofluorescence, the PpIX basis spectrum 
and a 61-term Fourier series. The individual autofluorescence basis spectrum is therefore a 
sum of fitted average autofluorescence and the Fourier series.  
The PpIX-induced photoproduct basis spectrum was constructed from the average of 10 
spectra acquired from 10 animals that demonstrated sufficient photoproduct fluorescence, 
i.e. had received between 5 and 10 J cm-2
 
of 514 nm illumination at 50 mW cm-2. Each 
spectrum was then fitted using an SVD as a combination of PpIX, average 
autofluorescence, the individual Fourier series and a single lorentzian. The average of these 
lorentzian fits, centered on 674 nm with a width of 28 nm full width half maximum was used 
as the PpIX photoproduct fluorescence spectrum. The three basis spectra, with equal 
weighting, are now used to fit the contribution of PpIX and its fluorescent photoproducts in 
all of the spectra acquired in this study.  
PDT illumination schemes. The normal kinetics of PpIX fluorescence were measured in a 
control group of five animals for 8 h after the application of ALA. The kinetics of PpIX 
fluorescence were also measured following illumination with 5, 10 and 50 J cm-2, 4 h after 
the application of ALA for 4 h (n = 5 in each group). The results from these data were used 
to design the next set of experiments in which we monitored the kinetics of porphyrin 
fluorescence during illumination and the biological damage induced in the illuminated area 
following PDT. This was done in a series of six different single and two-fold illumination 
schemes, with n = 5 animals in each: (1) a single illumination of 100 J cm-2 delivered at 50 
mW cm-2, 4 h after the application of ALA; (2) a single illumination of 100 J cm-2 delivered at 
50 mW cm-2, 6 h after the application of ALA; (3) a two-fold illumination of 50 J cm-2 at 50 
mW cm-2 delivered at 4 and 6 h after the application of ALA (cumulative fluence 100 J cm-2: 
2h interval between illuminations); (4) a two-fold illumination of 5 J cm-2 at 50 mW cm-2, 4 h 
after the application of ALA and 95 J cm-2
 
at 50 mW cm-2, 6 h after the application of ALA 
(cumulative fluence 100 J cm-2: 2 h interval between illuminations); (5) a two-fold illumination 
scheme in which we investigated the effect of reducing the fluence rate of the first light 
fraction to 5 mW cm-2; 5 J cm-2
 
at 5 mW cm-2
 
4 h after the application of ALA and 95 J cm-2
 
at 
50 mW cm-2, 6 h after the application of ALA (cumulative fluence 100 J cm-2: 2 h interval 
between illuminations); and (6) a two-fold illumination scheme in which we investigated the 
effect of reducing the cumulative fluence by reducing the length of the second illumination; 5 
J cm-2
 
at 50 mW cm-2, 4 h after the application of ALA and 45 J cm-2
 
at 50 mW cm-2, 6 h after 
the application of ALA (cumulative fluence 50 J cm-2: 2 h interval between illuminations). 
Based on these results the study was extended to determine the influence of the illumination 
parameters of the first light fraction in an extra series of 4 different two-fold illumination 
schemes with n=12 in each group unless stated differently: (7) a two-fold illumination of 1 J 
cm-2 delivered 4 h after the application of ALA and 99 J cm-2 6 h after the application of ALA; 
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(8) a two-fold illumination of 2.5 J cm-2 delivered 4 h after the application of ALA and 97.5 J 
cm-2 6 h after the application of ALA; (9) a two-fold illumination of 5 J cm-2 delivered 4 h after 
the application of ALA and 95 J cm-2 6 h after the application of ALA; and (10) a two-fold 
illumination scheme in which we investigated the effect that shortens the time of ALA 
application before the first illumination while maintaining the dose delivered during the first 
illumination; 10 J cm-2 delivered 2 h after the application of ALA and 90 J cm-2 delivered 4 h 
after the application of ALA (n=6).  
PDT damage. Biological damage to the irradiated area was assessed daily using a visual 
skin scoring system 17 by two independent observers (D.J.R. and H.S.B.) blinded from the 
treatments. Photographs were also taken daily in order to determine the degree and 
distribution of damage. Grade 1 represents minimal redness, grades 2, 3, 4 and 5 represent, 
redness, severe redness, thin and thick scab formation, respectively. Mean damage scores 
were calculated by scoring areas according to the degree of damage and the contribution to 
the total illuminated area. The scores from each treatment site were used to calculate a 
mean skin score for each group. The total PDT damage in a single treatment was quantified 
by integrating the mean skin score when plotted against time. The formation of scar tissue 
was not included in the visual skin scoring system. The statistical significance of differences 
in PDT damage was determined using an analysis of variance followed by a Student–
Newman–Keuls test as necessary, use of the word significant corresponds to a P value 
<0.05. The histological damage was also determined 48 h after therapy in each of the 
illumination schemes investigated. The depth of damage was quantified by dividing the skin 
into three layers: the epidermis, the upper or papillary dermis and the deep dermis. The 
extent of necrosis, either partial or complete, was assessed with in each layer. 
 
Results  
PpIX fluorescence kinetics after a single light fraction. 
The kinetics of PpIX fluorescence in normal hairless mouse skin after topical application 
of ALA is shown in Figure 1. PpIX fluorescence increases during the first 4 h of application. 
After the removal of excess ALA at 4 h, the fluorescence intensity reaches a maximum and 
does not change significantly over the time course investigated in this study. Illumination 
with 50 mW cm-2, 514 nm radiation 4 h after the application of ALA results in significant 
photobleaching of PpIX. The extent of this photobleaching is dependent on the fluence 
delivered during illumination, and increases as the fluence is increased from 5 to 10 J cm-2 
and again when the fluence is increased to 50 J cm-2. The increase in PpIX fluorescence in 
the 4 h after illumination is also dependent on the fluence delivered during illumination. The 
amount of PpIX fluorescence 2 and 4 h after illumination decreases significantly as the 
fluence is increased from 5 to 10 and to 50 J cm-2. In the 4 h following illumination, PpIX 
fluorescence does not return to the pre-treatment intensity or to the intensity that would be 
expected in the absence of illumination. PpIX fluorescence reaches a maximum intensity 
between 1 and 4 h after illumination, depending on the fluence delivered. The rate of PpIX 
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resynthesis following each illumination is less than that immediately after the initial 
application of ALA. It is also less than that at the corresponding PpIX fluorescence intensity 
in the normal kinetics of PpIX fluorescence before illumination.  
 
Figure 1. PpIX fluorescence kinetics following topical application of ALA, and following illumination 4 
h after the application of ALA with 5, 10 and 50 J cm-2 at a fluence rate of 50 mW cm-2. Note: kinetics do 
not include time elapsed during illumination. 
 
PpIX fluorescence photobleaching during illumination  
Figure 2 shows the typical mean normalised PpIX fluorescence intensity during a two-fold 
illumination. A first illumination of 50 J cm-2
 
is delivered at 50 mW cm-2, 4 h after the 
application of ALA; PpIX is rapidly photobleached during illumination. A dark interval of 2 h 
results in an increase in PpIX fluorescence (approximately 25% of that present prior to 
PDT). This PpIX fluorescence is then photobleached during the second illumination, 
performed 6 h after the start of ALA application.  
Figure 3a shows the mean normalised variation in PpIX fluorescence intensity during a 
single illumination at 50 mW cm-2, 4 or 6 h after the start of ALA application (note: the full 
range of fluence is not shown for clarity). There is no significant difference between the 
mean rate of photobleaching at 4 or 6 h after ALA application. Figure 3b shows the 
corresponding normalised variation in PpIX fluorescence during a two-fold illumination at the 
same fluence rate. The rate of photobleaching of PpIX during the second illumination is 
significantly less than both that during the first illumination and at the same time point (6 h) 
in the absence of a first illumination (Figure 3a). 
Figure 4 shows the mean normalised PpIX fluorescence intensity during three two-fold 
illumination schemes that are different with respect to the fluence and/or fluence rate of the 
first light fraction. In each case the fluorescence intensity during the first and second 
illumination is plotted in the same panel and normalised to the initial fluorescence intensity 
before the first illumination. The relative fluorescence intensities immediately before each 
illumination are therefore on the left edge of each plot. Figure 4a shows the fluorescence 
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Figure 2. Mean normalised PpIX fluorescence intensity during twofold illumination with 514 nm 
radiation of normal mouse skin (a) 4 h and again at (b) 6 h after the application of ALA with 50 J cm-2 
delivered in each light fraction. There is a dark interval of 2 h between illuminations. In each case the 
fluorescence intensity is normalised to that at the start of the first illumination. 
 
 
Figure 3. (a) Mean normalised PpIX fluorescence intensity during single illumination with 514 nm 
radiation at 50 mW cm-2, () 4 h or (○) 6 h after the application of topical ALA; and (b) mean normalised 
PpIX fluorescence intensity during a two-fold illumination with 514 nm radiation () 4 h and again (○) 6 
h after the topical application of ALA, with a dark interval of 2 h between illuminations. 
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intensity during a two-fold illumination where 50+50 J cm-2 is delivered with a 2 h dark 
interval. The mean fluorescence intensity before the second illumination is approximately 
25% of that before the first. Figure 4b shows the fluorescence intensity when two 
illuminations of 5+95 J cm-2 are delivered. The mean fluorescence intensity before the 
second illumination is now significantly greater, approximately 75% of that before the first 
illumination. Similarly Figure 4c shows the fluorescence intensity during a two-fold 
illumination; 5+95 J cm-2, except that the first illumination is delivered at 5 mW cm-2. The rate 
of photobleaching during the first illumination at 5 mW cm-2
 
is significantly greater than that 
during illumination at 50 mW cm-2
 (Figure 4b, open symbols). The mean fluorescence 
intensity before the second illumination is significantly less than that following 5 J cm-2
 
at 50 
mW cm-2
 (Figure 4b, closed symbols); approximately 35% of that before the first illumination.  
Two hours after the application of ALA, the PpIX fluorescence is approximately 50% of 
this maximum intensity as shown in Figure 5. Illumination with 50 mW cm-2 to a fluence of 10 
J cm-2 results in significant photobleaching of PpIX. Immediately after this illumination, 
approximately 18% of the PpIX fluorescence remains. In the 2h interval between light 
fractions, PpIX fluorescence returns. The intensity of PpIX fluorescence immediately before 
the second light fraction, 4h after the application of ALA, is greater than that before the first 
light fraction but is significantly less than that would have been present in the absence of the 
first fraction. During the second light fraction, PpIX fluorescence again decreases rapidly, 
and after the end of the illumination (90 J cm-2) it is not significantly different from the 
background fluorescence intensity.  
 
PpIX photoproduct fluorescence during illumination  
Compared to the PpIX fluorescence intensity the mean photoproduct fluorescence 
intensity is maximal less than 1%. The photoproduct fluorescence kinetics during PDT using 
the 50+50 J cm-2 and the 5+95 J cm-2 illumination schemes show distinct differences. 
Photoproduct fluorescence increases rapidly during the first illumination of the 50+50 J cm-2 
scheme, reaches a maximum between 10 and 20 J cm-2, and is subsequently 
photobleached during illumination. At the end of the first illumination a significant level of 
photoproduct fluorescence is present. After the 2 h dark interval, at the start of the second 
illumination, there is still photoproduct fluorescence that is not significantly different from that 
present at the end of the first illumination. During the second illumination photoproduct 
fluorescence increases again and reaches a maximum between 5 and 10 J cm-2, and 
photobleaches during the course of the second illumination. At the end of the second 
illumination a significant level of photoproduct fluorescence is still present.  
In the 5+95 J cm-2 scheme the first illumination ceases before the photoproduct 
fluorescence reaches a maximum intensity and a significant level of photoproduct 
fluorescence is present at the end of the first illumination. After the 2 h dark interval, at the 
start of the second illumination, there is still photoproduct fluorescence present that is not 
significantly different from that at the end of the first illumination. During the second 
illumination photoproduct fluorescence increases and reaches a maximum after between 10 
and 20 J cm-2. The increase in photoproduct fluorescence during the second illumination is 
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greater after a first illumination of 5 J cm-2 than that observed following a first illumination of 
50 J cm-2. The photoproduct again undergoes photobleaching during the second 
illumination. At the end of the second illumination a significant level of photoproduct 
fluorescence is again present. 
Figure 4. Mean normalised PpIX fluorescence intensity during three two-fold illumination schemes 
with illumination at 4 h () and 6 h (○) after the application of ALA; (a) 50 J cm-2 + 50 J cm-2 at 50 mW 
cm-2 (b) 5 J cm-2 + 95 J cm-2 at 50 mW cm-2 and (c) 5 J cm-2 at 5 mW cm-2 + 95 J cm-2 at 50 mW cm-2. In 
each panel all PpIX fluorescence intensities are normalised to the initial PpIX fluorescence intensity 
prior to the first illumination. 
 
 
Figure 5. PpIX fluorescence kinetics (n = 6) following topical application of ALA to normal hairless 
mouse skin () and PpIX fluorescence kinetics during a two-fold illumination scheme with a 2 h dark 
interval using 514 nm (○). A first fraction of 10 J cm-2 is delivered 2 h after the application of ALA and a 
second fraction of 90 J cm-2 2 h later (4 h after the application of ALA). A cumulative fluence of 100 J 
cm-2 is delivered at 50 mW cm-2. 
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Figure 6. Amount of PpIX that is synthesised during the 2 h dark interval between the two light 
fractions as a function of the fluence of the first light fraction delivered () 2 and (○) 4 h after the 
application of ALA (n 5 6 in each case). In each case the fluorescence intensity is represented as a 
percentage of that present 4 h after the application of ALA (note that the curve is used as an illustration 
of the amount of PpIX synthesised after llumination 4 h after ALA application). 
 
PDT-induced damage  
Control treatments using light only and drug only were performed and did not show any 
significant PDT induced damage. Figure 7 summarises the PDT damage (quantified by 
integrating the mean skin score when plotted against time) following each illumination 
scheme investigated. A single illumination at 4 or 6 h after the start of ALA application 
results in a maximum visual skin damage score corresponding to severe redness. There is 
no significant difference between the visual damage score obtained after illumination at 
either time point. We note that this is also the case for single illuminations of 50 and 200 J 
cm-2 (data not shown). 
A two-fold illumination scheme of 50+50 J cm-2 separated by a 2 h dark interval results in 
an increased visual damage score. Reducing the fluence of the first fraction from 50 to 5 J 
cm-2 while keeping the cumulative fluence 100 J cm-2
 
result in a large increase in the visual 
damage score corresponding to thick crust formation and is the most extensive visual 
damage we have observed in normal hairless mouse skin to date 12,16. Reducing the fluence 
of the second illumination from 95 to 45 J cm-2
 
results in a reduction in the visual damage to 
approximately that obtained with 50+50 J cm-2. Reducing the fluence rate of the first 
illumination from 50 to 5 mW cm-2
 
results in a similar reduction in the visual damage skin 
score following treatment. Delivering 2.5+97.5 J cm-2 results in the same damage as 5+95 J 
cm-2. Reducing the fluence of the first fraction still further to 1 J cm-2 (+99 J cm-2) results in 
significantly less damage such that this scheme is no longer significantly different from 
50+50 J cm-2. However, this illumination scheme still results in significantly more damage 
than delivering 100 J cm-2 in a single fraction. This Figure also shows that 10+90 J cm-2 
delivered 2 and 4 h after the application of ALA results in the same damage as at 5+95 J  
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cm-2 delivered 4 and 6 h after ALA.  
 
Figure 7. Visual skin damage (quantified by integrating the mean skin score for the first 7 days after 
illumination plotted against time) following each of illumination schemes. Indicated are the fluences 
delivered during the first and second light fractions at 50 mW cm-2, 4 and 6 h (unless indicated in 
parentheses) after the application of ALA respectively. Results are shown as mean +/- SEM. 
 
 
 
Histological damage  
Figure 8 shows the histological damage 48h after treatment for two of the illumination 
schemes investigated in this study - a single fraction of 100 J cm-2, delivered at 50 mW cm-2, 
4h after the application of ALA and a two-fold illumination scheme of 5+95 J cm-2 delivered 4 
and 6h after the application of ALA. Three representative sections from the five animals in 
each group are shown for each illumination scheme. Normal mouse skin is also shown for 
comparison. Illumination with a single fraction of 100 J cm-2 results in necrosis that is 
predominately restricted to the epidermis. Complete necrosis of the upper dermis was 
observed in only one animal, and two animals showed partial necrosis of the upper dermis. 
After a two-fold illumination (50+50 J cm-2), we did not observe a significant increase in the 
amount or depth of necrosis. However, reducing the fluence of the first light fraction (5+95 J 
cm-2) resulted in more necrosis in both the upper dermis and deep dermis. Four of the five 
animals showed complete necrosis of the upper dermis and two of the animals showed 
partial necrosis of the deep dermis. We also observed that the necrosis was accompanied 
by a large amount of inflammatory infiltrate in the deep dermis after this illumination scheme. 
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Figure 8. Histology of hairless mouse skin, (H&E 10x, E; epidermis, U D, upper dermis, L D, lower 
dermis). (a) normal skin and 48 h after illumination with (b – d) a single fraction of 100 J cm-2 delivered 
at 50 mW cm-2, 4 h after the application of ALA, and (e – g) a two-fold illumination scheme in which 5 J 
cm-2 and 95 J cm-2 are delivered at 50 mW cm-2, 4 and 6 h after the application of ALA respectively. 
 
Discussion  
PpIX fluorescence kinetics after illumination  
In the first part of this study we have investigated the kinetics of PpIX fluorescence 
following illumination and found that the kinetics of PpIX fluorescence after a single light 
fraction is dependent on the fluence delivered; the resynthesis of PpIX is progressively 
inhibited following fluences above 10 J cm-2. There is a range of factors that may or may not 
affect the kinetics of PpIX fluorescence within the illuminated volume following ALA-PDT. 
Before we consider the implications for optimizing therapy it is useful to discuss some of 
these factors in turn. Between 4 and 6 h after topical application there remains a significant 
concentration of ALA in normal mouse skin. Illumination in this time period may cause 
damage to critical cellular components, in particular, the mitochondria, and may decrease or 
completely inhibit the production of PpIX, despite the presence of ALA. ALA-PDT is also 
known to reduce the availability of oxygen during illumination 10,11,15,17. While it is unclear as 
to the extent of vascular effects following topical ALA-PDT 12, a reduced oxygen supply 
within the treatment volume, after illumination, may under some circumstances inhibit the 
ability of the cells to synthesis PpIX 23. Conversely, PpIX may under some circumstances be 
present in the circulation, and damage to vessels following PDT, may allow PpIX to return to 
the volume, from which it has been photobleached during illumination, and thus increase the 
fluorescence measured within the treatment volume. A similar result may occur if 
undamaged cells, initially outside the illumination volume, migrate toward it and then 
synthesise PpIX from ALA already present in the illuminated volume. There is also some in 
vitro evidence to suggest that the synthesis of PpIX may be modulated by the 
photoinactivation of the terminal enzyme in haem biosynthesis, ferrochelatase. 
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Ferrochelatase catalyses the addition of Fe2+ to PpIX producing haem. A number of studies 
have shown that adding ferrochelatase inhibitors such as dimethyl sulfoxide enhances the 
accumulation of PpIX. The close proximity of PpIX and ferrochelatase during PDT may 
reduce the activity of ferrochelatase and lead to enhanced PpIX production. It should be 
noted however that in vivo, heterogeneous cell populations may lead to a complex mixture 
of these effects.  
There are a number of reports in the literature that have investigated the kinetics of PpIX 
fluorescence after ALA-PDT. To our knowledge there have been two clinical studies where 
fluorescence of PpIX after illumination has been studied, both during ALA-PDT of human 
BCC 24,25. These data are similar to our own unpublished clinical findings that demonstrate a 
significant increase in PpIX fluorescence in the hours following ALA-PDT, after 
photobleaching during illumination. There have also been a small number of in vitro studies, 
the results of which are contradictory. Gibson et al. 26 recently reported in an in vitro study a 
significant reduction in the ability of R3230AC cells to synthesise PpIX immediately after 
illumination, 3 h after the start of ALA incubation. They showed that this reduction in PpIX 
synthesis persists for at least 24 h after illumination. As might be expected they found no 
enhanced efficacy with a second illumination with a dark interval of 24 h. In addition to 
reduced PpIX synthesis a concomitant reduction in porphobilinogen deaminase (PBGD) 
activity upon illumination was observed and the authors concluded that PBGD is an 
important enzyme target when ALA is administered exogenously. In contrast to these 
findings He et al. in two separate studies, reported increased levels of PpIX in two different 
cell lines between 2 and 48 h after illumination 27,28. Our data shows that the rate of PpIX 
resynthesis after illumination is both less than that immediately after the initial application of 
ALA, and less than that at the corresponding PpIX fluorescence intensity in the normal 
kinetics of PpIX fluorescence. The absence of an increased rate of production of PpIX after 
illumination seems to support the hypothesis that ferrochelatase cannot be photoinactivated 
without inhibiting the production of PpIX.  
The continued synthesis of PpIX after illumination has also been demonstrated in UVB-
induced tumours in the same animal model used in this study. Van der Veen et al. 12 showed 
an increase in PpIX fluorescence in areas of UVB-irradiated mouse skin after illumination 
with 100 J cm-2 at 100 mW cm-2. They reported that the subsequent rate of increase is the 
same as that in control areas in the same animal (i.e. ALA no illumination). These data seem 
to indicate a more rapid increase in fluorescence intensity after illumination in UVB-treated 
skin. However, as we have demonstrated the kinetics of PpIX fluorescence after illumination 
are dependent on the ‘‘dose’’ delivered. While this is difficult to determine, these treatment 
parameters, in particular the high fluence rate, may result in the deposition of a small ‘‘dose’’ 
and explain the rapid increase in PpIX fluorescence intensity after illumination. Van der 
Veen et al. 12 discussed the possibility that circulating porphyrins may play a role in the 
return of fluorescence in the hairless mouse. They compared two cases (1) where ALA is 
applied to large area (2 x 2 cm2). This is both large compared to the surface area of the 
mouse and the illuminated area (7 mm diameter, the same as we have used here); and (2) 
where ALA is only applied to the illuminated area. They reported no significant difference in 
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the kinetics of PpIX fluorescence after illumination 29. We have repeated these 
measurements (in preparation), and find no significant difference between the two methods 
of applying topical ALA. This is despite the fact that mouse skin is such that vessels are 
confined to the most superficial layers and areas are supplied from the periphery and not 
from beneath as in human skin. These observations seem to support the conclusion that 
PpIX is not transported back into the treated area after illumination. It is also possible that 
cells from outside the illuminated volume may enter and themselves synthesise PpIX from 
the ALA already present.  
 
PpIX and photoproduct photobleaching during illumination  
The kinetics of PpIX photobleaching are similar to those that we have published 
previously 15,17. PpIX is rapidly photobleached during illumination and the rate of 
photobleaching increases for decreasing fluence rate, supporting an oxygen-dependent 
mechanism of PpIX photobleaching. Since these data were published there have been two 
other studies that have reported the absence of fluence rate dependence of PpIX 
photobleaching 30,31. While it is difficult to determine the reasons for the difference in results 
between these studies and our own, there are some specific differences in experimental 
methods. In each of these studies red light (636 and 630 nm, respectively) was used to both 
perform PDT illumination and to excite PpIX fluorescence. In addition ALA was administered 
systemically in each case. Employing long-wavelength excitation and systemic 
administration of ALA may mean that during illumination the depth from which fluorescence 
emission is collected increases. Changes in optical properties during illumination may 
influence the measured kinetics of PpIX fluorescence. The effects of fluorescence 
originating from progressively deeper layer of tissue are not accounted for. Using shorter 
514 nm fluorescence excitation in combination with topical ALA administration and short 
application times alleviates this problem. Fluorescence spectra were not corrected for 
changes in tissue optical properties over the emission wavelengths during illumination. In 
addition Iinuma et al. 31 quantified PpIX photobleaching during illumination by integrating the 
spectral emission between 675 and 720 nm. Within this region PpIX photoproduct 
fluorescence overlaps with the emission from PpIX and may affect the measured kinetics of 
PpIX fluorescence.  
At constant fluence rate, the rate of photobleaching of PpIX during a single illumination 4 
or 6 h after the application of ALA is equivalent. However, this is not the case during a two-
fold illumination scheme (Figure 3b), when illumination at 6 h is preceded by illumination at 4 
h. In this case the initial rate of photobleaching is significantly less during the second 
illumination. This not a consequence of the lower fluorescence intensity before the second 
illumination where the mean fluorescence intensity is not significantly less than the lowest 
fluorescence intensities prior to the first illumination. Indeed, in the absence of other effects 
a lower concentration of PpIX would result in faster photobleaching of PpIX due to the 
reduced demand for oxygen. The reduced rate of photobleaching observed may be due to 
either, a reduced availability of oxygen at the time of the second illumination or possibly the 
differential cellular localisation of PpIX.  
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The kinetics of the fluorescent photoproducts of PpIX, centered on 674 nm, are again 
similar to those that we have published previously 15. Using the method of data analysis 
introduced by Foster and his colleagues we measure less of photoproduct bleaching after 
large fluences than we have reported previously. However photoproduct photobleaching 
remains a significant effect. It is interesting to note that we observe similar trends in PpIX 
and photoproduct photobleaching in individual animals under the same illumination 
conditions. More rapid PpIX photobleaching corresponds to a faster increase in 
photoproduct fluorescence and greater photoproduct photobleaching. Also, we do not 
observe a significant reduction or increase in photoproduct fluorescence during the dark 
interval between illumination.  
 
Two-fold illumination  
At constant fluence rate, PDT damage induced by a single illumination in hairless mouse 
skin is limited by the photobleaching of PpIX. There is no significant difference between the 
visual damage after illumination with 100 J cm-2 at 50 mW cm-2 obtained in this study and  
50 J cm-2 at 50 mW cm-2, obtained previously 15. We have also shown that increasing the 
fluence of a single illumination beyond 100 to 200 J cm-2 does not increase the PDT  
damage 12.  
Two-fold illumination with the same cumulative fluence 50+50 J cm-2 results in an 
increase in PDT damage. Reducing the fluence of the first illumination from 50 to 5 J cm-2 
results in a large increase in PDT damage which is significantly greater than that of all the 
other treatment schemes investigated. This is a surprising result. It seems that an 
illumination scheme with a small first fluence that results in the resynthesis of relatively more 
PpIX, which is then utilised during the second illumination, is more effective than a scheme 
in which more PpIX is bleached during the first illumination. It seems that there is a first 
illumination threshold above which delivering more dose reduces the effectiveness of the 
second illumination whatever dose is delivered during the second illumination. The 
difference between the first and second illumination is also demonstrated when we compare 
delivering 45 and 95 J cm-2 in the second illumination after a first illumination of 5 J cm-2. 
There is now significantly less damage when the second illumination is shortened. It seems 
necessary to deliver a large fluence in this illumination. This does not seem to hold for a 
single illumination; 100 J cm-2 does not cause significantly more damage than 50 J cm-2.  
The mechanism behind the increase in PDT response demonstrated in this study is 
unlikely to be solely determined by the amount of PpIX present before each illumination and 
the extent to which it is photobleached during illumination. Other mechanisms are likely to 
be complex and beyond the scope of this study. It is possible that a small first dose renders 
the cells in the illuminated volume sensitive to a second illumination, perhaps by inducing 
repair mechanisms that are subsequently damaged. It is also possible that the mechanism 
of cell death, apoptotic or necrotic, may be different after a small initial PDT dose. The dose 
delivered in the first fraction seems an important parameter that determines, at least in part, 
the response of tissue to a two-fold illumination.  
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The optimum dose of the first light fraction is unknown but it is clear that reducing the 
fluence of the first fraction from 50 to 5 J cm-2 is more effective therefore this study was 
extended to this in more detail. This was done by investigating the further reduction of the 
fluence of the first light fraction and by reducing the interval between the application of ALA 
and the first light fraction. Figure 7 shows that reducing the fluence of the first light fraction 
from 5 to 2.5 J cm-2 does not significantly reduce the visual skin damage after illumination. 
Both illumination schemes remain significantly more effective than a two-fold illumination 
scheme with equal light fractions and are almost twice as effective as a single illumination of 
100 J cm-2. Reducing the fluence still further to 1 J cm-2 results in a significant reduction in 
visual skin damage, but this is still significantly greater than for a single illumination scheme. 
We have shown that the optimum fluence of the first light fraction delivered 4 h after the 
administration of ALA at a fluence rate of 50 mW cm-2 is greater than 1 J cm-2. Our results 
also demonstrate that it is possible to reduce the overall treatment time by a first light 
fraction of 10 J cm-2 delivered 2 h after the application of ALA and the second light fraction 
delivered 4 h after the application of ALA. Because the results have demonstrated the 
sensitivity of the response after a twofold illumination to the dose delivered during the first 
light fraction, we were careful to choose an appropriate fluence for this early first light 
fraction. The concentration of PpIX available 2 h after the application of ALA is 
approximately 50% of that at 4 h. We therefore attempted to compensate for the reduced 
concentration of PpIX by increasing the fluence of the first illumination from 5 to 10 J cm-2. 
As Figure 7 shows, it is possible to reduce the time interval between the application of ALA 
and the first light fraction from 4 to 2 h with no significant reduction in visual skin damage 
from that seen with 5 J cm-2 delivered 4 h after the application of ALA. The findings 
described above are important for two reasons. First, they offer an indication of the optimum 
light dose and timing of a first light fraction that should be delivered to achieve the maximum 
visual skin damage. Second, they illustrate our lack of understanding of the mechanism 
behind the increase in PDT induced damage associated with a two-fold illumination scheme. 
We have shown that in this model the optimum first light fraction in a two-fold illumination 
scheme with a dark interval of 2 h is between 2.5 and 5 J cm-2. It should be noted that this 
result is only valid for an illumination performed, 4 and 6 h after the application of ALA, at 50 
mW cm-2. Changing these parameters will obviously affect the dose delivered during the first 
illumination, which determines the resulting visual skin damage. We have also shown that 
delivering as little as 1 J cm-2 in the first light fraction can significantly increase the visual 
skin damage above that seen after a single illumination. Again it is clearly demonstrated that 
the increase in damage is not due to the utilisation of additional PpIX that is synthesised 
during the 2 h dark interval. Relatively small amounts of PpIX (10% of that present before 
illumination 4 h after the application of ALA) are resynthesised in the dark interval between 
the two light fractions, as illustrated in Figure 6. Note that the total amount of additional PpIX 
photobleached is closely related to that resynthesised in the 2 h dark interval because there 
is no significant difference in the amount of PpIX that remains after the second light fraction 
for any of the illumination schemes. The histological damage after illumination shows some 
interesting results. We observed a trend toward increasing extent and depth of necrosis for 
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the two-fold illumination scheme in which the first light fraction is 5 J cm-2, compared with a 
single illumination scheme. We did not determine whether these effects were statistically 
significant, but they represent an area for future study.  
The relationship between the increase in PDT damage observed with a two-fold 
illumination and the length of the dark interval is a different area for future study. The shorter 
dark interval used in this study (2 not 6 h) does not significantly affect the increase in 
damage we have observed previously 12. The time interval between each illumination has a 
direct effect on the total treatment time, an important factor in the clinic. However a 
significant dark interval seems necessary (of the order of several tens of minutes). We have 
shown previously, in the model used in this study, that a single dark interval of 2 min after 3 
or 6 J cm-2, during illumination to a fluence of 50 J cm-2, does not significantly increase the 
PDT damage 17. This result is in contrast to the data of Cunrow et al. 31, who were able to 
show an increase in PDT damage with such an illumination scheme. It is not easy to 
determine the reason for the difference between these two results. However, the bare-fibre 
illumination geometry used by Cunrow et al. makes it difficult to compare their data with 
those obtained in our model and in clinical ALA-PDT.  
In summary, a fractionated illumination scheme in which a cumulative fluence of 100 J 
cm-2 at 50 mW cm-2 is delivered in two equal light fractions separated by a dark interval of 2 
h has shown to considerably increase the efficacy of ALA-PDT. The efficacy of such a 
scheme is further increased if the fluence of the first light fraction is reduced to 5 J cm-2. The 
significance of the illumination parameters is shown for both the first and the second light 
fraction. Reducing the fluence of the first fraction from 5 to 2.5 J cm-2 results in the same 
amount of visual skin damage whereas reducing the fluence to 1 J cm-2 or reducing the 
fluence rate to 5 mW cm-2 results in less damage. Reducing the fluence of the second light 
fraction from 95 to 45 J cm-2 also results in less damage but all the two-fold illumination 
schemes tested remain more effective than a single illumination of 100 J cm-2. Also, a first 
light fraction of 10 J cm-2 can be delivered 2 h earlier, 2 h after the application of ALA, with 
no significant reduction in visual skin damage obtained after a first light fraction of 5 J cm-2 
delivered 4 h after the application of ALA. 
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Abstract 
We have previously shown that light fractionation during topical aminolevulinic acid based 
photodynamic therapy (ALA-PDT) with a dark interval of 2 hours leads to a significant 
increase in efficacy in both pre clinical and clinical PDT. However this fractionated 
illumination scheme required an extended overall treatment time. Therefore we investigated 
the relationship between the dark interval and PDT response with the aim of reducing the 
overall treatment time without reducing the efficacy. Five groups of mice were treated with 
ALA-PDT using a single light fraction or the two fold illumination scheme with a dark interval 
of 30 minutes, 1, 1.5 and 2 hours. Protoporphyrin IX fluorescence kinetics were monitored 
during illumination. Visual skin response was monitored in the first 7 days after PDT and 
assessed as PDT response. The PDT response decreases with decreasing length of the 
dark interval. Only the dark interval of 2 hours showed significantly more damage compared 
to all the other dark intervals investigated (P<0,05 compared to 1.5 hours and P<0.01 
compared to 1 hour, 30 minutes and a single illumination). No relationship could be shown 
between the utilised PpIX fluorescence during the two fold illumination and the PDT 
response. The rate of photobleaching was comparable for the first and the second light 
fraction and not dependent of the length of dark interval used. We conclude that in the skin 
of the hairless mouse the dark interval cannot be reduced below 2 hours without a 
significant reduction in PDT efficacy.  
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Introduction 
Illumination with two light fractions separated by a dark interval of two hours significantly 
improves the therapeutic outcome of 5-aminolevulinc acid based photodynamic therapy 
(ALA-PDT) for human skin cancer 1,2. The higher efficacy of a two-fold illumination scheme 
was initially shown in several pre-clinical studies using either topical or systemic ALA 
administration 3-7.  
In our search for the mechanism behind the increased effectiveness we have shown that 
the PDT dose of the first as well as the second light fraction are important parameters in 
both clinically and in pre clinical models 1,2,6,7. For example, for the hairless mouse model 7 
this means that for a total illumination with 100 J cm-2 at 50 mW cm-2 a first fraction with 5 J 
cm-2 is more effective than 1 J cm-2. The details of the relationship between the dark interval 
and PDT response have not yet been determined. Previously 5,6 we have used intervals of 
two and six hours after topical ALA application and both were effective in pre-clinical 
models. Clinically, we routinely use a two-fold illumination scheme with a 2 hours dark 
interval between illumination at 4 and 6 hours after the start of ALA administration. The 
overall treatment time of this illumination scheme is relatively long. In the present study we 
therefore investigated if we could shorten the dark interval between the two light fractions 
without loss of effectiveness.  
Initially we hypothesised that the increased effectiveness could be explained by the 
utilisation of re-synthesised protoporphyrin IX (PpIX) during the second light fraction after 
photobleaching during the first light fraction. Although we have subsequently shown that the 
amount of re-synthesised PpIX is not a critical factor in either topical or systemic ALA-PDT 
we tested this hypothesis again in the present study 7,8. In the present study we have 
determined the amount of re-synthesised PpIX present at the start of the second light 
fraction and investigated if this is correlated with the response following PDT.  
A second hypothesis for increased effectiveness of a fractionated illumination scheme is 
re-oxygenation of tissue in the dark interval 8-15. Re-oxygenation of tissue during the dark 
interval may increase the generation of singlet oxygen and therefore enhance PDT. The rate 
of photobleaching of PpIX can be used as an indirect marker for the oxygenation of the 
tissue since a higher oxygenation of the tissue will result in faster photobleaching and more 
PDT induced damage 16. To test this hypothesis we have measured the rate of 
photobleaching during each light fraction to investigate if this is correlated to the PDT 
induced damage.  
 
Materials and Methods 
Animal model. Female inbred albino hairless mice (SKH1 HR, Charles River, Someren, 
NL), aged between 8 and 10 weeks old, were included in this study. Prior to treatment 
animals were fed on a diet free of chlorophyll (Hope Farms b.v., Woerden, NL) for a 
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minimum of two weeks in order to remove the autofluorescence emission from mouse skin 
centered on 675 nm attributed to pheophorbide-a. The animal experimental committee of the 
Erasmus University Medical Centre approved the experimental protocol. 
ALA application. Twenty percent 5-aminolaevulinic acid (ALA, Medac, Hamburg, DE) was 
dissolved in 3% carboxymethylcellulose in water. To prevent skin irritation, each ALA 
solution was prepared to approximately pH 4 by the addition NaOH (2 M). One layer of 
gauze (∅ 7 mm) was soaked in 37.5 mg ALA cream and placed on the dorsal skin. The skin 
was not pre-treated before ALA application. A polythene dressing (Tegaderm, 3M, NL) was 
used to occlude the area for 4 hours prior to treatment. Before the application of ALA 
animals received low dose anaesthesia (Hypnorm; fluanisol/fentanyl mixture, Janssen 
Pharmaceutics, BE and Diazepam, Centrafarm b.v., Etten-Leur, NL) to alleviate possible 
anxiety caused by the dressing. 
PDT light delivery and fluorescence detection. Four groups of mice received a 2-fold 
illumination scheme: The first light fraction of 5 J cm-2 light at 50 mW cm-2 was delivered 4 
hours after the administration of ALA. The second light fraction of 95 J cm-2 at 50 mW cm-2 
was delivered after a dark interval of 30 minutes, 1, 1.5 or 2 hours. One group of mice 
received a single illumination (100 J cm-2 at 50 mW cm-2) 4 hours after the administration of 
ALA. Other controls (single illumination at 6 hours after ALA, light only and ALA only) have 
been performed previously and were not repeated 5,6,16. During the therapeutic illumination 
animals were anaesthetised with a combination of 2% Ethrane or Isoflurane (Abbott, 
Amstelveen, NL) oxygen and N2O.  
The experimental set-up used for the PDT illumination and PpIX fluorescence detection 
has been described previously 7. In short; the illumination was performed using the 514 nm 
output from an argon ion laser delivered via a 400 µm fibre and imaged to a 7 mm diameter 
spot of homogeneous profile on the skin of the mouse using a microlens (QLT, Vancouver, 
BC, Canada). All treated animals were used to assess PDT induced damage as described 
below. The kinetics of PpIX fluorescence during illumination was determined in a sub-group 
of 5-6 animals for each illumination group. Scattered excitation light and fluorescence 
emission (550 - 792 nm) was collected from the whole of the illuminated area and focused 
into a 400 µm optical fibre coupled to a fibre optic spectrometer (Ocean Optics, Eerbeek, 
Netherlands). A long pass filter, OG 570 (Melles Griot, Zevenaar, Netherlands) was placed 
in the optical path to bock scattered 514 nm excitation light. Fluorescence emission spectra 
were acquired during illumination at intervals of 5 seconds using an integration time of 1.5 
seconds. In addition, immediately prior to and after treatment a reflectance spectrum was 
acquired using the same spectrograph. The output from a filtered halogen-lamp, (0.15 mW 
cm-2, Stortz, Tüttlingen, Germany), delivered by a second 400 µm fibre and microlens was 
imaged onto the 7 mm diameter treatment spot. A long pass filter (OG 530, Melles Griot, 
Zevenaar, Netherlands) was used to minimise fluorescence excitation of the tissue during 
reflection measurements. Using this set-up both fluorescence and reflectance 
measurements was acquired using the same source-detector geometry. 
A fluorescence image was acquired prior to each period of illumination using a CCD 
camera (Lambert Instruments, Leutingwolde, Germany) to re-locate the area of interrogation 
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and maintain a constant distance between the mouse skin and the head of the 
spectrometer.  
Data analysis. The spectral analysis of fluorescence data acquired in this study was the 
same as we have described previously 6 and based on that described by Foster and his co-
workers 17-19. We have again corrected for changes in tissue optical properties during 
illumination using the method introduced by Wu et al. 20. Since we have only acquired a 
reflectance spectrum immediately before and after each light fraction we have corrected all 
the fluorescence spectra acquired during each illumination period with a linear interpolation 
of these reflectance spectra. Fluorescence emission spectra, corrected for tissue optical 
properties were analyzed as a linear combination of basis fluorescence spectra using single 
value decomposition (SVD) algorithm. The 3 basis fluorescence spectra used in this 
analysis were the autofluorescence of normal mouse skin, PpIX and the hydroxyaldehyde 
chlorin photoproduct of PpIX. In each case basis spectra were determined from the average 
of 10 spectra from 10 animals. The fitted PpIX values measured during illumination was 
normalised to the first measurement and in case of a two-fold illumination to the first 
measurement of each illumination. To determine the initial rate of photobleaching for each 
light fraction the reciprocal of the normalised PpIX fluorescence was calculated and the 
slope over the first 5 J cm-2 was calculated using linear regression fitting 16. 
PDT damage. The PDT response within the illuminated area was assessed daily by two 
independent observers (HSB and APH) blinded from the treatments using a visual skin 
damage scoring system as described previously 21. No change in skin colour was scored as 
0. Scores 1 to 3 were used for increasing discoloration of the skin, 1 meaning minimal 
redness and 3 meaning severe redness. Thin crust formation was scored as 4 and thick 
crust formation was scored as 5. Damage was observed to be inhomogeneous in a number 
of treatments. Photographs were taken regularly in order to determine the degree and 
distribution of damage. The damage score of the total illuminated area in one animal at one 
time point was calculated by scoring areas according to the degree of damage related to the 
contribution to the total illuminated area. The visual skin damage value of a single mouse 
was quantified by integrating the damage score over the first 7 days.  
Statistics. Statistical analysis was performed on the PDT induced damage data using the 
ANOVA followed by a Student-Newman-Keuls test (SNK) and a P-value < 0.05 was 
considered significant. One way analysis of variance is performed to test for trends. 
 
Results 
PDT induced skin damage 
The cumulative visual skin damage score over the first 7 days post ALA-PDT is plotted 
against the duration of the dark interval between the two fractions in Figure 1. All groups 
were treated with a cumulative dose of 100 J cm-2 delivered at 50 mW cm-2. The mean (and 
SD) of the visual skin damage score for the illumination in a single fraction i.e. no dark 
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interval was 16.6 (3.5). Increasing the length of the dark interval resulted in an increasing 
damage score. 
Generally PDT using a single light fraction resulted in discoloration of the skin and 
sometimes in the formation of a thin crust around day 2-3. At day 7 minimal skin damage 
was seen; the skin was slightly thickened and showed minimal discoloration in most 
animals. In contrast PDT using a two-fold illumination with a dark interval of two hours 
resulted in oedema at day one followed by the formation of a thin crust that developed into a 
thick crust between days 2 to 3. At day 7 after PDT this thick crust was detached but the 
tissue underneath still showed severe redness that developed, in some animals, in the 
formation of a second thin crust. The skin damage after a two-fold illumination with shorter 
time intervals also resulted in the formation of crusts, but these were mostly thin and the 
area that responded to PDT was smaller and healed quicker. 
Statistical analysis showed no significant difference in PDT damage between a single 
fraction and dark intervals of 30 minutes and 1 hour. PDT with a dark interval of 1.5 hours 
resulted in significantly more damage compared to PDT with a single light fraction of equal 
cumulative fluence (P<0.05). Treatment with a 2 hours dark interval showed the most severe 
damage compared to all other groups (P<0.05 compared to 1.5 hours and P<0.01 compared 
to 1 hour, 30 minutes and a single illumination). The skin damage shows a trend for 
increasing skin damage with increasing length of dark interval (P< 0.001). 
 
Figure.1. The mean visual skin damage score (quantified by integrating the skin damage score for 
the first 7 days after ALA-PDT) plotted against the length of the dark interval the two light fractions of 5 
and 95 J cm-2. A control group of mice (n=9) received a single illumination of 100 J cm-2 (no dark 
interval) 4 hours after the administration of ALA. The lengths of dark tested were 0.5 (n=12), 1 (n=11), 
1.5 (n=10) and 2 hours (n=15). The maximum skin damage score would be 35. Results are shown as 
mean ± SD. A 2 hour dark interval resulted in significantly more damage compared to the shorter dark 
intervals tested. 
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PpIX fluorescence kinetics during therapy  
The initial fluorescence was 1744 ± 396 counts. The normalised PpIX fluorescence during 
the different two fold illumination schemes with variable dark intervals obtained from the 
recorded fluorescence spectra is shown in Figure 2. PpIX fluorescence was rapidly 
photobleached during the first illumination of 5 J cm-2 at 50 mW cm-2 to 41.8 ± 5.5% of the 
intensity at the start of illumination. In time after the end of this first illumination PpIX 
fluorescence increased again. At 30 minutes this increase was not statistically significant. At 
1, 1.5 and 2 hours the PpIX fluorescence significantly increased (P<0.05) although not 
significantly different from each other (P=0.53) as the kinetics of PpIX re-synthesis plateaus. 
PpIX fluorescence was almost completely photobleached during the second illumination of 
95 J cm-2 delivered at 50 mW cm-2.  
The average rate of photobleaching during that first light fraction of 5 J cm-2 was 
determined from each group of animals and found to be 0.29 ± 0.07 cm2 J-1. The initial rate 
of photobleaching during the second light fraction, delivered after a dark interval of 30 
minutes, 1, 1.5 and 2 hours, were 0.18 ± 0.03, 0.20 ± 0.03, 0.17 ± 0.03, 0.18 ± 0.04 cm2 J-1 
respectively, and not significantly different from each other.  
 
 
 
Figure 2. Mean normalised PpIX fluorescence intensity during 5 different illumination schemes using 
514 nm illumination of normal mouse skin 4 h after the application of ALA. A cumulative fluence of 100 J 
cm-2 was delivered at 50 mW cm-2. In panel (a) the results after a single light fraction is presented (, 
n=5). In panel (b) the results of the two-fold illuminations of 5 and 95 J cm-2 are presented. The results 
of the first light fraction are combined as this was similar for all treatment schemes (, n=21). The 
second fraction was delivered after a dark interval of 0.5 (, n=6), 1 (, n=5), 1.5 (, n=5) and 2 hours 
(○, n=5). The fluorescence intensity is normalised to the PpIX fluorescence at the start of the first light 
fraction. 
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Discussion  
In this study we investigated the relationship between the PDT response and the length 
of the dark interval between the two light fractions of a two-fold illumination scheme. 
Previously we have investigated the use of a longer (6 h) dark interval in both normal skin 
and in UVB induced tumours in the mouse 5. This interval combined with the 4 hours 
preceding the first light fraction results in an overall treatment time in excess of 10 hours. 
This is not easily accommodated into clinical practice. We therefore shortened the dark 
interval from 6 to 2 hours and found that this does not detrimentally affect PDT efficacy in 
our pre clinical model; the two-fold illumination scheme is still significantly more effective 
than the single illumination in mouse skin 6. Clinically we have shown that fractionated PDT 
with a dark interval of two hours results in a significantly better treatment response 
compared to a single illumination 1,2. Star et al. 1 recently published a clinical report on the 
long-term response to ALA-PDT using the two-fold illumination scheme. Efficacy was found 
to be significantly better compared to published results using a single illumination scheme. 
This is despite the fact that this illumination scheme was not optimised; i.e. the total fluence 
was divided over two equal light fractions. After pre-clinically determining the optimum 
illumination scheme 6,7, the clinical protocol was adjusted. One-year follow-up for this 
optimised illumination scheme shows that fractionated ALA-PDT results in a significant 
increase in clinical response 2. 
Figure 1 shows that decreasing the length of the dark interval decreases the PDT 
response. A two-fold illumination with a dark interval of 30 minutes or 1 hour does not result 
in more damage compared to a single fraction illumination. A dark interval of 1.5 hours 
resulted in significantly more damage compared to a single illumination, although no 
difference with the shorter dark intervals could be shown. Only the two hours dark interval 
resulted in significantly the most severe skin damage compared to the shorter intervals 
tested. Therefore we conclude that the dark interval can not be shortened without loss of 
effectiveness and needs to be at least 2 hours. Since our aim was to investigate if we could 
shorten the clinical treatment without loss of effectiveness, we only investigated dark 
intervals shorter than 2 hours. However the results presented here show a significant trend 
for increasing damage with increasing length of dark interval suggesting that it may be 
possible that a dark interval of more than 2 hours results in an even more effective 
treatment. A longer dark interval (6 hours) has been investigated previously 5 but this interval 
was used in combination with an un-optimised illumination scheme in which two equal light 
fractions of 100 J cm-2 were delivered at 50 mW cm-2. This and the fact that the details of the 
data analysis of response were slightly different to that of the present study make a direct 
comparison of data difficult. When response data is assessed in an identical manner the 
mean skin damage (3.5 ± 0.4) is comparable with that of the present study (3.7 ± 0.5). It is 
probable that any enhanced response due to the longer dark interval is negated by the high 
fluence of the first light fraction 7. 
The results obtained lead us to the conclusion that reducing the dark interval below 2 
hours will reduce treatment efficacy. While we have not investigated the effect of intervals 
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shorter then 30 minutes in the present study we have previously investigated the effect of an 
interval of 150 seconds after 3 or 6 J cm-2 at 150 mW cm-2 in the skin 21. Although the 
illumination parameters were not exactly comparable, i.e. fluence rate of 150 mW cm-2 
compared to 50 mW cm-2, this short dark interval did not show a significant increase in PDT 
response in the skin. Furthermore, in a different model using systemic ALA-PDT and 
implanted rhabdomyosarcoma we investigated the use of both short (single interruption of 
150 sec or multiple interruptions of 30 sec on/off) and long dark intervals. Only the long term 
dark interval showed a significant increase in growth delay 4. These results are contradictory 
to data from a series of studies investigating the response of normal colon to ALA-PDT 
using light fractionation that have shown a significant increase in tissue response using short 
dark intervals 12,14,22. Intervals of 150 seconds result in a significant larger area of necrosis in 
the colon when it is illuminated with a bare cut - end fibre in contact with the tissue. The 
mechanism behind this increase in response was found to be due with re-oxygenation 
during the dark interval and associated with vascular reperfusion injury. The reason for the 
apparent contradiction between these findings and those of our studies on short term light 
fractionation is not immediately clear but we note that the radial variations in fluence rate 
that results from an illumination geometry in which a cut-end fibre is placed in contact with 
skin are large 1. We and others have shown that there are strong fluence rate variations in 
PDT response using the photosensitiser PpIX that would make a comparison of data 
between the skin and colon model difficult. 
That a longer rather than a shorter dark interval increases the response was also found 
by Babilas et al. 9. They were unable to show any improvement in the therapeutic outcome 
of the subcutaneously implanted tumour after ALA-PDT using a fractionated illumination 
scheme with a 15 minute dark interval between two light fractions. Furthermore they 
concluded that improvement of the therapeutic effect could only be reached in normal tissue 
and not in tumour tissue. Although the present study is performed on normal tissue we have 
previously shown increased effectiveness of the two-fold illumination in tumour tissue 3-5. 
Also our results in normal mouse skin were the basis for the clinical treatment protocol that 
resulted in an increase in CR after 12 months follow-up for superficial basal cell carcinoma 2. 
To date two hypotheses have been postulated for the mechanism behind the increased 
effectiveness of the two-fold illumination (a) re-oxygenation during the dark interval and (b) 
utilisation of the PpIX re-synthesised during the dark interval during the second light fraction. 
The re-oxygenation of tissue during the dark interval may increase the generation of singlet 
oxygen and therefore enhance PDT. However this argument is mostly used for fractionation 
schemes with short intervals, in the order of seconds and minutes 8-15. In a previous study 
we have shown that the rate of photobleaching is correlated to the oxygenation of tissue; a 
higher oxygenation results in faster photobleaching 16. Here we observe equal rates of 
photobleaching during the second light fraction for all the dark intervals investigated 
therefore it is unlikely that re-oxygenation plays a role in the two-fold illumination with a dark 
interval of two hours. The hypothesis that re-synthesised PpIX that is utilised during the 
second light fraction explains the increased effectiveness is rejected since we measured 
comparable levels for re-synthesised PpIX for the 1 and the 2 hours dark interval whereas 
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the damage for the two hour dark interval is higher. This is supported by the results obtained 
in several previous studies in which we also have shown that there is no relationship 
between the amount of re-synthesised PpIX and PDT induced damage 7,8.  
The mechanism behind the increase in efficacy after the two-fold illumination scheme is 
unclear. The mechanism of cell death after ALA-PDT is complex and heterogeneous. Early 
after the application of ALA PpIX is localised in the mitochondria and it is well known that 
cell death can occur by apoptosis and or necrosis 23. Grebenova et al. 24 have shown that 
during and after illumination the mitochondria of HL 60 cells are damaged resulting in 
cytochrome c release and caspase 3 activation followed by necrosis. Simultaneously a 
secondary route to apoptosis is activated. The present study shows that the timing of the 
second illumination is important. Previously 6,7 we have shown that the fluence delivered in 
the first fraction is important and for hairless mouse skin this is 5 J cm-2 at 50 mW cm-2. A 
single illumination with this fluence results in minimal skin damage at day 1 to 7 after 
treatment (data not shown), despite the fact that almost 60% of the total amount of PpIX is 
photobleached. Gederaas et al. 25 have shown a similar process in vitro. Illumination of WiDr 
cells with a small light fluence induced a rapid increase in [Ca2+] due to influx of calcium from 
the medium, without substantial cell death. Numerous cellular and tissue responses are 
initiated by PDT that may or may not result in cell death. These and potentially other cellular 
processes may be initiated in cells surviving the first light fraction and most likely are 
developing over time. The fact that the timing of the second light fraction is an important 
factor implies that these cellular processes may have an influence on the susceptibility of 
cells to PDT. Whether these processes are important for the understanding of the increased 
effect after the two-fold illumination is unclear and needs further investigation. 
In conclusion we have shown that the overall treatment time for ALA-PDT using the two-
fold illumination can not be shortened without a reduction in efficacy. The most effective 
illumination scheme for topical ALA-PDT on hairless mouse skin found to date is a 2 hour 
dark interval between a first fluence of 5 J cm-2 and a second fluence of 95 J cm-2 delivered 
at a fluence rate of 50 mW cm-2.  
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Abstract 
Background/purpose: A significant increase in the number of circulating and tumour 
neutrophils immediately after therapy was observed while investigating the increase in 
response of tissues to aminolevulinic acid based photodynamic therapy (ALA-PDT) using a 
two-fold illumination scheme with a prolonged dark interval. The action of (tumour) 
neutrophils is an important therapeutic adjunct to the deposition of singlet oxygen within the 
treatment volume, for many photosensitisers. It is not known if those phagocytes contribute 
to the improved outcome of ALA-PDT. In this study we investigated the role of neutrophils in 
the response to PDT using systemic ALA with and without light fractionation. 
Methods: Rhabdomyosarcoma, transplanted in the thigh of female WAG/Rij rats were 
illuminated transdermally using 633 nm light following i.v. administration of 200 mg kg-1 ALA. 
The pharmacokinetics of PpIX within the tumour tissue during therapy were determined to 
compare with that observed in other models for topical administration of ALA. PDT was 
performed under immunologically normal or neutropenic conditions using various 
illumination schemes. The number of neutrophils in tumour and in the circulation were 
determined as a function of time after treatment and compared to growth delay of each 
scheme. 
Results: Fluorescence spectroscopy revealed similar pharmacokinetics of PpIX to those 
observed during and after topical ALA-PDT. The number of neutrophils within the illuminated 
tumour and in the circulation increased significantly following therapy. This increase in the 
number of neutrophils was associated with an increase in the efficacy of therapy: the more 
effective the therapy the greater the increase in tumour and blood neutrophils. 
Administration of anti granulocyte serum treatment prevented the influx of neutrophils after 
ALA-PDT, but did not lead to a significant decrease in the efficacy of the PDT treatment on 
the growth of the tumour for any illumination scheme investigated. 
Conclusion: These results indicate that the magnitude of damage inflicted on the tumour 
by ALA-PDT does not depend on the presence of neutrophils in the tumour or circulation 
and that the role of neutrophils in ALA-PDT is much less important than in PDT using other 
photosensitisers. These data contribute to the understanding of the mechanism of response 
of tissue to systemic ALA-PDT. 
 
 The role of neutrophils in ALA-PDT 
 71 
Introduction 
Neutrophils are closely associated with the response of tissues to photodynamic therapy 
(PDT) using photosensitisers like Npe6, mTHPC, HPPH and Photofrin 1-6. After PDT the 
number of neutrophils in illuminated tumour tissue is increased. The presence of (activated) 
neutrophils provides an adjunct to the therapeutic PDT dose that originates from the 
deposition of reactive oxygen species and is associated with a subsequent decrease in 
tumour volume following therapy. When PDT is performed under neutropenia tumour 
regression is significantly reduced. We have shown for example that the effectiveness of 
Photofrin-PDT on the rat rhabdomyosarcoma is decreased under neutropenic conditions 6. 
The role of neutrophils in PDT using 5-aminolevulinic-acid (ALA) is not known and the 
subject of the present study. 
ALA-PDT is widely used as an experimental therapy that is now recognised as a first line 
treatment for a number of (pre-) malignant cutaneous indications. We have shown in 
different animal models and using systemic and topical ALA administration that the efficacy 
of ALA-PDT is significantly increased if a two-fold illumination scheme with a dark interval of 
more than one hour was applied instead of a single illumination 7-10. For example, after 
systemic administration of ALA, the growth of the rat rhabdomyosarcoma is significantly 
delayed using a fractionated illumination with a dark interval of 75 minutes compared with a 
single illumination 8. We are investigating the mechanism behind this increase in 
effectiveness. During PDT the endogenous photosensitiser protoporphyrin IX (PpIX) is 
rapidly photobleached. After illumination new PpIX is formed which we have shown can be 
utilised in a second illumination 7,11. However, the increase in PpIX during the dark interval is 
relatively small and therefore not considered as the main mechanism behind the increased 
effectiveness. While investigating the histological response of rat rhabdomyosarcoma to 
ALA-PDT using a fractionated illumination scheme we observed an increase in the number 
of tumour neutrophils immediately after therapy. We therefore designed the present study to 
investigate the role of neutrophils in the response to PDT with ALA with and without light 
fractionation to determine if neutrophils contribute to the increase in the efficacy of ALA-
PDT. Here we perform ALA-PDT on rat rhabdomyosarcoma under normal and neutropenic 
conditions and determine if the outcome is dependent on the number of neutrophils in blood 
and in tumour tissue. 
 
Materials and Methods 
Tumour model. Rat rhabdomyosarcoma, originally derived from a syngeneic 
undifferentiated rhabdomyosarcoma, was maintained by subcutaneously transplanting small 
pieces of tumour (∼ 1 mm³) on the thigh of female WAG/Rij rats (12 - 13 weeks old). Since 
the tumours were grown subcutaneously it was possible to monitor tumour growth daily by 
measuring the three orthogonal diameters using callipers and the tumour volume was 
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estimated by the formula of an ellipsoid, V=(pi/6)∗D1∗D2∗D3. Tumours were randomly 
assigned to control or treatment groups when their volume reached 50 mm³. “The 
Committee on Animal Research” of the Erasmus University of Rotterdam approved the 
animal experimental protocol. 
ALA. ALA (Medac, Wedel, Germany) was dissolved in sterile NaCL solution 0.9%. A 
freshly prepared ALA solution (90 mg ml-1) was administered i.v. to a dose of 200 mg kg-1 
body weight under ethrane/O2/N2O anaesthesia. After administration the animals were kept 
under subdued light for the first 24 hours 
PDT light delivery. PDT was carried out under general anaesthesia using intra muscular 
Hypnorm, 0.5 ml kg-1 (Janssen Pharmaceutica, Tilburg, The Netherlands) and diazepam, 2.5 
ml kg-1. Prior to the light treatment the skin overlying the tumour was shaved. The animals 
were placed on a temperature-controlled stage and covered with a black polythene mask. 
Tumours were transdermally illuminated with a 10 mm diameter plane parallel light beam 
(633 nm) at a fluence rate of 100 mW cm-2. 
Fluorescence spectroscopy. In separate series of animals the pharmacokinetics of PpIX 
fluorescence in rhabdomyosarcoma was determined. This was achieved by resecting the 
skin overlying the tumour and placing a fibre-optic probe (approximately 800 µm in diameter) 
gently in contact with its upper surface. The filtered output from a Xenon arc lamp (400 – 
410 nm) was coupled into a 400 µm optical fibre was used to excite PpIX fluorescence in the 
uppermost layers of the top of each tumour. Scattered excitation light and fluorescence 
emission (550 - 792 nm) were collected using a second 400 µm immediately adjacent to the 
delivery fibre and coupled to a fibre optic spectrometer (Oriel Instaspec IV and Oriel ms 257, 
Heidelberg, Germany). A long pass filter, OG 520 (Melles Griot, Zevenaar, Netherlands) was 
placed in the optical path to block scattered excitation light. Similar spectra were acquired 
from the underside of the skin overlying the tumour and from muscle adjacent to the base of 
the tumour. In all cases the intensity of the excitation illumination was approximately 100 µW 
cm-2 and acquisition times were of the order of 2 seconds. This corresponds to a light 
fluence of less than 0.2 µJ cm-2 for each tumour. 
Fluorescence spectra were acquired every 30 minutes following ALA administration until 
4 h and then again 5, 6, 16 ands 24 h after ALA administration. The kinetics of PpIX 
fluorescence following illumination were determined in a further 4 groups of animals that 
received 10, 20, 50 and 100 J cm-2, 1 h after the administration of ALA, that corresponds to 
the time point of the first light fraction in the present study. Fluorescence was acquired 45 
and 90 minutes after the end of illumination where the last time point would be the one 
before the second light fraction in a two-fold illumination scheme. An average 
autofluorescence spectrum, determined in a separate series of animals that did not receive 
ALA, was subtracted from the PpIX fluorescence emission. Spectral analysis of data 
acquired in this study were analysed as a linear combination of basis fluorescence spectra 
using single value decomposition as described previously 12. 
Neutropenia. Neutropenia was induced by treatment with anti-granulocyte serum (AGS, 
absorbed polyclonal rabbit anti rat polymorphonuclear cells, Accurate, Westbury, NY, USA). 
The first dose (0.2 ml AGS, tenfold diluted with saline) was injected i.v. 30 minutes before 
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illumination, followed by an i.p. injection of 0.2 ml tenfold diluted AGS at day 1, 4 and 7 as 
long as the animals were in experiment. Blood samples were collected just before each AGS 
injection using either an orbital puncture or a tail vein puncture (Multivette® 600k3e blood 
collection system, Starstedt, Germany). The amount of neutrophils in whole blood was 
determined using the ADVIA® 120 Haematology System and the multi-species software 
application (Bayer B.V. HealthCare Diagnostics, Mijdrecht, The Netherlands).  
Neutrophils in blood and tumour after ALA-PDT. The systemic and local neutrophilic 
response to ALA-PDT was determined by collecting blood and tumour samples before ALA 
administration and at 6, 16 hrs, 1, 2 and 4 days after start of photodynamic therapy. Animals 
were treated according to 6 different treatment schemes (n=2-5 per group). The first two 
treatment schemes served as control and received only ALA and no light under normal and 
neutropenic conditions. The second two treatment schemes were the single illumination 
scheme, i.e., a single light fraction of 100 J cm-2 at 100 mW cm-2 one hour after ALA 
administration, under normal and neutropenic conditions. The last two treatment schemes 
were a two-fold illumination scheme, i.e., two light fractions of 100 J cm-2 at 100 mW cm-2 
delivered at 1 and at 2.5 hours after ALA administration, under normal condition and under 
neutropenia induced before the first illumination. Blood samples were collected and the 
amount of neutrophils was determined as described above. Tumours were harvested, snap 
frozen and dissolved to determine the concentration of free- and cell-associated 
myeloperoxidase (MPO) per gram wet tissue as described below. 
Assessment of MPO activity. As an index of the number of neutrophils the tumour 
myeloperoxidase (MPO) content was assessed. We adapted the biochemical assay 
described by Graff et al. 13 for tumour tissue. To overcome the interference of endogenous 
(enzymatic and nonenzymatic) reductants two wash steps in the presence of N-
ethylmaleimide (NEM) after homogenisation were introduced. To inhibit the 
pseudoperoxidase activity of remaining haemoglobin derived from the increasing numbers of 
tumour associated erythrocytes upon PDT hexadecyltrimethylammonium bromide (HTAB) 
was added to the assay mixture.  
In short, the tumour was excised, weighed and homogenised in 3 volumes (v/w) of ice-
cold modified RIPA buffer (containing 1% NP40, 0.25% sodiumdeoxycholate, 1 µg ml-1 
aprotinin, leupeptin and pepstatin, 50 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 1 mM 
PMSF, 1 mM NaVO4, and 1 mM NaF; pH 7.4) using a Polytron homogeniser. The 
homogenate was centrifuged at 12,000 g for 30 min at 4°C. Next, the supernatant was 
collected to determine free MPO. MPO can only be liberated from the primary granules of 
the neutrophil by treating with the ionic detergent HTAB 14. Thus any MPO in the 
supernatant was apparently secreted by activated neutrophils in the tumour before its 
excision 15. The pellet was resuspended in ice-cold 50 mM sodium phosphate buffer (pH 
7.4) containing 10 mM NEM, centrifuged again, and if the number of erythrocytes was high, 
resuspended in ammoniumchloride for 20 min at 4°C and centrifuged. The pellet was 
sonicated in 50 mM sodium phosphate buffer (pH 6.0) containing 0.5% HTAB (PB-HTAB) by 
three bursts of 10 sec, subjected to three cycles of freezing and thawing, and centrifuged 
(12,000 g, 30 min, 4°C). The MPO activity was determined by its ability to catalyze the 
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hydrogen peroxide-dependent oxidation of o-dianisidine (o-DA). The reaction was started by 
the addition of 100 µl pre-warmed substrate solution (hydrogen peroxide and o-DA) to 50 µl 
aliquots of the serially diluted supernatant in PB mixed with 50 µl PB-HTAB (final 
concentrations: 3.43 mM HTAB, 0.35 mM hydrogen peroxide, and 0.63 mM o-DA). We 
found that under those conditions optimal reaction rates were attained, while the 
pseudoenzymic activity of haemo- and myoglobin was inhibited by a factor of > 100. The 
change in absorbance at 450 nm was measured during 2 min at 37°C in a thermostatted 
microplatereader (Thermomax, Sopachem, Driebergen, The Netherlands). Initial rates of 
enzyme activity were determined from the linear part of the curve, and converted to enzyme 
units using the molar extinction coefficient of o-DA 13 of 10,062 M-1 cm-1. We defined one 
unit of MPO as the amount of enzyme that oxidises o-DA at a rate of 1 µmol min-1 under the 
present assay conditions. Under those assay conditions 1 U of bovine MPO (Sigma) 
catalyzes the oxidation of o-DA at a rate of 0.15 µmol min-1. Enzymatic MPO activity was 
routinely confirmed by its complete inhibition with 1 mM sodium cyanide or 10 mM sodium 
azide.  
To establish the relationship between neutrophil number and MPO activity, in eight 
experiments, the amount of MPO recovered from rat blood neutrophils was determined and 
amounted to 5.70 (± 0.87) x10-7 U MPO per cell. This is similar to the value of 5.04x10-7 U 
reported earlier by Bradley et al. 14. 
Response to ALA-PDT. The tumour response to ALA-PDT was determined separately in 
a total of 7 groups of animals (n=5). The first four groups were treated as described before, 
i.e., the control and the single illumination groups. The last three groups were treated with a 
two-fold illumination scheme, i.e., two light fractions of 100 J cm-2 at 100 mW cm-2 delivered 
at 1 and at 2.5 hours after ALA administration, under normal and neutropenic condition 
started either before the first or second illumination. 
Tumour re-growth after treatment was monitored as described before 8. In short, every 1 
or 2 days following therapy the tumour volume was measured until the size of the tumour 
had reached 5 times its treatment volume. From these measurements the time point after 
PDT at which each tumour reached 100, 200, 300, 400 and 500% of its treatment volume 
was calculated and used to determine the mean time point in each treatment group. The 
mean tumour volume doubling time (VDT) defined as the number of days it took the tumour 
to double its pre-treatment volume determined the effectiveness of each treatment scheme.  
Statistical analysis. Results are presented as means ± SD. The number of neutrophils in 
blood of rats was always compared to the pre treatment value. To evaluate the statistical 
significance of differences between means student-t test or analysis of variance was used 
followed where appropriate by a Student-Newman-Keuls test. A P value of less than 0.05 
was considered to be statistically significant.  
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Results 
PpIX fluorescence pharmacokinetics 
Figure 1a shows the kinetics of PpIX fluorescence in rhabdomyosarcoma, normal skin 
overlying the tumour and in muscle adjacent to the tumour, following the administration of 
ALA. PpIX fluorescence peaked in tumour and muscle between 2 and 3 hours after the 
administration of ALA. At this time point there was approximately 3 times the fluorescence 
intensity in tumour compared to normal skin and muscle. The peak in PpIX fluorescence in 
normal skin was broader and occurred somewhat later, 4 hrs after the administration of ALA.  
Figure 1b shows the relationship between the normal kinetics of PpIX fluorescence and 
those following illumination, 1 h after the administration of ALA. Illumination with increasing 
fluence (10, 20, 50 and 100 J cm-2) at constant fluence rate resulted in progressively more 
PpIX photobleaching during illumination and a concomitant decrease in both the rate and 
extent of re-synthesis of PpIX after the illumination. The amount of PpIX re-synthesis in the 
superficial layers of the tumour following a first light fraction of 100 J cm-2 (i.e. the light 
fluence used in the two-fold illumination scheme) was relatively small. Thirty one percent of 
that present immediately before the first light fraction (1 h after ALA) was available at the 
end of the dark interval. This is less than 10% of that present before a single illumination 2.5 
hours after the administration of ALA.  
Figure 1. (a) The pharmacokinetics of PpIX following administration of 200 mg kg-1 ALA (i.v.) 
administration in () rhabdomyosarcoma; () normal muscle; and in (▲) skin overlying the tumour. (b) 
The return in PpIX fluorescence in rhabdomyosarcoma following transdermal illumination (using 633 nm 
radiation at an irradiance of 100 mW cm-2 at 1 hour after ALA administration) to a light dose of (■) 10; 
() 20; () 50 and () 100 J cm-2, respectively, compared to the normal pharmacokinetics () shown in 
(a). Results are shown as mean ± S.D. and n = 5. 
 
Neutrophil response to ALA-PDT 
The mean normal count of neutrophils in blood of all measured tumour-bearing WAG/Rij 
rats was found to be 1.29 ± 0.48 109 per litre blood. Treatment of the subcutaneously 
growing tumour with ALA-PDT resulted in a significant increase in the number of blood 
neutrophils during the first several days after illumination with the highest numbers at 16 and 
24 hours after the start of PDT illumination (Figure 2a). This increase was significantly  
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Figure 2. The time course of the number of neutrophils in the circulation of normal (a) and 
neutropenic rats (b) upon PDT using two different illumination regimens; control (white bar), single 
illumination (grey bar) and two-fold illumination (black bar). AGS was administered 30 minutes after ALA 
injection. Results are shown as mean ± S.D. 
Figure 3. The time course of the number of neutrophils in the tumour of normal (a) and neutropenic 
rats (b) upon PDT using two different illumination regimens; control (white bar), single illumination (grey 
bar) and two-fold illumination (black bar). AGS was administered 30 minutes after ALA injection. Results 
are shown as mean ± S.D.  
Figure 4. The time course of the release of myeloperoxidase (MPO) in tumours of normal (a) and 
neutropenic rats (b) upon PDT using two different illumination regimens; control (white bar), single 
illumination (grey bar) and two-fold illumination (black bar). AGS was administered 30 minutes after ALA 
injection. Results are shown as mean ± S.D. 
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higher when tumours were treated with the two-fold illumination scheme. At 16 hours the 
number of blood neutrophils increased 4.2 ± 2.6 fold after a single illumination of the tumour, 
and increased even further to a factor of 6.0 ± 2.5 after using the two-fold illumination 
scheme (P =0.02 and 0.0001 resp.).  
AGS treatment resulted in a decrease in circulating neutrophils to 11.5 ± 6.7% within 30 
minutes after the first AGS injection (P <0.0001). Using NaCl instead of AGS resulted in a 
decrease to 91.6 ± 39.8% (P =0.67). At day 1 and day 4 of the AGS treatment the number of 
neutrophils increased a little to respectively 24.8 ± 15.6 and 26.5 ± 11.5% (P = 0.001 and 
0.01 compared to control). The time course of the number of neutrophils in the circulation of 
AGS-treated animals post ALA-PDT is shown in Figure 2b. After illumination of the tumour in 
neutropenic rats a slight elevation in the concentration of circulating neutrophils was found 
that never exceeded the normal pre treatment level. Also, no difference was found between 
the two different illumination schemes. 
The influx of neutrophils in treated tumours was assessed by determining the amount of 
cell-associated MPO at different time points after ALA-PDT. The normal amount of 
neutrophils in the rhabdomyosarcoma was found to be 1.15 ± 0.7 106 per gram tumour. The 
accumulation of neutrophils in the tumour after ALA-PDT was maximal at 24 hours in 
immunocompetent rats (Figure 3a). Again, the influx of neutrophils was significantly higher in 
tumours treated with the two-fold illumination scheme amounting to an increase factor of 4.8 
compared to 3.3 after a single illumination (P <0.0001 and P <0.001 compared to control). In 
rats treated by AGS the number of neutrophils in the tumour lesion remained within the pre 
treatment range after ALA-PDT (Figure 3b). Compared to the response in 
immunocompetent rats, the neutrophilic influx at 24 hours post treatment was depressed by 
a factor of 2.9 (P=0.008).  
Upon activation, neutrophils release MPO 15. In the tumours of immunocompetent rats the 
single illumination did not lead to a significant increase in the amount of free MPO in time 
after ALA-PDT (Figure 4a). The two-fold illumination, however, resulted in a significantly 
higher release of MPO in time from day 1 up to at least day 4 (P<0.0001 compared to 
control and P=0.004 compared to single illumination at day 1). Contrary, ALA-PDT did not 
elicited MPO release in tumours from AGS-treated rats (Figure 4b).  
 
Tumour response to ALA-PDT 
To study if the neutrophils in the circulation and/or tumour lesion contribute to the efficacy 
of ALA-PDT the growth delays of tumours treated under normal and neutropenic conditions 
were compared (Figure 5). The results show that administration of AGS did not affect 
tumour growth and the normal treatment volume doubling time (VDT) was 1.10 ± 0.11 days. 
A single illumination one hour after ALA administration with 100 J cm-2 at 100 mW cm-2, 
resulted in a significantly prolonged treatment VDT of 4.08 ± 1.62 days (P=0.003). The VDT 
increased to a similar level under neutropenic conditions, i.e., to 3.43 ± 1.89 days (no 
significant difference between the two conditions). 
A two-fold illumination at 1 and 2.5 hours after ALA administration with 100 + 100 J cm-2 
at 100 mW cm-2, resulted in a significantly longer growth delay of 8.93 ± 4.77 days (P=0.006 
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compared to control). But again the increase in VDT did not differ from the increase in VDT 
when the illumination was performed under neutropenic condition regardless if that condition 
was evoked before the first or second illumination, respectively to 8.70 ± 4.67 and 8.82 ± 
3.95 days.  
Figure 5. Growth delay of the rhabdomyosarcoma of normal (solid lines) and neutropenic rats 
(dashed lines) after ALA-PDT using two different illumination regimens; control (ALA only,  and ), 
single illumination (1 hr, 100 J cm-2 at 100 mW cm-2, ■ and ) and two-fold illumination (1 + 2.5 hrs, 
100+100 J cm-2 at 100 mW cm-2, ▲,  and ▲). Neutropenia was induced before the first () or second 
illumination (▲). Results are shown as mean ± S.E.M. with n=5 per group. 
 
Discussion 
The kinetics of PpIX fluorescence following systemic ALA-PDT in transplanted 
rhabdomyosarcoma were very similar to those that we have previously reported during 
topical ALA-PDT in normal mouse skin 12,15. Again it is important to stress that while the 
original rationale for performing a two-fold illumination scheme was the utilisation of the re 
synthesised PpIX at the start of the second illumination the data presented earlier and here 
shows that this is not the case. In fact significantly more (~2.2 times) PpIX is available for a 
single illumination 2.5 hrs after the administration of ALA compared to the total amount of 
PpIX utilised in a two-fold illumination of 100+100 J cm-2 1 and 2.5 hrs after the 
administration of ALA (P<0.001). To find out which (alternative) mechanism underlies the 
improved outcome of ALA-PDT, we investigated the contribution of neutrophils to the 
efficacy of ALA-PDT and in particular their effect on the response of tumour tissue to a two-
fold illumination scheme. First we analysed the neutrophilic response to ALA-PDT in 
immunocompetent rats. The number of neutrophils increased in the circulation and locally in 
the tumour with a maximum respectively at 16 hours and 1 day after the start of therapy. 
The neutrophils that accumulated in the tumour became activated as reflected by the 
release of MPO enzyme. Furthermore, the magnitude of the neutrophilic increase and 
activation was associated with the severity of the ALA-PDT treatment, i.e., a higher increase 
after the more effective two-fold illumination of the tumour.  
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The increase in the number of circulating neutrophils after ALA-PDT was higher and a 
little later in time compared to Photofrin mediated PDT. Cecic et al. reported a 2.5-fold and a 
4-fold increase of circulating neutrophils in mice treated with Photofrin-PDT depending on 
the treated tumour 2. This increase was seen up to 10 hours after therapy and at 24 hours 
the amount of neutrophils was decreasing again. In the present study we show a 4.9-fold 
increase after a single and a 6.7-fold increase after a two-fold illumination of the 
rhabdomyosarcoma tumour in rats at 16 hours.  
The increase in the number of neutrophils in tumour after ALA-PDT was comparable or 
even larger than following Photofrin or HPPH-PDT. Tumour associated neutrophils 
increased by a factor of 3 using Photofrin-based PDT and HPPH-PDT at respectively 10 
hours and 4 hours up to 3 days post PDT 2,4. We found a 3.3-fold increase in tumours after a 
single illumination with ALA-PDT and even a 4.8-fold increase after a two-fold illumination at 
24 hours. 
The underlying mechanism of the accumulation of neutrophils in the circulation and at the 
lesion site was not studied here. Gollnick et al. has shown that neutrophils migrate into the 
treated area in a response to the chemokines MIP-2 and KC and the increased adhesion 
molecule expression of ICAM and E-selectin after HPPH-PDT 4. The ischaemia and 
reperfusion injury caused by Photofrin-PDT might be the proinflammatory insult that causes 
the release of those chemokines 17,18. The magnitude of the inflammatory reaction upon 
PDT is highly dependent on the therapeutic parameters 5. Previously, we as well as others 
have shown that neutrophils are involved in the response of tissues to PDT, i.e. depletion of 
neutrophils results in less damage 6,17. However, from the recent work of Henderson et al. 
using HPPH-PDT it became clear that the inflammatory response is not critical to tumour 
control 5. In fact, they state that the crucial factor for optimal PDT is the preservation of a 
significant level of tumour oxygenation. Under optimal PDT treatment conditions achieved by 
a low fluence rate at a sufficient high fluence, tumour cells die by apoptosis and do not have 
a chance to elicit an inflammatory response by the release of MIP-2. Only after sub-optimal 
PDT the affected and surviving tumour cells have time to evoke an inflammation that 
contributes to a better outcome of the treatment 5.  
In the present study we found that in neutropenic rats the efficacy of ALA-PDT using a 
single or a two-fold illumination scheme did not differ from those in immunocompetent rats. 
Apparently and contradictory to earlier findings using other photosensitisers, neutrophils do 
not appear to contribute significantly to the efficacy of systemic ALA-PDT. Despite the fact 
that a regimen-dependent inflammatory and treatment outcome under ALA-PDT was found, 
suggesting a direct relationship between the two, depleting the neutrophils under both light 
regimens did not decrease the efficacy of the PDT treatment. Why neutrophils do not 
contribute to the efficacy of ALA-PDT of this type of tumour is not immediately clear. If 
tumour cells have been lethally injured by PDT neutrophils entering the lesion site will be 
redundant and depletion of neutrophils will not significantly affect the therapeutic outcome. 
On the other hand, if tumour cells that have been affected only sub-lethally by ALA-PDT do 
not express the adequate cellular adhesion molecules on their cell membrane they may not 
be recognised by the neutrophils of the inflammatory exudate 19.  
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The evidence found here for a bystander role of neutrophils in ALA-PDT means that other 
factors should be taken into consideration to explain the response of tissues to ALA-PDT. 
Besides the fact that ALA-PDT can directly kill the tumour cells, such a factor could be 
complement activation 20. Of relevance might also be the timing of the inflammatory 
response that became maximal between 16 and 24 hours after treatment. Obviously, further 
study is warranted to clarify this issue. 
In summary, we have shown a systemic and local increase in the number of neutrophils 
in time after ALA-PDT of a rat rhabdomyosarcoma. The magnitude of the numerical increase 
of neutrophils is directly dependent on the severity of the illumination regimen. However, 
those neutrophils do not contribute significantly to the efficacy of systemic ALA-PDT and 
apparently only play a bystander role. The role of neutrophils in clinical PDT using topical 
ALA may be an area for future investigation.  
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Abstract 
Protoporphyrin IX (PpIX) fluorescence that is bleached during aminolevulinic acid (ALA) 
mediated photodynamic therapy (PDT) increases again in time after treatment. In the 
present study we investigated if this increase in PpIX fluorescence after illumination is the 
result of local re-synthesis or of systemic redistribution of PpIX. We studied the spatial 
distribution of PpIX after PDT with and without cooling using the skin-fold observation 
chamber model. We were unable to show a correlation between the local PpIX fluorescence 
increase and the distance from a blood vessel. The spatial distribution of PpIX fluorescence 
within normal tissue or tumour is not changed in response to the illumination. These 
observations suggest that there is no diffusion of PpIX into the treated tissue. Cooling the 
tissue to 12°C, a temperature at which PpIX synthesis is inhibited, inhibited the PpIX 
fluorescence increase normally observed after illumination. We also found a strong 
correlation between local PpIX photobleaching during illumination and the fluorescence 
intensity one hour after illumination similar to what we have observed in patients treated with 
ALA-PDT. Therefore we conclude that the increase in PpIX fluorescence after illumination is 
due to local cellular re-synthesis. 
Local resynthesis of PpIX after PDT 
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Introduction 
The clinical response of human skin cancer to photodynamic therapy (PDT) using 
aminolevulinic acid (ALA) is significantly improved after illumination with two light fractions 
separated by a dark interval of two hours 1,2. The increased efficacy of a two-fold illumination 
scheme was first shown in studies using pre-clinical animal models 3-6. This type of light 
fractionation has been developed to utilise the PpIX fluorescence that returns after 
illumination 1,7-11. The increased effectiveness of the two-fold illumination, however, can not 
simply be explained by the increase in PpIX fluorescence that is utilised as we found no 
relationship between the total amount of PpIX utilised and the efficacy 3,4,6,10. Still, the return 
in fluorescence is important in some way as the photosensitiser is the start of the 
photochemical reaction initiating the damage. 
While the kinetics and localisation of PpIX fluorescence after ALA administration have 
been investigated extensively 5,9-17 only a few studies were performed investigating the PpIX 
fluorescence kinetics after illumination 5,9-11 and little is known about the spatial distribution 
or the source of PpIX fluorescence after illumination. In both preclinical 3-6,9-11 and  
clinical 1,7,18 circumstances PpIX fluorescence increases again after illumination. Orenstein 
et al. 18 even showed a difference in the amount of return in PpIX fluorescence for superficial 
and nodular BCC and suggested that this is due to a continued PpIX production in the 
deeper located areas and diffusion of PpIX to the surface. The increase in fluorescence after 
illumination could either be the result of local PpIX re-synthesis or of systemic PpIX 
redistribution or a combination of both. It is important to determine this as it may have 
important implications on the cellular localisation of the photosensitiser and the possible 
mechanism of action to the two-fold illumination as a result of that 19.  
Systemic redistribution requires transport of porphyrins through the circulation, followed 
by passive diffusion of PpIX from the vasculature into the tissue. In this case fluorescence 
images recorded in time after illumination should show a gradient of fluorescence around the 
blood vessels. Henderson et al. 16 has shown circulating porphyrins after topical ALA 
application on mouse skin showing that systemic redistribution of PpIX is theoretically 
possible. Local re-synthesis, on the other hand, requires local enzyme activity. Several 
investigators have shown that the enzymatic conversion of ALA to PpIX is inhibited at a 
temperature below 15°C. 20,21. In case of local re-synthesis cooling the tissue below this 
temperature should inhibit the fluorescence increase in time after PDT.  
In the present study we determined the source of the return in PpIX fluorescence after 
illumination in the skin-fold observation chamber model. In the chamber we can distinguish 
tumour, vessels and normal tissue allowing us to investigate the spatial distribution of PpIX 
fluorescence after ALA-PDT in a 2-dimensional geometry. We have determined the 
relationship between the fluorescence kinetics at different distances from the vessel and the 
vascular response during and immediately after PDT. We have also determined the effect of 
cooling the tissue to a temperature at which the enzymatic conversion of ALA to PpIX is 
inhibited 20,21 on the fluorescence kinetics after illumination. While we hypothesised in a 
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previous study that the tissue localisation of PpIX fluorescence might be involved in the 
mechanism of action behind the increased effectiveness of ALA-PDT 6 we also investigated 
the spatial distribution of PpIX fluorescence within tissue and determined the influence of the 
first light fraction on the fluorescence distribution after illumination. 
 
Materials and Methods 
Animal model. Skin-fold observation chambers were prepared using a slightly modified 
technique to that that has been described previously 24,26. Briefly, the chamber was prepared 
on the back of female 5 weeks old fisher-344 rats in four operations spread over a period of 
two weeks. As a result of these operations a thin layer of subcutus tissue was clamped 
between mica and a cover slide without obstruction of the circulation (Figure 1a). All 
operations were carried out under general Ethrane/O2/N2O anaesthesia. In the first 
operation sterile air (12 ml) was subcutaneously injected on the back of the rat to gently 
separate the skin from the underlying tissues. In the second operation, a few days later, a 
home made plastic ring and cover slide was positioned under the skin above the 
subcutaneous tissue containing vessels. The air of the first operation is still below this 
subcutaneous tissue. In the third operation, one week later, the skin was folded, prepared 
and fixed in the splint so that it can be placed under the microscope for observation. In the 
final operation the R3230AC tumour was transplanted in the layer of normal tissue, which 
could be reached by unscrewing the cover slide on top of the chamber. Within four to eight 
days the chamber was ready for treatment when the transplanted tumour was supported by 
blood vessels and had grown. 
 
 
Figure 1. (a) A schematic drawing of the chamber on the back of a rat. (b) Typical transmission 
image of the skin-fold observation chamber, diameter 1 cm. Ideally the chamber consists of different 
types of tissues and vessels; tumour cells and capillaries (T), normal cells and capillaries (N), arterioles 
(A), venules (V). The white bar represents 1 mm. (c) A typical example of the different regions of 
interest in which the fluorescence was determined. The different regions were: normal tissue, vascular 
tissue accompanied by the two perpendicular regions in which the correlation to the distance from the 
vessels was determined and tumour tissue including the four smaller areas in which the heterogeneity 
within the tumour was determined. 
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Ideally the chamber contained fat cells and capillaries over an area of approximately 1 cm 
in diameter with some supporting arterioles and venules within. In a small number of animals 
one or more types of tissue was not available. Table 1 shows the actual number of animals 
used per tissue type for each experimental group. The animal experiments committee of the 
Erasmus University Medical Centre approved the experimental protocol  
Experimental design. The animals were divided over five experimental groups. The PpIX 
fluorescence kinetics after ALA administration was determined in the first group. In three 
groups the increase in PpIX fluorescence in time after ALA-PDT was investigated. PDT was 
performed one hour after systemic ALA administration, the time point of the first illumination 
of a two-fold illumination scheme, using 514 nm light at a fluence rate of 50 mW cm-2 to a 
fluence of 5, 50 or 100 J cm-2. Fluorescence and transmission images were recorded every 
30 minutes until 2.5 hours after the end of illumination. In the final group the effect of cooling 
on the PpIX fluorescence increase after ALA-PDT was investigated. PDT was performed 
one hour after ALA administration using 514 nm light at a fluence rate of 50 mW cm-2 to a 
fluence of 100 J cm-2. Immediately after completion of PDT the tissue was cooled to 10-12°C 
for one hour. Thereafter the temperature of tissue was allowed to return to normal (28 -
30°C). Fluorescence and transmission images were recorded before and after PDT after 
cooling and 30 minutes after the temperature had returned to normal. 
 
Table 1. The number of animals used for each tissue type 
Fluence Normal Tumour Arterioles Venules 
0 J cm-2 3 3 3 3 
5 J cm-2 8 6 7 8 
50 J cm-2 4 4 4 4 
100 J cm-2 7 6 6 7 
100 J cm-2 cool 10 7 6 10 
 
ALA preparation and administration. 5-aminolevulinic acid hydrochloride (ALA, Medac, 
Wedel, Germany) was dissolved in sterile 0.9% NaCl infusion solution to a concentration of 
90 mg ml-1. A freshly prepared ALA solution was administered i.v. to a dose of 200 mg kg-1 
body weight under ethrane/O2/N2O anaesthesia. NaOH 4M was added to the solution to 
obtain pH 5-6. After PDT animals were kept under subdued light conditions for the first 24 
hours. 
Experimental set-up for PDT illumination, fluorescence and transmission imaging. PDT 
illumination and fluorescence/transmission imaging was accomplished using the same 
experimental set-up. The animal was placed on a temperature-controlled X-Y stage. For 
PDT illumination green, 514 nm, excitation laser light (Spectra Physics, Darmstadt, 
Germany) with a fluence rate of 50 mW cm-2 was projected on the backside of the whole 
chamber using a system of condensing lenses to produce a uniform fluence rate distribution. 
Fluorescence and transmission images were recorded before ALA administration, at the 
start and at the end of the PDT treatment and every 30 minutes until 2.5 hours after 
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illumination. The fluorescence and transmission images recorded at the start and end of 
illumination were collected within the treatment session. For the fluorescence and 
transmission images recorded before ALA administration and in time after illumination the 
same excitation light was used although at a lower fluence rate to prevent additional PDT 
induced tissue damage. The extra delivered fluence due to these measurements was 
approximately 0.15 J cm-2 per measurement times five is 0.75 J cm-2 per animal. Light 
transmitted through the chamber was imaged onto a Peltier-cooled 16 bit, 512 x 512, slow 
scan CCD camera (Princeton Instruments Inc., Princeton, USA) using a f2.8/105 mm macro 
lens. The different detection filters were placed in a filter wheel (Oriel, Stratford, USA) 
between the macro lens and the CCD camera in order to obtain the fluorescence (625 ± 20 
nm) and transmission (514 ± 2 nm) images. Before each measurement a fluorescence 
standard, an inert plastic card, was recorded to correct for small differences in excitation 
light intensity. The PDT treatment and fluorescence measurements were carried out under 
general Ethrane/O2/N2O anaesthesia. Between measurements animals were conscious and 
placed in a dark and warm environment. 
Chamber cooling. In one group of animals the chamber tissue was cooled immediately 
after illumination with 100 J cm-2 (1 h after the administration of ALA) for one hour. A copper 
rod was placed in iced water in direct contact with the mica on the base of the window 
chamber and a small reservoir of iced water on top of the chamber. The temperature of the 
cover slide on top of the chamber was monitored continuously during the cooling period 
using a thermocouple. In all cases the temperature of the cover slide on top of the chamber 
was < 12°C within 8 minutes after the end of illumination and maintained between 10 -12°C 
for one hour. Warming was initiated by removing the iced water from the top and the copper 
rod from the bottom of the chamber. Within 2 minutes the temperature of the cover slide on 
top of the chamber had returned to normal (28-30°C). The body of the animal was placed on 
a temperature-controlled stage to maintain normal body temperature. The general 
anaesthesia that was used during PDT was maintained during the cooling period.  
PpIX fluorescence kinetics of different tissue types. Fluorescence and transmission 
images were recorded at several time points; before ALA administration (autofluorescence), 
before PDT illumination and in time after PDT illumination. Fluorescence images were 
corrected for intensity differences using a reference standard. The sequence of fluorescence 
images from each animal was registered by translation and rotation using anatomical 
landmarks identified in the corresponding transmission images. The registration of images 
enabled us to determine the fluorescence intensity of each tissue type from the same area. 
In the corresponding transmission image the regions of interest were chosen for each tissue 
type as shown in Figure 1. Tumour and normal tissue regions of interest were chosen so 
that no large chamber vessels were in or close to the region. The heterogeneity of the 
fluorescence in tumour was determined in four smaller regions in the tumour area as 
observed using white light microscopy. The position of these four arias was determined in 
the fluorescence image collected at the start of illumination with the aim to investigate the 
highest and lowest fluorescing aria in the centre and at the border. The relationship between 
the increase in PpIX fluorescence and distance from an arteriole and a venule was 
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investigated by determining the return in fluorescence within three regions of interest 
associated with each vessel. A rectangular region of which the width of the short side was 
equal to the width of an arteriole was placed within an arteriole. A second and third rectangle 
was placed adjacent to the arteriole at increasing distances from it. These regions were 
carefully chosen so that no other vessel was close to the arteriole under investigation. A 
similar procedure was followed for venules.  
Vascular response. We distinguish two vascular responses; the change in diameter of 
arterioles and venules and the disruption in flow. The change in vascular diameter due to the 
treatment was scored at the end of PDT, 60 and 90 minutes after PDT using the collected 
transmission images. While the original vessel size was variable between animals we 
scored the change in vascular diameter in percentages of constriction. No change in vessel 
diameter was scored 0, mild vasoconstriction (less then 50%) was scored 1, severe 
vasoconstriction (more than 50%) was scored 2 and complete vasoconstriction was scored 
3. The status of the blood flow in tumour and normal capillaries was determined at the end 
of PDT and 2 hours after PDT using 50 and 100 J cm-2 using white light microscopy. While it 
is our experience that capillary flow in the chamber model is not fluently we used a rough 
discrimination and scored flow (0) or no flow (1). In normal tissue we determined the size of 
the region whereas tumours were scored when all capillaries showed stasis.  
Statistics. Student t test was used to determine significance for the fluorescence kinetics 
measurements and vascular damage scores. The Spearman-rank test was used to 
determine the significance of the relationship between the photobleaching and re-synthesis 
of PpIX. Results with a P value below 0.05 were considered significant. Data is presented as 
mean ± SD. 
 
Results  
Fluorescence kinetics after ALA administration  
The autofluorescence of tumour, vessels and normal tissue was highly variable but not 
significant different (3368 ± 1380 counts, n=117). At one hour after ALA administration the 
fluorescence intensity in tumour tissue was 1.5 times higher compared to normal tissue 
(9551 ± 4834 counts and 6451 ± 3069 counts respectively with P=0.004). Vessels and 
normal tissue showed no significant difference in fluorescence intensity over the investigated 
time frame. The fluorescence kinetics for all tissues reached a plateau at approximately the 
same intensity 2.5 hours after administration (11597 ± 739 for tumour and 10196 ± 1327 
counts for normal tissue). 
 
Fluorescence kinetics after PDT in tumour, vessels and normal tissue 
Figure 2 shows the increase in fluorescence after illumination using different fluences for 
tumour, normal tissue, arterioles and venules. Illumination with 5 J cm-2 resulted in 
photobleaching in tumour and normal tissue to 69 and 76% respectively of that present 
before illumination. Similar amounts of photobleaching were observed in arterioles and 
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venules (74% of the initial fluorescence intensity for both). Thirty minutes after illumination 
the average fluorescence intensity in each tissue type increased to the initial fluorescence 
intensity. The fluorescence kinetics thereafter closely followed that of the ALA only control. 
Illumination with 50 J cm-2 resulted in relatively more photobleaching with 39, 51, 47 and 
48% of the fluorescence intensity remaining in tumour, normal tissue, arterioles and venules 
respectively. The increase in fluorescence in time after PDT was less than that following 
illumination with 5 J cm-2. Illumination with 100 J cm-2 showed similar levels of 
photobleaching and increase in fluorescence compared to that observed with 50 J cm-2.  
Figure 3 shows the correlation in individual tissue locations between the extent of 
photobleaching during the illumination and the increase 1 hour after PDT in tumour and 
normal tissue in this model (Spearman rank correlation, rS = 0.56; CI, 0.316 - 0.735; P = 
0.0004). The fluorescence intensity at the start of illumination was inhomogeneous in most 
Figure 2. Normalised PpIX fluorescence kinetics after PDT at one hour after ALA administration 
using different light doses (■ no PDT,  5 J cm-2, ○ 50 J cm –2,  100 J cm-2) in tumour (a), normal (b), 
arteriole (c) and venule (d) tissue. Data was normalised to the pre-illumination fluorescence intensity for 
each individual rat and each tissue type. Differences between tissue types in the pre-illumination 
fluorescence intensity are displayed in the relative re-scaling of the Y-axis of the kinetics graphs. 
Results are shown as mean ± sem. 
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Figure 3. The relative return in PpIX 
fluorescence 1 hour after ALA-PDT using different 
fluences ( 5 J cm-2,  50 J cm-2, ▲ 100 J cm-2) 
in relation to the relative fluorescence at the end 
of PDT of normal and tumour tissue. Rank 
correlation = 0.56, 95% CI = 0.316 - 0.735, P = 
0.0004 
 
 
 
Figure 4. The relative PpIX fluorescence 
kinetics in time after ALA-PDT using 100 J cm-2 in 
two representative tumours (■ and ). Data is 
normalised to the region with the highest 
fluorescence intensity measured before 
illumination (■) to show the intra-animal variation. 
For each tumour data from the highest (solid line) 
and lowest (dashed line) fluorescence intensity 
region are displayed to show the inter-tumour 
variations. 
 
 
 
tumours. In more than two thirds of tumours, the difference between the highest and lowest  
intensity region was greater than 15% and showed no correlation with the location in the 
tumour, i.e., the centre or border. Figure 4 illustrates the distribution of PpIX fluorescence 
and shows that the variation within a single tumour is much smaller than the variation 
between tumours. Overall these variations in fluorescence intensity observed at the start of 
illumination were not significantly different in time after PDT with any of the light doses 
investigated in the present study 
 
Fluorescence kinetics after PDT in relation to the distance from the vessels 
The fluorescence increase after ALA-PDT was independent of the distance from the 
nearest vessel. The average diameter for arterioles was 51 ± 25 µm (n=20). The two regions 
in which the fluorescence increase in relation to the distance from the arteriole was 
determined were at a distance of 84 ± 38 µm and 217 ± 70 µm. The average diameter for 
venules was 126 ± 54 µm (n=23). The two regions in which the fluorescence increase in 
relation to the distance from the arteriole was determined were at a distance of 127 ± 25 µm 
and 368 ± 115 µm. While we observed no difference in the return of fluorescence in relation 
to the distance from a vessel for all fluences investigated we only the results after 
illumination with 100 J cm-2 (Figure 5).  
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Figure 5. The PpIX fluorescence kinetics in time after PDT at one hour after ALA administration 
using 100 J cm-2 in relation to the distance from an arteriole (a) or a venule (b); (○) in the vessel, () 
close to the vessel and () further away form the vessel. Results are shown as mean ± sem. 
 
Vascular response immediately after ALA-PDT 
Figure 6 shows the vascular response of arterioles and venules in the first hours after 
PDT using different light fluences and Table 2 shows the number of animals that showed 
stasis of capillary flow in tumour and normal tissue. Immediately after illumination with 5 J 
cm-2 none of the blood vessels in the chambers showed vasoconstriction. Only 1 out of 8 
animals showed mild vasoconstriction of both the arteriole and the venule 60 minutes after 
PDT. The venule returned to the normal diameter within 30 minutes, the arteriole was still 
mildly constricted at 90 minutes after PDT.  
Illumination with 50 J cm-2 resulted in significantly more animals showing arteriole 
constriction compared to 5 J cm-2 (P = 0.01, 0.009 and 0.009 immediately, 60 and 90 
minutes after illumination respectively). At the end of PDT 3 out of 4 animals showed 
arteriole constriction ranging from mild to complete developing in severe constriction at 60 
and 90 minutes. Only two animals showed venule constriction, one mild and one severe in 
the hours after illumination. Immediately after PDT all animals showed normal flow in the 
capillaries of normal and tumour tissue. Two hours after PDT 2 out of 3 animals showed 
stasis in a small region in the normal tissue whereas the blood flow in the tumour was not 
hampered. 
Illumination with 100 J cm-2 resulted in arteriole constriction in all animals at the end of 
PDT; 2 animals showed severe and 4 showed complete constriction. At 60 and 90 minutes 
after PDT 3 out of 6 showed a small recovery resulting in 1 normal, 3 severely constricted 
and 2 completely constricted arterioles. Compared to 50 J cm-2 the damage was more 
severe although not statistically significant (P = 0.08, 0.38 and 0.49; immediately, 60 and 90 
minutes after illumination). No change in diameter of the venules was observed at the end of 
PDT. At 60 to 90 minutes after PDT 2 out of 7 showed mild constriction. The constriction of 
venules after 100 J cm-2 was not statistically different from that observed after 5 and 50 J 
cm-2. Immediately after illumination the 3 out of 6 animal showed large areas of blood stasis 
in the capillaries of normal tissue. The number of animals showing stasis and the region size 
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increased in time after PDT. For tumours the result was comparable; 2 out of 5 tumours 
showed complete stasis in all capillaries immediately after PDT increasing to 4 out of 6 
tumours 2 hours after PDT. 
Figure 6. Arteriole (a) and venule (b) constriction at 0 60 and 90 minutes after ALA-PDT using 
different light doses; 5 J cm-2 (white bar), 50 J cm-2 (dotted bar), 100 J cm-2 (black bar) and 100 J cm-2 
followed by 1 hour of cooling (dashed bar). Results are shown as mean ± sem. 
 
Table 2. Capillary stasis in response to ALA-PDT. The number of animals showing stasis of 
the blood flow in tumour and normal capillaries immediately and two hours after PDT. In 
normal tissue the size of the region showing stasis was determined whereas tumours were 
scored when all capillaries showed stasis.  
 Normal tissue Tumour tissue 
Fluence 0 2 hrs 0 2 hrs 
50 J cm-2 0 / 3* 2 (25%) / 3* 0 / 3* 0 / 3* 
100 J cm-2 3 (60%) / 6* 5 (79%) / 7 2 / 5* 4 / 6 
* the response of one animal could not be determined 
 
 
Influence of temperature 
The vascular response observed in the first hours after ALA-PDT was not influenced by 
the drop in local tissue temperature to 10-12°C for one hour after the end of illumination 
(Figure 6). Microscopically, we did not observe blood stasis before or after cooling in the 
arterioles and venules in any of the animals. Figure 7 shows that the fluorescence increase 
in time after illumination using 100 J cm-2 was temperature dependent. During illumination 
the fluorescence bleached to 35, 43, 49 and 49% of the initial fluorescence intensity in 
tumour, arterioles, venules and normal tissue respectively. After one hour of cooling to 10-
12°C there was no significant increase in fluorescence in arterioles and tumour (P = 0.68 
and 0.28, respectively). There was a small increase in fluorescence both in venules and in 
normal tissue (P = 0.04 and 0.03 respectively) but this increase was lower compared to the 
increase in the normal tissue and venules of animals kept at normal temperature (P = 0.002 
and 0.03, respectively). Subsequent warming the chambers to normal conditions after the 
cooling period resulted in an increase in PpIX fluorescence in all of the tissues investigated. 
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Figure 7. Normalised PpIX fluorescence kinetics after PDT at one hour after ALA administration 
using 100 J cm-2 either followed with one hour of cooling the tissue to 10-12°C (▲) or kept at normal 
temperature () in tumour (a), normal (b), arteriole (c) and venule (d) tissue. Results are shown as 
mean ± sem. * significant less PpIX increase at this time point compared to normal temperature groups. 
** no significant PpIX increase at this time point compared to immediately after PDT. 
 
Discussion 
The aim of the present study was to determine if the increase in PpIX fluorescence after 
ALA-PDT is due to local re-synthesis or systemic redistribution. We investigated this by 
studying the spatial distribution of PpIX after PDT with and without cooling in the skin-fold 
observation chamber model. By cooling the tissue to a temperature at which no PpIX is 
formed (10-12°C) 20,21 we were able to inhibit the return in PpIX fluorescence after 
illumination (Figure 7). Also we found that PpIX fluorescence increases after the tissue is 
returned to normal temperature. These observations are consistent with those of Juzenas et 
al. in the skin after topical ALA application 20. It is important to consider that changing the 
temperature of tissue has been shown to affect the vessel diameter. Untank 22 showed that 
cooling normal rat skin from 35 to 25°C resulted in significant constriction of arterioles in the 
subcutus. ALA-PDT is also known to induce vasoconstriction and stasis 16,23,24. The 
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combined effects of cooling and PDT may influence our ability to detect the systemic 
redistribution of PpIX. We have shown that the extent of vasoconstriction following PDT is 
dependent on the light fluence (Figure 6). Although 60% of the animals treated with 100 J 
cm-2 show complete arteriole constriction immediately after illumination the circulation in the 
chamber is not completely shut down; the venules and most capillaries are still flowing 
(Table 2). Cooling the tissue for one hour after ALA-PDT with 100 J cm-2 did not result in 
significantly more vasoconstriction of both arterioles and venules. Based on our results we 
assume that the blood supply within the chamber after PDT is similar with or without cooling. 
Our results on the spatial distribution of the fluorescence kinetics in and around vessels 
(Figure 5) shows there is no correlation between the distance from a blood vessel and the 
rate of PpIX fluorescence increase after PDT independent of the vascular response of that 
vessel. This result contradicts the hypothesis of Diagaradjane et al. 17 that the return in PpIX 
after systemic ALA-PDT might be the result of diffusion from the surrounding tissue. 
Although Henderson et al. 16 showed circulating porphyrins after topical application of ALA to 
mouse skin we show that the level of fluorescence in a blood vessel was as high as the 
surrounding tissue suggesting that the amount of circulating porphyrins, if any, is small. In 
Figure 3 we demonstrate a strong correlation between the local level of photobleaching and 
the fluorescence increase one hour after PDT. More photobleaching during illumination 
suggests more damage to the tissue resulting in a reduced capacity to convert ALA into 
PpIX, reflected in a lower fluorescence increase 1 or 2 hours after illumination. This result is 
consistent with that we have observed in our clinical study treating superficial BCC using 
topical ALA-PDT 1. Also other investigators 7,18 have shown re-appeared PpIX fluorescence 
after ALA-PDT in both superficial and nodular BCC. All our data supports the conclusion that 
the return in PpIX fluorescence after PDT is the result of local re-synthesis. That we show 
this to be true in an animal model after systemic ALA administration implies that this is also 
true after topical ALA. In the clinical situation a systemic redistribution of PpIX after PDT 
using topical ALA application is unlikely due to the much smaller ALA dose to body mass 
ratio in humans.  
The rate and magnitude of PpIX re-synthesis after illumination in the window chamber is 
relatively high compared to our previous studies using other pre-clinical models 5,10,11. In 
normal mouse 5 or in pig skin 11 the re-synthesis kinetics were dependent on the fluence 
delivered but did not increase to the pre-PDT level even after illumination with a small 
fluence. In transplanted rhabdomyosarcoma we have also shown that re-synthesis is 
dependent on the fluence delivered 10. In this model illumination with a small fluence 
resulted in a fluorescence intensity higher than the pre-PDT level although not to the dark 
control. Apparently the tissue under investigation, the main difference between these and 
the present study, has an influence on the fluorescence kinetics observed after PDT. In 
mouse skin epidermal cells that are supported by capillaries in the dermis dominate the 
fluorescence data. The transplanted rhabdomyosarcoma model consists of tumour cells, 
connective tissue and vessels. The subcutis of the chamber is highly vascularised and 
contains fat cells and transplanted tumour cells. Consistent to the observations of Roberts et 
al. 25 our results in Figure 2 and 5 show that the vascular endothelium synthesises PpIX and 
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contributes significantly to the fluorescence intensity. Interestingly, 5 out of 48 lesions 
treated in our clinical study also show a fluorescence increase to the pre-PDT value or 
higher two hours after illumination. 
Although the increase of PpIX after illumination was the motivation for designing a two-
fold illumination scheme we have shown earlier that the mechanism of action behind this 
scheme in ALA-PDT is more complicated as we found no correlation between the total 
amount of PpIX utilised and the efficacy 3,4,6,10. Recently 6 we hypothesised that the spatial 
distribution of PpIX and the site of PDT response within the illuminated volume is an 
important factor in the mechanism underlying the two-fold illumination scheme. One could 
even imagine that the first light fraction influences the spatial distribution of PpIX 
fluorescence. In the present study we show that the PpIX fluorescence intensity at the start 
of PDT was very variable between animals and within each chamber as shown by a 
representative example (Figure 4). Although the preparation of the chambers was 
standardised it was impossible to create chambers with standard tissue thickness or 
vascular structure density. The heterogeneity in the tumour fluorescence intensity as shown 
in Figure 4 might be explained by the heterogeneity in their oxygen supply and metabolic 
activity. More important is the observation that the spatial distribution of PpIX (re)-synthesis 
in the tumour is not influenced by the illumination. A tumour area that showed little 
fluorescence compared to the rest of the tumour also showed a relatively lower rate of re-
synthesis after illumination independent of the fluence used. Also the observed differences 
between tumour, vascular and normal tissue in fluorescence intensities at the start of PDT 
remained the same after illumination. Apparently, the relative capacity to convert ALA to 
PpIX is equally affected in tumour, vascular or normal tissue. It is important to bear in mind 
that the tissue in this model is highly vascularised which means that the fluorescence 
kinetics determined in tumour and normal tissue also contain information from the vascular 
endothelial cells of the capillaries.  
In summary; we have shown that cooling the tissue to 10-12°C inhibited the PpIX 
fluorescence increase after illumination. We were also unable to show a gradient of 
fluorescence around the vessels. Therefore we conclude that the increase in PpIX 
fluorescence after illumination is the result of local cellular re-synthesis in rats after systemic 
ALA administration. Furthermore we have shown that the spatial distribution of fluorescence 
within normal tissue and tumour is not changed after PDT. 
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Abstract 
Previous work demonstrated that fractionated illumination using two fractions separated 
by a dark interval of 2 hours, significantly enhanced the clinical efficacy of photodynamic 
therapy (PDT) with 5-aminolevulinic acid (ALA). Considering the increasing clinical use of 
methyl 5-aminolevulinate (MAL) and the expected gain in efficacy by light fractionation we 
have investigated the response to MAL-PDT using a single and a two-fold illumination 
scheme and compared that with ALA-PDT. Our results show that fractionated illumination 
does not enhance the efficacy of PDT using MAL as it does using ALA despite the 
comparable fluorescence intensities at the end of the first light fraction and at the start of the 
second light fraction. Only the initial rate of photobleaching was slightly greater during ALA-
PDT although the difference was small. Previously we hypothesised that cells surviving the 
first fraction are more susceptible to the second fraction. Since this is not true for MAL-PDT 
our data suggest that the distribution of MAL and ALA in tissues, and therefore the site of 
PDT induced damage, is an important parameter in the mechanism underlying the two-fold 
illumination scheme. 
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Introduction  
Photodynamic therapy employing the administration of porphyrin precursors has been 
under investigation for over a decade 1. It is now the treatment of choice for superficial non-
melanoma skin cancer 2 and an experimental therapy for a number of other conditions 3,4. 
Recently we have shown that light fractionation using a 2-hour dark interval enhances the 
response of superficial basal cell carcinoma (sBCC) to ALA-PDT significantly 5,6. The 
increased effectiveness of this type of illumination scheme was first shown in a series of pre-
clinical studies 7-10. Initially the fluence was split in two equal light fractions. In a further 
series of pre-clinical studies using the hairless mouse model we optimised the illumination 
scheme 10-12. The efficacy of the two-fold illumination scheme increases when the fluence of 
the first light fraction is relatively low compared to the second light fraction. These data 
guided us to the design of two clinical studies. The first, a pilot study used a non-optimised 
two-fold illumination scheme with equal light fractions 5. While the long-term response data 
in this study showed that complete response rate (CR) remains high compared to CR in the 
literature, we found no significant difference in CR 1 year after PDT. The second, large-scale 
randomised comparative study using the optimised illumination scheme showed a significant 
increase in CR of sBCC at one year compared to ALA-PDT in a single light fraction 6. 
A number of alternative approaches targeted at enhancing the efficacy in ALA-PDT have 
been investigated. These have focussed on improving the uptake of ALA and/or the 
accumulation of protoporphyrin IX (PpIX) using penetration enhancers, iontophoresis, and 
iron chelators 13-17. An important development in this area has been the use of other 
porphyrin precursors that are derivatives of ALA 18-21. The use of methyl 5-aminolevulinate 
(MAL/Metvix®) has been studied extensively both in-vitro and clinically. MAL based PDT is 
now an approved treatment modality for actinic keratosis (AK) in the USA and for non-
melanoma skin cancers, such as sBCC and Bowen’s disease, in Europe and Australia. The 
recommended treatment protocol involves the topical application of MAL cream (160 mg g-1) 
for 3 hours followed by a single red light illumination and a repetition of this treatment one 
week later 22. Considering the increasing clinical use of MAL and the expected gain in 
efficacy by light fractionation we have investigated the response of normal hairless mouse 
skin to MAL-PDT using a single and a two-fold illumination scheme. Although every two-fold 
illumination scheme ever investigated using ALA resulted in more damage compared to a 
single illumination scheme we chose to investigate the most effective scheme 11,12. We 
compare these data to our earlier published data on ALA-PDT using the same illumination 
schemes 12. 
 
Materials and Methods 
Animal model. Female inbred albino hairless mice (SKH1 HR, Charles River, Someren, 
The Netherlands), aged between 8 and 10 weeks old, were included in this study. Prior to 
Chapter 7 
 102 
treatment animals were fed on a chlorophyll free diet (Hope Farms b.v., Woerden, The 
Netherlands) for a minimum of two weeks in order to remove the autofluorescence emission 
from mouse skin centered on 675 nm attributed to pheophorbide-a. The animal experiments 
committee of the Erasmus University Medical Centre approved the experimental protocol. 
Chemicals. The ALA cream was freshly prepared as described previously 23. Twenty 
percent 5-aminolevulinic acid (ALA, Medac, Hamburg, Germany) dissolved in 3% 
carboxymethylcellulose in water. To prevent skin irritation, the ALA solution was prepared to 
approximately pH 4 by the addition NaOH (2 M). MAL (Metvix®, 160 mg g-1, Galderma, 
Freiburg, Germany) or ALA was topically applied to a 7 mm diameter area on the dorsal skin 
and covered with a thin layer of gauze. A polythene dressing (Tegaderm, 3M, The 
Netherlands) was used to occlude the area for 4 hours prior to treatment. Before application 
of cream animals received anaesthesia (Hypnorm; fluanisol/fentanyl mixture, Janssen 
Pharmaceutics, Belgium or Ketamine; Alfasan Woerden, The Netherlands and Diazepam, 
Centrafarm b.v., Etten-Leur, The Netherlands) to alleviate possible anxiety caused by the 
dressing.  
Experimental design. The visual and histological response to MAL-PDT using either a 
single or a two-fold illumination was investigated in two separate series of experiments using 
the normal mouse model. We have previously shown that visual response data obtained in 
this model correlates well with the visual response of UVB induced tumour and tumour 
growth delay 4,5. We have also shown that optimisation of response in normal mouse skin 
can lead to the design of clinically relevant fractionation schemes 1,2. In the first series the 
visual skin damage in the first 7 days after MAL-PDT was investigated (n=6, in each) and 
compared to that after ALA-PDT using data obtained previously 12. A power analysis showed 
that this number of animals would be sufficient to resolve a difference in response to the 
single and two-fold illumination similar to that observed after ALA-PDT. In a second series of 
experiments the histological damage after PDT with ALA and MAL was investigated. In total 
14 groups of mice (n=5-6) were treated. Two groups served as ALA and MAL dark controls 
in which skin samples were collected at the end of the application period. In the 12 
remaining groups skin samples were collected at 2.5, 24 or 48 hours after the end of 
illumination. In both series the PpIX fluorescence kinetics were recorded during illumination.  
PDT light delivery and fluorescence detection. After 4 hours of topical application with 
ALA or MAL the skin was illuminated using either a single light fraction of 100 J cm-2 at 50 
mW cm-2 or a two-fold illumination scheme with 5+95 J cm-2 at 50 mW cm-2 separated by a 2 
hour dark interval. The experimental set-up used for the PDT illumination and fluorescence 
detection was based on that described previously 24. The 514 nm output from the argon ion 
laser was focussed on a 7 mm diameter spot of homogeneous profile on the skin of the 
mouse. The fluorescence emission from the illuminated area was focussed through a 
system of lenses onto a CCD camera (ORCA-ER, Hamamatsu, Japan). Excitation light was 
filtered using a dichroic mirror (535 nm, Omega Optical, Barttleboro, US) and a 635 nm 
interference filter (Melles Griot, Didam, The Netherlands). Fluorescence images were 
collected before pre-cursor application, during application and during illumination using the 
therapeutic light without interruption of the illumination using different light fluences and 
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different integration times. Before each measurement a fluorescence standard was recorded 
to correct for these differences. The fluence used for each fluorescence measurements 
before and during the application period was approximately 0.005 J cm-2 at 0.5 mW cm-2. 
Mice were anaesthetised with a combination of 2% Ethrane or Isoflurane (Abbott, 
Amstelveen, The Netherlands) oxygen and N2O for each illumination or fluorescence 
measurement. 
Visual skin damage. The biological damage to the irradiated area was assessed daily by 
two independent observers (HSB and APH) blinded from the treatments using the visual 
skin damage scoring system described previously 25. No change in skin colour was scored 
as 0. Scores 1 to 3 were used for increasing discoloration of the skin, 1 meaning minimal 
redness and 3 meaning severe redness. Thin crust formation was scored as 4 and thick 
crust formation was scored as 5. Damage was observed to be inhomogeneous in a number 
of treatments. Photographs were taken regularly in order to determine the degree and 
distribution of damage. The damage score of the total illuminated area in one animal at one 
time point was calculated by scoring areas according to the degree of damage related to the 
contribution to the total illuminated area. The visual skin damage of a single mouse was 
quantified by calculating the area under the curve of skin damage when plotted against time, 
over the first 7 days resulting in the integrated damage score.  
PpIX fluorescence imaging and data analysis. Fluorescence images were recorded 
before application of the precursor (autofluorescence), during the application period at 1 and 
2 hours and during illumination (every 10 seconds). The mean gray scale value was 
calculated over a large field at the centre of the illuminated area (approximately 65%). To 
calculate the absolute PpIX fluorescence the background values and the individual 
autofluorescence were subtracted. A series of measurements during an illumination was 
normalised to the first measurement of that illumination. The rate of photobleaching over the 
first 5 J cm-2 of each illumination was determined as the slope of the reciprocal of the 
normalised PpIX fluorescence using linear regression fitting 24. In total 79 mice were 
illuminated. Data of 16 mice was excluded from analysis due to technical reasons like 
computer storage failures or focussing and movement problems, resulting in n=12 for the 
two ALA-PDT groups and n=20 and 19 for the MAL-PDT groups treated according to a 
single or a two-fold illumination scheme respectively.  
Histology. A pathologist (KH) blinded from the treatments scored the histological 
response by analysing the H&E stained sections of the obtained skin samples. The 
response of the different layers of the skin was scored separately. We distinguished the 
epidermis, the upper dermis, the lower dermis and muscle. Tissue damage was observed 
and scored according to 4 categories: coagulative necrosis (eosinophilia, loss of structure 
and undetectable nuclei) was scored 3, karyorhexis (eosinophilia, loss of structure but 
(fragmented) nuclei could still be recognised) was scored 2, pyknosis (nuclei were shrunk 
and showed basophilia) was scored 1 and no visual damage was scored 0. The most severe 
damage observed was scored. Epidermal thickening (hyperplasia) and demarcation of dead 
tissue by dense polymorphonuclear infiltrates/crust formation were signs of sub-lethal and 
Chapter 7 
 104 
lethal cellular damage, respectively. Expected late effects are loss of hair follicles and 
sebaceous glands and dermal fibrosis. 
Statistics. The significance of differences in PDT damage and rate of photobleaching was 
determined using the student-t test and P <0.05 was considered significant. Results are 
shown as mean ± standard deviation. 
 
Results 
Response to PDT 
The mean visual skin damage scored over the first 7 days post MAL-PDT with a single or 
a two-fold illumination scheme is plotted in Figure 1. Thin crusts were formed already at day 
one after MAL-PDT using a single light fraction that developed into thick crusts over time. 
These crusts became detached at day 4. Light fractionation using the two-fold illumination 
scheme didn’t show a significantly different response. The skin damage at day 1 was less 
pronounced, crusts were formed in all animals but became detached between day 3 to 5.  
The mean of the integrated visual skin damage scores over day 1-7 was 22.6 ± 1.2 and 
21.1 ± 3.1 for the single and the two-fold illumination scheme respectively. The use of a two-
fold illumination scheme after MAL application did not result in significantly more PDT 
induced visual damage compared to a single illumination scheme (P=0.29) in contrast to the 
results previously obtained with ALA-PDT 12.  
 
Figure 1. The visual skin damage scores for the 
first 7 days after MAL-PDT. All groups were 
illuminated with 50 mW cm-2 to a cumulative light 
fluence of 100 J cm-2 delivered in a single fraction 
(■) or in two fractions (5+95 J cm-2 with a 2 hours 
dark interval) (). Mean ± SD (n=6 in both groups). 
The results after ALA-PDT are shown in gray with 
n=4 and 11 for a single and a two-fold illumination 
respectively 12.  
Figure 2. The mean PDT induced damage 
scored using histology at 24 hours ALA or MAL-
PDT using a cumulative fluence of 100 J cm-2 
delivered in a single fraction or in two fractions 
(5+95 J cm-2 with a 2 hours dark interval). The 
most severe damage was scored in each layer 
of the skin separately; epidermis (black bar), 
upper dermis (gray bar) and lower dermis 
(white bar). Mean ± SE. 
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Figure 3. The mean PpIX fluorescence during illumination with 50 mW cm-2 to 100 J cm-2 delivered in 
(a) a single fraction or in (b) two fractions (5+95 J cm-2 with a 2 hours dark interval) after topical ALA (■) 
or MAL (○) application (n=12 for both ALA groups and 20 and 19 for the MAL groups respectively). The 
results over the first 10 J cm-2 are shown in the inserts for clarity. Mean ± SD. 
 
 
 
 
 
Figure 4. The weighted mean reciprocal of the 
normalised PpIX fluorescence during the first 5 J 
cm-2 of each light fraction of illumination with 50 
mW cm-2 to 100 J cm-2 delivered in (a) a single 
fraction or in (b) two fractions (5+95 J cm-2 with a 
2 hours dark interval) after topical ALA (■) or 
MAL (○) application (n=12 for both ALA groups 
and 20 and 19 for the MAL groups respectively). 
Mean ± SD. 
Figure 5. A box & whisker plot of the rate of 
photobleaching for during the first 5 J cm-2 of 
each illumination after topical ALA or MAL 
application. * significant difference in rate of 
photobleaching with P=0.005 between MAL and 
ALA. ** significant difference in rate of 
photobleaching with P< 0.001 between the first 
and the second light fraction of the two-fold 
illumination.
 
0.00 
0.05 
0.10 
0.15 
0.20 
0.25 
0.30 
0.35 
R
a
te
 
o
f p
ho
to
bl
e
a
ch
in
g 
ALA MAL ALA MAL
single and first
fraction 
second 
fraction 
* 
** 
** 
 
0,5
1,0
1,5
2,0
2,5
0 5
1/
n
or
m
al
is
ed
 
flu
or
es
ce
n
ce
0 5 10
Fluence / J cm-2 
a b 
0
200
400
600
800
1000
1200
0 25 50 75 100
Light dose / J cm-2
Ab
so
lu
te
 
flu
or
es
ce
n
ce
 
/ c
ou
n
ts
200
400
600
800
1000
1200
0 2 4 6 8 10
0
200
400
600
800
1000
1200
0 25 50 75 100
Light dose / J cm-2
Ab
so
lu
te
 
flu
or
es
ce
n
ce
 
/ c
ou
n
ts
200
400
600
800
1000
1200
0 2 4 6 8 10
a b 
Chapter 7 
 106 
In general, the histological observations were in agreement with the visual skin damage 
scores; after a single illumination MAL-PDT resulted in more damage compared to ALA and 
the increase in damage after a two-fold illumination was not seen using MAL. At 2.5 hours 
after the end of PDT all groups showed a similar picture of no damage or only slight 
pycnosis in the epidermal layer. Thereafter marked differences occurred. While with ALA 
both a single and a fractionated illumination resulted in a variable response that slightly 
increased from 24 to 48 hours, MAL-PDT showed a deeper damage in more animals for 
both illumination and both time points. Figure 2 shows the mean histological response score 
for each skin layer at each time point for both ALA and MAL. Note that the most severe 
damage observed in the tissue layer is scored and that we have not compensated for 
differences in spatial distribution of damage as we have done in the visual skin damage 
scoring system. Non-illuminated controls showed no damage. 
 
Fluorescence intensity during MAL and ALA application 
The mean PpIX fluorescence kinetics after topical MAL or ALA application and during 
illumination are shown in Figure 3. An insert shows the kinetics during the first 10 J cm-2 for 
clarity. The autofluorescence of normal mouse skin was 39.3 ± 9.7 counts. The PpIX 
fluorescence 4 hours after the application of ALA or MAL was not significantly different 
(1107 ± 358 or 1021 ± 408 counts respectively, P =0.40). The relative fluorescence intensity 
during the application period at 1 and 2 hours was higher using ALA compared to MAL (15 ± 
2% and 10 ± 6% at 1 h and 47 ± 11% and 32 ± 13% at 2 h respectively, P =0.17 and 0.22). 
 
Fluorescence kinetics during MAL and ALA-PDT 
There was no significant difference in the extent of photobleaching during the first 
illumination using ALA or MAL (46.8 ± 3.3% and 50.1 ± 5.3% respectively, P =0.06). 
Furthermore, we saw no significant difference in the amount of PpIX re-synthesis during the 
dark interval between the two light fractions (62.1 ± 14.0% and 71.3 ± 24.6% respectively, P 
=0.25). The photobleaching kinetics during illumination followed a second order decay for 
both porphyrin precursors. This is illustrated by the linearity of the reciprocal of the 
normalised PpIX fluorescence, as a function of light fluence. Figure 4 shows the kinetics of 
photobleaching over the first 5 J cm-2 for each light fraction. Figure 5 shows the variation 
between animals in the calculated initial rate of photobleaching for each light fraction. 
Combining photobleaching data from the first 5 J cm-2 of the single illumination scheme and 
the first light fraction of the two-fold illumination, PpIX fluorescence bleached at a greater 
rate following the application of ALA compared to MAL. While this difference is small it is 
significant (P = 0.005; n=39 for MAL-PDT and n=24 for ALA-PDT). The rate of PpIX 
photobleaching during the second light fraction of the two-fold illumination was not 
significantly different using ALA or MAL although for both PpIX precursors it was significantly 
lower compared to the first light fraction. 
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Discussion 
Contrary to our expectations, we have found significant differences in the response of 
normal mouse skin to MAL-PDT compared to ALA-PDT 12. We have shown that there is 
significantly more visual skin damage following MAL-PDT compared to ALA 12 using a single 
light fraction although the difference was small and may not be clinically relevant. More 
importantly, we have also shown that light fractionation does not enhance efficacy in MAL-
PDT in the way it does using ALA. Histological examination 24 and 48 h after therapy 
supports these findings. While the differences in response to PDT using ALA and other pro-
drugs of ALA is an interesting subject for investigation they may also expand our 
understanding of the mechanism underlying the response of tissues to PDT using the two-
fold illumination scheme. Numerous in-vitro studies have compared the uptake of ALA and 
its derivatives, and investigated porphyrin synthesis and cell survival 26,27. However relatively 
few in-vivo pre-clinical studies have compared the pharmacokinetics of PpIX synthesis 28 
and importantly none, to our knowledge, have investigated the response to PDT. Only two 
clinical studies have compared the clinical response of AK 29 and BCC 30 to ALA and MAL-
PDT. Both studies found no difference in clinical response to PDT with ALA and MAL 
although they were probably insufficiently powered to detect small differences in response of 
the magnitude that we have observed in the present study.  
The pharmacokinetics of PpIX fluorescence in normal mouse skin during the 4-h 
application period is similar for both porphyrin pre-cursors. At 1, 2 and 4 hours during the 
application period the fluorescence intensity is not significantly different for animals receiving 
MAL or ALA. This is in agreement with the results reported by Moan who found similar PpIX 
fluorescence intensities and concentrations in mouse skin after 1 and 5 hours topical ALA or 
MAL application 28. We have chosen a 4-h application period for both precursors. While this 
is longer than the 3 hours that is normally used clinically Juzenas et al. 31 have shown that 
there is no clear difference in PpIX fluorescence intensity using an application time of 3 or 4 
hours. That equal PpIX fluorescence intensities are found immediately prior to the start of 
the first light fraction is advantageous since large variations in initial PpIX concentration can 
influence visual skin response for standardised illumination conditions 24.  
The kinetics of PpIX fluorescence during the two-fold illumination scheme shows that we 
do not observe significant differences in the extent of photobleaching after each light fraction 
between ALA and MAL. The kinetics of PpIX fluorescence during MAL-PDT are similar to 
that published by Moan et al. 32. Also we observed similar amounts of PpIX re-synthesis in 
the dark interval between light fractions for both ALA and MAL. Therefore the total amount of 
PpIX utilised during the 2-fold illumination is not significantly different for MAL and ALA. The 
fact that these observations are accompanied by a dramatically different PDT response 
adds weight to our previous conclusions that the total amount of PpIX re-synthesised during 
the dark interval is not involved in the mechanism of action behind the response of tissues to 
the two-fold illumination scheme 11,33. We have previously shown that the PDT dose 
delivered during the first light fraction is a critical parameter that can strongly influence the 
effectiveness of the 2-fold illumination scheme 10,11. Furthermore we have shown that the 
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rate of PpIX photobleaching can be used as an indirect measure of the amount of singlet 
oxygen produced during PDT and can be used to report PDT dose and correlates with 
response 24,25,34,35. Recently direct evidence for the relationship between the generation of 
singlet oxygen during PDT and visual skin response in normal mouse skin has been 
reported 36. Monitoring photobleaching during fractionated ALA-PDT gives an important 
indication of the PDT dose delivered. A faster rate of photobleaching correlates with a higher 
PDT dose. In the present study we observe that the rate of photobleaching during the first 
light fraction of ALA-PDT is slightly but significantly greater than that of MAL-PDT. According 
to our current understanding of the magnitude of the PDT dose delivered during the first light 
fraction on the response of tissues to the 2-fold illumination scheme, this difference in the 
rate of photobleaching is small and does not explain the lack of an increase in efficacy in 
MAL-PDT. The rate and extent of PpIX photobleaching during the first light fraction of MAL-
PDT is well within the margins of what is considered optimal using ALA 11. 
An important difference between ALA and MAL, and other ester derivatives of ALA, is 
their tissue distribution due to their different biophysical and biochemical characteristics. The 
cellular uptake of MAL is different from that of ALA 37. While the vehicle in which the pre-
cursors are dissolved might also effect the distribution this seems less important since Moan 
et al. 28 used the same vehicle for both MAL and ALA and still showed a different 
distribution. The authors detected PpIX fluorescence at distant sites after topical ALA 
application whereas it remained within the application site after MAL application. From this 
observation they concluded that ALA is systemically distributed after topical application 
whereas MAL is not. The consequences of these effects for the distribution of ALA or MAL 
and therefore PpIX within the treatment volume are unknown. It is possible that there is a 
different distribution of PpIX following the application of ALA and MAL and this has an 
important effect on the response of tissues to PDT. The present study is limited by the fact 
that normal mouse skin is relatively thin (approximately 50 µm) and layered and that the 
PpIX fluorescence is monitored from the surface of the skin. The microscopic distribution of 
PpIX fluorescence within mouse skin has not been systematically investigated. Besides the 
difference in (depth) distribution of MAL or ALA within the tissue also other factors may play 
a role. The microenvironment of a cell may be different when it is loaded with MAL or ALA 
due to the differences in molecular structure and processes involved in the de-esterification 
of MAL. How these factors affect the PDT response in mouse skin is unknown but they have 
not been found to be important factors in vitro 26,27.  
A different distribution of MAL and therefore PpIX in the treatment volume leads to a 
different site of PDT damage and could explain the difference in visual damage following 
ALA and MAL-PDT using the single illumination scheme. The small but significantly lower 
initial rate of PpIX photobleaching during MAL-PDT (Figure 5) may be a consequence of a 
different microenvironment due to a different localisation of PpIX. We acknowledge that 
superficial photobleaching measurements are probably not a particularly sensitive method of 
determining differences in photosensitiser localisation. It is important to recognise that it is 
necessary to perform a first light fraction followed by a two-hour interval to observe a 
significant increase in response using ALA 12. Previously we have hypothesised that cells 
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surviving the first light fraction are more susceptible to the second light fraction 12. Since this 
is not true for MAL-PDT the site of PDT induced damage should be considered as an 
important parameter in the mechanism underlying the 2-fold illumination scheme. Apparently 
the site of PDT induced damage combined with the two-hour dark interval between light 
fractions is important for the increased efficacy observed using light fractionation during 
ALA-PDT.  
We have previously shown that pre-clinical results obtained in normal mouse skin using 
ALA-PDT can be successfully translated to a clinical treatment protocol for sBCC that results 
in a significantly improved CR 6. The results of the present study imply that simply combining 
MAL-PDT and the most effective two-fold illumination scheme, determined for ALA, in the 
clinic would not enhance the efficacy of MAL-PDT using a single light fraction. It is possible 
that the illumination parameters used in the present study are not optimal for MAL. However, 
it is important to note that light fractionation in ALA-PDT always enhances the response of 
tissue compared to a single illumination. We note that more pre-clinical research on the 
mechanism behind the increased effectiveness of the two-fold illumination using ALA and 
the mechanism of PDT induced damage using MAL is needed to confirm this assumption.  
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Abstract 
Light fractionation does not enhance the response to photodynamic therapy (PDT) after 
topical methyl-aminolevulinate (MAL) application whereas it is after topical 5-aminolevulinic 
acid (ALA). The differences in biophysical and biochemical characteristics between MAL and 
ALA may result in differences in localisation that cause the differences in response to PDT. 
We therefore investigated the spatial distribution of protoporphyrin IX (PpIX) fluorescence in 
normal mouse skin using fluorescence microscopy and correlated that with the PDT 
response histologically observed at 2.5, 24 and 48 hours after PDT.  
As expected high fluorescence intensities were observed in the epidermis and 
pilosebaceous units and no fluorescence in the cutaneous musculature after both MAL and 
ALA application. The dermis showed localised fluorescence that corresponds to the 
cytoplasm of dermal cells like fibroblast and mast cells. Spectral analysis showed a typical 
PpIX fluorescence spectrum confirming that it is PpIX fluorescence. There was no clear 
difference in the depth and spatial distribution of PpIX fluorescence between the two 
precursors in these normal mouse skin samples. This result combined with the conclusion of 
Moan et al. that ALA but not MAL is systemically distributed after topical application on 
mouse skin [Moan et al., Int. J. Cancer 103 (2003) 132-135] suggests that endothelial cells 
are involved in increased response of tissues to ALA-PDT using light fractionation. 
Histological analysis 2.5 hours after PDT showed more oedema formation after ALA-PDT 
compared to MAL-PDT that was not accompanied by a difference in the inflammatory 
response. This suggests that endothelial cells respond differently to ALA and MAL-PDT. 
Further investigation is needed to determine the role of endothelial cells in ALA-PDT and the 
underlying mechanism behind the increased effectiveness of light fractionation using a dark 
interval of 2 hours found after ALA but not after MAL-PDT.  
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Introduction 
Previously we reported the difference in response to light fractionated photodynamic 
therapy (PDT) between methyl-aminolevulinate (MAL) and 5-aminolevulinic acid (ALA) 1. 
Using MAL we were unable to increase the efficacy of PDT by the use of a two-fold 
illumination scheme in which the two light fractions are separated by a dark interval of two 
hours. This is different from ALA-PDT where the response following the two-fold illumination 
scheme is significantly increased compared to the response to a single illumination scheme 
as demonstrated in several pre-clinical and clinical studies 2-5. While the mechanism behind 
the increased efficacy is still unknown 3,6-8 this difference between MAL and ALA warrants 
further investigation.  
The use of ester derivatives of ALA was suggested since they are more lipophillic and are 
therefore expected to result in an enhanced bio-availability compared to ALA 9. Differences 
in the biophysical and biochemical characteristics of MAL and ALA may be of importance for 
the response to PDT and potentially to the difference in the response to fractionated PDT. 
For example, Moan et al. 10 showed that prolonged application with ALA resulted in different 
PpIX fluorescence at distance from the applied area whereas it did not after MAL 
application. They concluded that ALA but not MAL becomes systemically distributed after 
topical application leading to the formation of PpIX at distant sites. It is known that the local 
distribution of photosensitiser in cells and tissue can have a critical impact on the response 
to PDT 11,12. Furthermore Rud et al. 13 have shown that the cellular up-take mechanism is 
different for MAL compared to ALA suggesting that certain cell populations may show 
differential uptake of ALA and MALA.  
Although there are techniques available to determine ALA or MAL concentrations they 
can’t be used to investigate the spatial distribution within a tissue section. The fluorescence 
of the accumulated PpIX observed after MAL or ALA application can give an indication of 
the spatial distribution. In a previous study 1 we have found comparable PpIX fluorescence 
intensities after 4 hours of topical application of MAL and ALA. This result was obtained 
using surface fluorescence measurements therefore little is known about the distribution of 
PpIX within the tissue. In the present study we investigated the spatial distribution of PpIX 
fluorescence within normal mouse skin after topical application of either MAL or ALA using 
fluorescence microscopy. These results are correlated with the histological response after 
MAL and ALA-PDT using the single and the two-fold illumination scheme.  
 
Materials and Methods 
Animal model. The animal experiments committee of the Erasmus University Medical 
Centre approved the experimental protocol. We investigated the localisation of PpIX within 
tissue after topical application with MAL and ALA for 4 hours in three groups of female 
inbred albino hairless mice (SKH1 HR, Charles River, Someren, The Netherlands), aged 
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between 8 and 10 weeks. Prior to the experiment, mice were fed on a chlorophyll free diet 
(Hope Farms B.V., Woerden, The Netherlands) for at least two weeks to minimise the 
contribution of pheophorbides to the autofluorescence emission spectrum. 
Porphyrin precursor application. Prior to the application of porphyrin precursor mice were 
anaesthetised using 2% Isoflurane (Abbott, Amstelveen, The Netherlands) oxygen and N2O. 
One group served as control receiving the vehicle alone (3% carboxymethylcellulose in 
water). The two other groups received either ALA or MAL cream. ALA or MAL (Metvix®, 160 
mg g-1, Galderma, Freiburg, Germany) cream was topically applied to a 7 mm diameter area 
on the dorsal skin and covered with a thin layer of gauze. ALA cream was freshly prepared 
as described previously 14. In brief, 20% (w/v) 5-aminolaevulinic acid (ALA, Medac, 
Hamburg, Germany) was dissolved in 3% carboxymethylcellulose in water. NaOH (2M) was 
added to adjust the pH to approximately 4. A polythene dressing (Tegaderm, 3M, The 
Netherlands) was used to occlude the cream for 4 hours. During the application period the 
animals were placed in a dark and warm environment. At the end of the application period 
the mice were again anaesthetised using 2% Isoflurane (Abbott, Amstelveen, The 
Netherlands) oxygen and N2O to remove the cream, collect the surface fluorescence 
measurement and harvest the skin sample.  
Tissue handling and fluorescence microscopy. The applied skin area was excised 
immediately after removal of excess cream at 4 hours after the start of topical application. It 
was snap frozen in liquid nitrogen and stored at -80°C until preparation for fluorescence 
microscopy. Tissue tec II (Leica, Leiden, The Netherlands) embedding compound was used 
to mount the skin sample on the sample holder of the cryostat. Cross-sections were cut (20 
and 5µm) and singularly mounted on clean glass slides (Menzel, Braunschweig, Germany). 
Skin samples and sections always handled under subdued lighting conditions to prevent 
unwanted photobleaching of PpIX. Sections were allowed to thaw at room temperature for 
between 30 minutes and one hour after sectioning and before imaging. 
Fluorescence microscopy images were acquired using a cooled CCD camera 
(Hamamatsu ORCA-ER, Hamamatsu photonics Germany GmbH, Herrsching am 
Ammersee, Germany) mounted on DM RB fluorescence microscope (Leica, Leiden, The 
Netherlands) equipped with a N2.1 filter cube (Leica, Leiden, The Netherlands). This cube 
contains a 515-560 nm band pass excitation filter and 590 nm long pass detection filter. 
Light from the sample was additionally filtered using a 635 ± 5 nm interference filter (BP635, 
Melles Griot, Didam, The Netherlands). Tissue sections were imaged using 5 and 40 times 
objectives to interrogate various structures in epidermis and dermis. The fluorescence 
images were collected using an integration time of 120 seconds. Before recording the image 
the tissue section was localised and focussed using red light filtered through a 695 nm long 
pass filter to minimise photobleaching. A fluorescence image of a KV 470 filter (Schott, Tiel, 
The Netherlands) was recorded as a spatial fluorescence standard. All images of tissue 
samples were divided by the corresponding image of the fluorescence standard to correct 
for spatial in-homogeneity in the beam profile and differences in excitation light intensities.  
Fluorescence spectra were also acquired from these tissue sections under blue light 
excitation using a 405 nm filter in combination with a 460 short pass filter. The fluorescence 
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light was filtered through a 460 nm long pass filter and focussed into an optical fibre which 
was connected to the spectrograph (USB4000, Ocean optics Duiven, The Netherlands) via a 
home-made optical fibre adapter placed in the camera mount of the microscope 15. Fibre 
diameters were chosen in combination with a 20 times objective lens so that light was 
collected from a defined region within the tissue section. The epidermis is thin compared 
with the dermis or the cutaneous musculature therefore we chose the fibre diameters so that 
the size of the spot from which the spectra were collected was actually epidermis (12.5 µm) 
or dermis and cutaneous musculature (67.5 µm). The region in the dermis was chosen so 
that it only contained upper dermal tissue and no pilosebaceous units. Spectra were 
collected using an integration time of 20 seconds for epidermis and 30 seconds for dermis 
and cutaneous musculature.  
Histology. The histological damage after PDT with ALA and MAL was investigated in 14 
groups of mice (n=5-6 in each). Two groups served as ALA and MAL dark controls in which 
skin samples were collected at the end of the application period. In the 12 remaining groups 
the response following two different illumination schemes was investigated; a single light 
fraction of 100 J cm-2 at 50 mW cm-2 or a two-fold illumination scheme with 5+95 J cm-2 at 
50 mW cm-2 separated by a 2 hour dark interval. In each case PDT was performed using 
514 nm light as we have described previously 16. In short, the excitation light was focussed 
on a 7 mm diameter spot of homogeneous profile. Mice were anaesthetised with a 
combination of 2 % Ethrane or Isoflurane (Abbott, Amstelveen, The Netherlands) oxygen 
and N2O. The illuminated skin was excised 2.5, 24 and 48 hours after the end of illumination. 
Tissue was fixed in 4% buffered formalin solution and embedded in paraffin within 48 hours 
after harvesting. Paraffin sections were cut and stained with haematoxylin and eosin (H&E) 
for light microscopy evaluation. 
 
Results 
Fluorescence distribution within the skin after MAL or ALA 
Figure 1 shows the fluorescence images obtained from cryo-sections of skin applied with 
vehicle, ALA and MAL. Skin applied with vehicle showed weak fluorescence intensities in all 
layers with slightly higher intensities in the stratum corneum and the pilosebaceous units. 
After both MAL and ALA application high fluorescence intensities were observed in the 
epidermis and the pilosebaceous units. Besides these locations fluorescence was also seen 
in the upper dermis as well as in the adipose cells of the lower dermis. Only the cutaneous 
musculature showed no elevated levels of fluorescence above autofluorescence. 
Fluorescence spectra were obtained from the epidermis, upper dermis and cutaneous 
musculature of the skin in all groups (Figure 2). Skin applied with vehicle showed a typical 
autofluorescence pattern in all layers. Skin topically applied with MAL or ALA showed the 
characteristic PpIX fluorescence spectrum with peaks at 636 nm and 707 nm in the 
epidermis and the upper dermis. Only the cutaneous musculature exhibited fluorescence 
that was identical to the auto fluorescence spectrum.  
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Figure 1. H&E stained image (a) and fluorescence images of hairless mouse skin sections after 4 
hours of application with cream (b), ALA (c) or MAL (d) of 20 µm sections using the 5 times objective (E, 
epidermis; UD, upper dermis; LD, lower dermis and CM, cutaneous musculature). Note that in some 
images some areas of the epidermis are saturated. The integration time used to obtain these images 
was 120 seconds in order to investigate and show the fluorescence in the dermal and cutaneous 
musculature layer. 
Figure 2. Spectra obtained from the epidermis (a), upper dermis (b) and cutaneous musculature (c) 
of hairless mouse skin sections after 4 hours of application with cream (black), ALA (blue) or MAL 
(magenta). 
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Figure 3. H&E stained image (a-c), fluorescence images (d-f) and combined images (g-i) of normal 
mouse skin sections after 4 hours of application with cream (left panel), ALA (middle panel) or MAL 
(right panel) of 5 µm sections using the 40 times objective. The bar represents 50 µm. 
 
 
Figure 4. H&E stained images of hairless mouse skin; untreated (a) or 2,5 hours after PDT using 
MAL (b,c) or ALA (d,e). The bar represents 200 µm. 
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To investigate the location of the PpIX fluorescence in the upper dermis we obtained 
fluorescence images using a higher magnification (Figure 3). Again in skin applied with 
vehicle weak autofluorescence was observed in the stratum corneum. In the upper dermis 
some regions showed sparsely localised fluorescence. After ALA or MAL application the 
cytosol of epidermal cells showed high fluorescence intensities and the nuclei could be 
recognised as dark regions. Also the upper dermis showed regions with high fluorescence 
intensities. Co-localisation with the H&E stained images of the same sections showed that 
this is the cytosol of fibroblasts and/or mast cells. No clear difference in the localisation of 
PpIX fluorescence after MAL or ALA application could be observed in these images. 
 
Histological response following PDT 
Figure 4 shows the H&E stained sections of control and MAL or ALA-PDT treated skin 2.5 
hours after treatment. In skh-1-hr mouse skin it is normal to find areas with acute infiltration 
in the upper and lower dermis associated with the degeneration of hair follicles due to the 
loss of hair process (Figure 4a). Two and a half-hour after illumination the stratum corneum 
has (partly) detached from the epidermis. At this time point we also observed pycnosis of 
epidermal cells in most animals, independent of the PpIX precursor or light fractionation 
scheme used. In dermis we observed a number of events. The level of inflammatory cells 
was elevated compared to the normal untreated control skin. While the collagen fibres 
appeared to be damaged in some animals the clearest observation was the formation of 
oedema. This caused the thickening of the skin that was greater after ALA-PDT compared to 
MAL-PDT. The cutaneous musculature showed no response at this time point after PDT.  
The histological response observed at 24 or 48 hours after illumination did not show large 
differences in the type or depth distribution response between a two-fold or single 
illumination after either MAL or ALA-PDT therefore the damage is described in general 
below. Twenty-four hours after illumination the epidermis showed coagulative necrosis in 
most animals. In 7 out of 23 animals we observed impetiginisation (inflammatory cells in the 
epidermis) and in some sections we observed oedema between the epidermal cells, i.e., 
plasmodesmen. The border between damaged epidermis and not responding epidermis 
could be sharp-edged. In the upper dermis close to necrotic epidermis we could observe 
regions with variable responses regarding the degree of inflammation. This variation in the 
inflammatory response is actually seen through the whole dermis since it could be found 
loosely spread in the tissue or in a front with only necrotic tissue above it. This front could be 
found at variable levels; just below the basal membrane or at the level of sebaceous glands 
or just above or even in the adipose cell layer of the dermis. The collagen fibres appeared 
coagulated in some animals. In some animals we noticed that the fat cells in the lower 
dermis disappeared completely. The cutaneous musculature of 13 out of the 17 evaluated 
animals showed damage in the form of an inflammatory response sometimes accompanied 
with karyohrexis or coagulative necrosis.  
Forty-eight hours after illumination regeneration of the epidermis had started in most 
animals. In the dermis we still observed coagulation of the collagen. Inflammatory cells were 
again found loosely spread in the tissue or in a front. In one animal we even observed two 
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fronts at different depths. Tissue above a front of inflammatory cells is or will become 
necrotic and detached. Healing of the skin was started from the hair follicles below the front. 
Furthermore we observed proliferating endothelial cells generating new vessels in the 
border areas next to heavily damaged dermal tissue. Dermal tissue that didn’t show the 
heavy inflammatory response sometimes showed a significant loss of sebaceous glands. 
Similar to what we observed at 24 hours we noticed that the adipose cells in the lower 
dermis had disappeared in some animals but at this time point it was accompanied with 
atrophic or disappeared muscle.  
 
Discussion 
In the present study we investigated the local distribution of PpIX after topical MAL or 
ALA application using fluorescence microscopy. In agreement with our expectations, topical 
MAL or ALA application on normal mouse skin results in high fluorescence intensities in the 
epidermis and sebaceous glands. Low fluorescence intensities are observed in the dermis 
and almost no fluorescence is seen in the cutaneous musculature. High magnification 
imaging of the dermis, however, reveals regions with high fluorescence intensities that 
correspond with the cytoplasm of cells. Fibroblasts, mast cells and even the adipose cells in 
the lower dermis show fluorescence after topical application of MAL and ALA. Importantly, 
our spectral analysis confirms that PpIX is the fluorescent species (Figure 2). Our high 
magnification images show high fluorescence intensities in the dermal cells compared to the 
dermal connective tissue. Compared to epidermal cells the dermal cells show around 45% 
of the fluorescence intensity and dermal connective tissue shows only 10% of the intensity 
(data not shown). In vitro studies have shown those fibroblasts are capable of PpIX 
accumulation 17. While the contribution of dermal connective tissue in the dermis is high the 
low cellular density partly explains the low fluorescence intensity generally measured in 
dermis 18. 
Previously Moan et al. 10 have observed differences in the distribution of the two PpIX 
precursors suggesting that MAL but not ALA becomes systemically distributed. In-vitro 
studies have shown differences in cellular up-take mechanism 13 that potentially could lead 
to cells taking up ALA and not MAL or visa versa. Based on these studies and the known 
differences in biophysical and biochemical characteristics between the two PpIX precursors 
we expected to find differences in the PpIX fluorescence distribution with penetration depth 
and possibly cellular function. However, in the present study we were unable to find a clear 
difference in PpIX distribution within the applied area. All cells in the epidermis and dermis 
show PpIX fluorescence and there is no difference in the penetration depth. PpIX 
fluorescence is observed over the whole dermal layer up to the adipose cells adjacent to the 
cutaneous musculature after both MAL and ALA application. Blood vessels and in particular 
capillaries are found throughout the dermis. This suggests that both PpIX precursors 
penetrate to a depth below the level of the blood supply. Considering the results presented 
here and the results of the study of Moan et al. this would mean that ALA and not MAL 
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penetrates into the blood stream either by diffusing through or passing between the 
endothelium cells. Garcia et al. 19 have reported ALA efflux through diffusion in LM3 cells in-
vitro. It will be interesting to determine if MAL efflux also occurs and if there are specific 
differences between tumour and endothelial cells. In an attempt to investigate the capacity 
of endothelial cells to synthesis PpIX we stained them using CD31 and CD34 antibodies. 
Unfortunately we were not successful in these mouse sections. Our previous work on the 
highly vascularised skin fold chamber model suggests that endothelial cells are capable of 
synthesizing PpIX after systemic ALA administration 20. Furthermore it has been shown that 
ALA-PDT results in vascular damage, even after topical application 21,22, also suggesting 
that endothelial cells accumulate PpIX. Whether or not MAL is taken up by or transported 
through the endothelial cells could not be investigated in the current study.  
In a previous study 1 we showed the histologically scored damage in skin tissue after MAL 
and ALA-PDT using either a single or a two-fold illumination scheme at different time points 
after PDT. Then we used a table that grades the different cellular responses like coagulative 
necrosis, karyorhexis and pyknosis that can be observed and we found no differences in this 
between MAL and ALA-PDT. In the present manuscript we explored the histological 
response in greater detail looking also on the tissue responses like oedema and 
inflammation. Histologically, we found significantly more oedema in the dermis of skin 2.5 
hours after ALA-PDT compared to MAL-PDT, independent of the illumination scheme used 
(Figure 4). The severity of oedema is usually not used to score PDT induced damage while 
oedema is considered to be an indirect result of a complex of reactions that deals with an 
imbalance between the osmotic and hydrostatic pressure acting across the semi-permeable 
capillary walls of blood and lymphatic vessels. Inflammation has a big influence on this as it 
changes the permeability of capillary walls and increases the oncotic pressure outside 
vessels. In general, inflammation and oedema is a common tissue response to PDT using 
ALA or other photosensitisers 23 but also vascular responses are reported 24-26. PDT using 
Photofrin is known 24 to result in direct cytotoxic endothelial cell damage and vascular 
leakage. Also ALA-PDT is known to result in vascular leakage 25,26. If and how the extent of 
oedema formation can be used to score PDT induced damage and if this could be used as a 
measure of vascular damage is unknown. To our knowledge only Sheng et al. 27 have used 
oedema to score the damage to the oesophagus after ALA-PDT. The observed difference 
the oedema formation in the present study was not accompanied by a difference in the 
inflammatory response. This suggests that the formation of oedema was not only due to the 
inflammatory response. While endothelial cells are involved in the oedema response this 
difference in oedema formation might suggest that the damage to endothelial cells is 
different after MAL compared to ALA-PDT.  
We were unable to show any PpIX fluorescence in the cutaneous musculature using 
either fluorescence imaging or spectral analysis. Still the histological evaluation 24 and 48 
hours after treatment showed severe cutaneous muscular damage in some animals. We 
have also observed this phenomenon for ALA-PDT in oesophagus and other organs 28-30. 
Van den Boogert et al. 28 suggested that the threshold to induce necrosis might be lower for 
muscle than for other tissues. In our most recent study we showed that the muscle of the 
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oesophagus accumulates PpIX after oral ALA administration 30. However, we were unable to 
find any PpIX fluorescence in the cutaneous musculature of the skin after topical ALA or 
MAL application and still found severe necrosis. It is known that tissue close to necrotic 
tissue may become necrotic as a result of the inflammatory reactions. In some of our 
samples this could very well be the explanation, although not all the necrotic cutaneous 
musculature is found close to necrotic dermal tissue. Collagen fibres in some areas in the 
dermis appeared to be coagulated. PDT does not induce heating to a temperature that is 
sufficient enough to denature collagen 32. Direct cell damage to the fibroblast and mast cells, 
normally responsible for the collagen production, may cause the release of proteins that 
result in the coagulation of collagen fibres. In an in-vitro study Karrer et al. 32 showed an 
increase in the synthesis of matrix metalloproteinase (MMP)-1 in dermal fibroblast after ALA-
PDT. While MMP-1 is an interstitial collagenase that is known to be involved in the 
degradation of extra cellular collagen fibres (types I, II, III, IX and XI) it could be involved in 
the observed collagen coagulation in our mouse skin samples. The observed 
impetiginisation within the epidermal layer suggests that the damaged cells release factors 
involved in the inflammation process. Furthermore we have seen a front of inflammation 
cells at variable depth within the dermis. It is unusual to find inflammation in such a 
particular orientation in tissue and it will be interesting to investigate the regulation of this 
phenomenon.  
In conclusion, we investigated the distribution of accumulated PpIX after topical MAL and 
ALA application and found no clear difference in the spatial distribution of PpIX 
fluorescence. Cells in the epidermis but also in the dermis of normal mouse skin accumulate 
significant PpIX after topical MAL or ALA application as confirmed by our spectral analysis. 
Histological analysis showed a distinct difference in the formation of oedema 2.5 hours after 
PDT that was not accompanied by a different inflammatory response to PDT. This suggests 
that endothelial cells are involved in the different between the response of tissue to MAL and 
ALA to light fractionation. Further investigation is needed to determine the underlying 
mechanism behind the increased effectiveness of light fractionation using a dark interval of 2 
hours found after ALA but not after MAL-PDT.  
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Introduction 
The exogenous administration of 5-aminolevulinic acid (ALA) to cells and tissues leads to 
the accumulation of protoporphyrin IX (PpIX) by bypassing the feedback inhibition of ALA-
synthase that normally regulates the haem synthesis pathway 1. The last step of this 
pathway, the chelation of iron to protoporphyrin IX (PpIX) by ferrocelatase (FC), is a 
relatively slow process and this leads to the temporary accumulation of PpIX. This process 
is the basis for the use of porphyrin pre-cursors for photodynamic therapy (PDT) that is now 
used to treat a variety of (pre-) malignant conditions 2-4. PDT using light fractionation, where 
a dark interval separates two periods of illumination has shown to significantly increase the 
efficacy of ALA-PDT in both pre-clinical models and in non-melanoma skin cancer 5-7. In a 
series of studies the treatment parameters for light fractionation were optimised and the 
greatest increase in efficacy was found when the treatment fluence was split into two 
unequal fractions in which the PDT dose of the first fraction is relatively low and the dark 
interval between light fractions is two hours 5-10.  
The mechanism behind this increase in effectiveness of the two-fold illumination scheme 
is unknown. We, and other investigators have shown that PpIX continues to be synthesised 
in-vivo after PDT 5,9,11-15 and that this re-synthesis is a local cellular effect 13. The original 
rationale behind the design of this type of light fractionated illumination scheme was the 
utilisation of re-synthesised PpIX after photobleaching during the first fraction. However in a 
range of pre-clinical models we were unable to find a correlation between the amount of 
PpIX re-synthesis and the effectiveness of light fractionation 8,9,14. The efficacy of light 
fractionated PDT seems to be determined by the damage induced during the first 
illumination and the timing of the second light fraction. We have hypothesised that a cellular 
mechanism is involved in which cells that are sub-lethally damaged by the first light fraction 
may be vulnerable to a second light fraction delivered two hours later 9.  
The effect of fractionated illumination on cells in vitro has been studied previously by 
Hinnen et al. 15. They found that human EBV (Epstein Barr Virus transformed) 
lymphoblastoid cells showed reduced FC activity leading to more PpIX accumulation after 
ALA-PDT compared to un-treated controls. They also found that light fractionation resulted 
in more cell death compared to a single illumination. However, their aim was to increase the 
efficacy of the treatment and not to compare the efficacy of different illumination schemes. 
The authors did not use the same cumulative fluence for both illumination schemes and the 
single illumination was always performed on the earliest time point.  
The aim of the present study was to investigate the effect of various two-fold and single 
illumination schemes with the same cumulative fluence in-vitro using the optimal illumination 
parameters previously found for light fractionated PDT in-vivo 9. It is difficult to translate 
these illumination parameters since the ones used to treat cells in vitro are typically much 
lower than those used to treat tissue in-vivo. In the present study we therefore investigated 
the effect of different two-fold illumination schemes varying the fluence of the first and 
second light fraction and compared these results with those after a single illumination with 
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the same cumulative fluence delivered on any time point used for light fractionation. As a 
starting point we used the results obtained in the hairless mouse model in which we have 
previously 5,8,9 determined an optimised treatment scheme; topical ALA 4 hours, 5 J cm-2 at 
50 mW cm-2, 2 hours dark interval and 95 J cm-2 at 50 mW cm-2. The mouse skin shows only 
some discolouration after a single illumination of 5 J cm-2 (data not published). This was 
translated to an in-vitro illumination that results in 5 to 15% cell death. The fluence of the 
second light fraction results in more skin damage in-vivo and is translated to an illumination 
that would result in more but not complete cell death, i.e., approximately 50% cell death, in-
vitro. During the dark interval between light fractions, ALA should be available to the cells to 
replicate the conditions following topical ALA administration to the skin. This study was 
performed on LM3 and PAM212 cells 16,17. 
 
Materials and Methods 
Cell lines and cell cultures: Cell line LM3 from Hospital Roffo 18 derived from the murine 
mammary adenocarcinoma M3 was cultured in minimum essential Eagle’s medium, 
supplemented with 2 mM L-glutamine, 40 µg gentamycin ml-1 and 5% fetal bovine serum. 
The tumourigenic PAM 212 cell line which is derived from murine epidermal keratinocytes 19 
was cultured in RPMI-1640 medium and supplemented with L-glutamine, gentamycin and 
10% fetal bovine serum. The cells were incubated at 37°C in an atmosphere containing 5% 
CO2 and employed at confluency.  
ALA administration: The cells were seeded in triplicate in 6-well plates containing 7x104 
cells ml-1 and incubated 48 h at 37°C. Afterwards, LM3 cells were incubated with serum free 
medium containing 0.6 mM ALA which leads to plateau porphyrin values 16. A dose of 2 mM 
results in plateau porphyrin values in PAM212 cells (data not shown).  
Light fractionation schemes: Irradiation was performed according to a single and two-fold 
illumination scheme using different light fluences. Cell survival curves were determined, as 
described below, for a single illumination using different ALA exposure times in both LM3 
and PAM212 cells. Alternatively, light was fractionated in two doses separated by a dark 
interval of 2 or 3 hours. During the dark interval cells remained exposed to ALA and were 
incubated at 37°C . The light fluence of the first and second light fraction in our pre-clinical 
model were optimised and resulted in approximately 10% and 55% response respectively 5.  
For LM3 cells we translated these fluences based on the results obtained in the previous 
study 16. The fluence that induced 5 or 10% cell death (LD 5 or 10) was used for the first 
fraction and LD 40 or 55 were used for the second light fraction, i.e., (0.17 J cm-2 split into 
0.034+0.136 J cm-2 and 0.255 J cm-2 split into 0.054+0.204 J cm-2). The first fraction was 
delivered after 3 hours of ALA exposure and the second fraction was delivered at 5 hours 
after the start of ALA exposure.  
For the PAM212 cells we chose four different two-fold illumination schemes for three 
different total fluences; 0.34, 0.408 and 0.510 J cm-2 based on the results described in this 
study. The total fluence of 0.34 J cm-2 was split into 0.102+0.238 J cm-2, the total fluence of 
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0.408 J cm-2 was split in 0.136+0.272 J cm-2 and the total fluence of 0.510 J cm-2 was split in 
0.170+0.34 J cm-2. The first fraction was delivered either at 2 or 3 hours after ALA exposure 
followed by a second fraction at 5 hours, i.e., 2+5 or 3+5 hrs. 
PDT illuminations: A bank of two fluorescent lamps (Osram L 36W/10) was used for the 
therapeutic illumination. The output spectrum of this light ranged from 400 to 700 nm with 
the highest radiant power at 600 nm. The plates were irradiated from below, at 20 cm 
distance from the light source. Fluence rate was measured with a radiometer, (Yellow 
Springs Kettering model 65, Yellow Springs, OH, USA). Fluences between 0.1 and 1 J cm-2 
were used at a power density of 0.5 mW cm-2. After the end of the treatment procedure, 
medium was replaced by ALA-free medium +FBS and the cells were incubated for 19 h and 
tested for cell viability.  
MTT viability assay: Phototoxicity was documented using the MTT assay 20, a method 
based on the activity of mitochondrial dehydrogenases. Following appropriate treatments, 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) solution was added to 
each well in a concentration of 0.5 mg ml-1, and plates were incubated at 37°C for 1 h. The 
resulting formazan crystals were dissolved by the addition of DMSO and absorbance was 
determined at 560 nm. 
Statistical analysis: Data are expressed as mean ± standard error of the mean, and they 
are the average of three independent experiments run in triplicate. A paired two-tailed 
Student’s t-test was used to determine statistical significance between means. P values 
<0.05 were considered significant. 
 
Results  
Cell survival curves for LM3 cells 
Figure 1 shows the cell survival of LM3 cells after ALA-PDT using various single and two-
fold illumination schemes. After a single illumination the cell survival decreases with 
increasing fluence for both 3 and 5 hours ALA exposure. Furthermore, increasing the ALA 
exposure time from 3 to 5 hours results in a lower cell survival, i.e., a more effective 
treatment. A single illumination with a fluence of 0.17 J cm-2 delivered at 5 hours results in 
15.9 ± 11.4% cell survival, which is significantly more effective than an illumination at 3 
hours resulting in 51.7 ± 1.6% cell survival (n=2, P =0.048). The same applies for a single 
illumination with a fluence of 0.255 J cm-2. Delivery at 5 hours results in 5.1 ± 4.7% cell 
survival that is significantly more effective than illumination at 3 hours resulting in 33.2 ± 
3.0% cell survival (n=2, P =0.019).  
A two-fold illumination scheme with the same cumulative fluences results in 36.8 ± 13.6% 
cell survival for 0.17 J cm-2 (split into 0.034+0.136 J cm-2) and 4.4 ± 4.0% for 0.255 J cm-2 
(split into 0.051+0.204 J cm-2). The response to a two-fold illumination is not significantly 
different from that compared to a single illumination performed after 5 hours of ALA 
exposure (P =0.24 and 0.90, respectively). 
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Cell survival curves for PAM212 cells 
Similar results are obtained with PAM212 cells (Figure 2). For single illumination schemes 
the cell survival decreases with increasing fluence for all exposure times. In addition, the 
illumination is more effective after longer ALA exposures. Illumination with a fluence of 0.34 
J cm-2 at 5 hours results in 25.8 ± 9.5% cell survival whereas illumination at 3 hours results 
in 46.7 ± 10.9% cell survival (n=3, P =0.38). Illumination at 2 hours is even less effective and 
results in 72.8 ± 6.2% cell survival (n=3, P = 0.15 compared to PDT at 3 hrs and 0.027 
compared to PDT at 5 hrs).  
A two-fold illumination with the same cumulative fluence, i.e. 0.34 J cm-2 split into 
0.102±0.238 J cm-2, results in 52.7 ± 15.4% cell survival for a 2+5 hours scheme, which is 
not significant from 33.7 ± 23.3% for 3+5 hours (n=3, P =0.45). The response following the 
most effective two-fold illumination scheme (3+5 hrs) is not significantly increased when 
compared with the most effective single illumination (5 hrs, P =0.62). Similar results are 
obtained for illuminations with a cumulative fluence of 0.408 or 0.510 J cm-2.  
 
Figure 1. Cell survival of LM3 cells after ALA-
PDT using different fluences and illumination 
schemes. Cells were exposed to 0.6 mM ALA in 
FBS-free medium. Single illuminations were 
performed after 3 () or 5 hours (○) of ALA 
exposure. Two-fold illuminations were performed 
after 3+5 hours of ALA exposure (■). Cell survival 
was determined 19 hours after PDT using the 
MTT assay and was expressed as percentage of 
the non-irradiated control incubated in the 
presence of ALA. 
 
Figure 2. Cell survival of PAM212 cells after 
ALA-PDT using different fluences and illumination 
schemes. Cells were exposed to 2 mM ALA in 
FBS-free medium. Single illuminations were 
performed after 2 (), 3 () and 5 hours (○) of 
ALA exposure. Two-fold illuminations were 
performed at 2+5 hours (▲) or 3+5 hours (■) of 
ALA exposure. Cell survival was determined 19 
hours after PDT using the MTT assay and was 
expressed as percentage of the non-irradiated 
control incubated in the presence of ALA. 
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Discussion 
Our results show that light fractionated ALA-PDT does not enhance the response of LM3 
or PAM212 cells in-vitro. This result is contrary to our findings in a range of in-vivo models 
and for ALA-PDT of human basal cell carcinoma 5-7. We have previously hypothesised that 
there may be a cellular mechanism by which cells are sub-lethally damaged following the 
first light fraction are vulnerable to the second fraction two hours later 9. Our data seem to 
preclude this hypothesis, at least in the cells that we have investigated to date. In both LM3 
and PAM212 cells light fractionation with dark intervals of the order of 2-3 hours does not 
enhance the effectiveness of ALA-PDT over that observed with a single illumination with the 
same cumulative fluence. 
Hinnen et al. 15 were the first to compare the response of cells grown in-vitro to ALA-PDT 
using a single and a two-fold illumination scheme. They found a significantly lower cell 
survival after a two-fold illumination, delivered 2 and 5 hours after ALA exposure, compared 
to a single illumination scheme 2 hours after ALA exposure. While the aim of the authors 
was not to compare the effectiveness of different illumination schemes the cumulative 
fluences of the schemes were not the same. The fluence delivered during a single 
illumination was half (12.5 J cm-2) of the cumulative fluence delivered during the two-fold 
illumination (25 J cm-2). It is therefore unclear if the increased efficacy of the two-fold 
illumination is due to light fractionation. It is possible that a single illumination with the same 
cumulative fluence would have been as effective as the two-fold illumination. Furthermore it 
is important to carefully consider the accumulation of PpIX at the time point at which each of 
the illuminations is performed. In the above mentioned paper, the two fractions of the two-
fold illumination scheme were delivered at 2 and 5 hours after the start of ALA exposure 
whereas the single illumination was performed at 2 hours. The authors showed that there 
was significantly more PpIX accumulation 5 hours after the start of ALA exposure compared 
to 2 hours, which is also shown by Perotti et al. 21. This suggests that an illumination at this 
time point would be more effective. The results of the present study support this conclusion 
and show that a single illumination after a 5 hour incubation period is significantly more 
effective. It would be interesting to investigate if the two-fold illumination scheme is still more 
effective in treating human EBV-transformed lymphoblastoid cells when the influence of 
these effects is considered. 
A limitation of the present study is the absence of data on porphyrin intensities in cells 
during light fractionated ALA-PDT. The fluence of the first light fraction alone results in 5-
10% cell death for the lowest fluence used. It is likely that the surviving cells will accumulate 
PpIX from the ALA present in the medium based on the results obtained by Perotti et al. 21 
and Hinnen et al. 15. In un-treated cells the PpIX accumulation has shown to increase 
linearly with the incubation time up to 24 hrs 21. Also Hinnen et al. 15 found a significant 
increase in the PpIX accumulation in illuminated cells. 
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In addition it is well known that different cell lines respond differently to PDT. The results 
here show that LM3 cells are more sensitive to ALA-PDT than the PAM212 cells. LM3 cells 
accumulate more PpIX and the fluence needed to kill 50% of the cells was lower (0.18 J  
cm-2 for LM3 cells compared to 0.36 J cm-2 for PAM212 cells). However, notwithstanding 
these differences the general correlation between ALA exposure time and PDT efficacy is 
similar. A single illumination is more effective when it is delivered after 5 hours of ALA 
exposure compared to 2 or 3 hours. This is due to the increase in PpIX accumulation with 
incubation time that results in a greater exposure to reactive oxygen species during PDT. 
The response of each cell line to a two-fold illumination is comparable and not significantly 
different from that following a single illumination delivered at any of the time points tested. 
Both the LM3 cells and PAM212 cells do not show an increased cell death after ALA-PDT 
using a two-fold illumination. However, other cell lines may respond differently and it is our 
intention to extend these experiments to different cells from a range of origins, in particular 
vascular endothelial cells. 
The contribution of the tissue (or host) component to the PDT response is not included in 
in-vitro studies. ALA-PDT induced damage is mostly attributed to direct cell damage 
however vascular responses have been reported 22,23. Moan et al. 24 showed that ALA is 
systemically re-distributed after topical ALA application. This indicates that ALA is available 
for the endothelial cells and it is likely that they will generate PpIX and therefore are a target 
for PDT damage. In a previous study we showed that light fractionated PDT using methyl 
aminolevulinate (MAL) does not lead to an increase in response in normal mouse skin 25. In 
addition ALA-PDT resulted in significantly more oedema compared to MAL-PDT, reinforcing 
the hypothesis that the vasculature may play a role in the increased efficacy of light 
fractionation. 
In conclusion, the results in the present study show that the increased efficacy of light 
fractionated ALA-PDT is not found in-vitro. This suggests that the mechanism involved is 
more complicated than the cellular mechanism proposed. 
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The subject of this thesis is ALA-PDT and the mechanism underlying the increased 
efficacy achieved by fractionated illumination. The results of the work are discussed in detail 
below. In short; light fractionation, in which two light fractions are separated by a dark 
interval of more than 1 hour, leads to a significant enhancement in treatment response. The 
light treatment parameters that are used for fractionation are critical with respect to the 
degree of the improvement in efficacy. The mechanism behind this increased efficacy has 
proven to be significantly more complex than first anticipated. 
 
Photodynamic therapy using ALA and other porphyrin pre-cursors is widely accepted as a 
treatment option for a number of predominately cutaneous (pre-) malignancies. It has also 
been applied to a variety of non-malignant skin diseases and is under investigation for the 
treatment of other conditions in various organs. While, initial complete response rates of 
more than 90% were reported for superficial basal cell carcinoma the need for improvement 
is illustrated by the low long-term response rates of 50%. Also 25% of the patients treated 
for Barrett’s oesophagus fail to respond to ALA-PDT using a single light fraction. 
The use of light fractionated ALA-PDT was inspired by a clinical observation of Star 1 who 
noted the reappearance of the photosensitiser PpIX fluorescence in the hours after 
treatment in a skin lesion that showed complete photobleaching of fluorescence during 
treatment. The initial rationale behind light fractionation using a long dark interval was to 
utilise this additional PpIX for PDT. The results obtained in the first studies using this type of 
light fractionation were promising 2,3. In order to maximise the potential increase in efficacy, 
before translating the approach to the clinic, studies were performed to optimise light 
fractionated ALA-PDT and investigate the mechanism underlying the increase in 
effectiveness.  
 
Chapters 2, 3 and 4 describe a series of pre-clinical studies in which the treatment 
parameters of light fractionated PDT were investigated in order to optimise treatment 
efficacy. The data presented in Chapter 2 are acquired from a transplanted tumour model 
using systemic ALA. In Chapters 3 and 4 ALA is applied topically to normal mouse skin. In 
both cases the data illustrate that light fractionation with a dark interval of more than 1 hour 
results in significantly increased efficacy. In both cases also the response to a single 
illumination delivered at different time points after ALA administration is not different. 
Illumination at 4 or 6 hours after topical ALA on normal mouse skin results in a similar 
response. This is explained by the PpIX fluorescence kinetics that shows a similar PpIX 
fluorescence intensity at these two time points. For the solid tumour model this is different. 
Here the fluorescence intensity at 2.5 hours is almost 2.6 times higher compared to 1 hour 
after systemic ALA administration. The growth delay is slightly but not statistically significant, 
increased for illumination at 2.5 hours compared to 1 hour. It is known that the PDT 
response is influenced by the availability of three parameters; light, oxygen and 
photosensitiser concentration. An increased photosensitiser concentration will result in a 
higher demand for oxygen for the formation of singlet oxygen when the same light 
parameters are used. The result that the growth delay was not significantly increased after 
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illumination at a time point at which significantly more PpIX was available suggests that 
oxygen is the parameter that limited the response to PDT 4,5. 
 
The length of the dark interval is critically important for the degree of improvement in 
efficacy of light fractionated PDT. Reducing the length of the dark interval from 2 hrs to 1.5 
hrs, 1 hr or 30 minutes significantly decreases the efficacy of light fractionated ALA-PDT 
measured in the hairless mouse model. While the aim of that study was to investigate 
whether the length of the dark interval could be shortened without loss of effectiveness only 
shorter intervals were tested. The results show however a significant trend for increasing 
damage with increasing length of dark interval. It is therefore possible that a longer dark 
interval would be more effective. The response to light fractionation using a dark interval of 
30 minutes or 1 hour is not significantly different from that to a single illumination. That a 
dark interval shorter than 1.5 hours does not increase the efficacy of light fractionated ALA-
PDT was also shown by Babilas et al. 6. They used a dark interval of only 15 minutes and 
were unable to show a difference in the growth delay of subcutaneously growing amelanotic 
melanoma after fractionated PDT compared to PDT using a continuous illumination with the 
same cumulative fluence. It seems that the increased effectiveness found after fractionated 
PDT is only observed when a dark interval of more than 1 hour is used. A 1.5 hours dark 
interval significantly improves the response compared to a single illumination. Moreover, 
only the two hour dark interval resulted in significantly the most severe skin damage 
compared to the shorter intervals tested. Light fractionation using dark intervals in the order 
of seconds and minutes represents an alternative approach for improving the efficacy of 
ALA-PDT. These fractionation schemes (i.e. multiple interruptions 30 sec on/off or single 
interruptions of 150 sec) were shown to result in a significant larger area of necrosis in 
normal colon 7-9. This was attributed to re-oxygenation in the dark interval and associated 
with vascular reperfusion injury (I/R injury). A previous study on normal mouse skin 10 
showed that this type of light fractionation does not have an effect on the PDT response of 
normal mouse skin. Also in the solid tumour model this is not as effective as light 
fractionation using a dark interval of more than 1 hour. For light fractionation using a dark 
interval of more than 1 hour the I/R injury mechanism seems not to be involved. Oxygen was 
measured indirectly through photobleaching and the PDT doses were too small to induce 
vascular response and significant oxygen depletion, which is needed to induce I/R injury. 
Furthermore in a previous study 11 it was shown that the vasoconstriction induced by the first 
light fraction is not significantly decreased during the dark interval. Although this was only 
assessed visually in the highly vascularised skin-fold chamber model using white light 
microscopy this suggests that there is no significant reperfusion during that time interval.  
The results described in Chapter 4 show that besides the duration of the dark interval 
also the PDT dose of the first light fraction is crucially important for the degree of 
improvement in efficacy of light fractionated PDT. The efficacy of light fractionated PDT is 
significantly improved when the fluence is split in 5+95 J cm-2 at 50 mW cm-2 compared to 
50+50 J cm-2 at 50 mW cm-2. Further reduction of the fluence of the first light fraction, i.e., 
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decreasing the PDT dose, will not improve the efficacy. Reducing the fluence rate from 50 to 
5 mW  
cm-2, i.e., increasing the PDT induced damage, reduces the efficacy of this light fractionation 
scheme. These illumination parameters were optimised for illuminating normal mouse skin 
and should be carefully translated for other application areas taking the treatment volume in 
consideration. The distribution of light in tissue is not homogeneous and the fluence rate 
decreases with increasing depth. This is important for treatment volumes that are not 
optically thin as the normal mouse skin is. The results described in Chapter 2 show that the 
fluence rate in the solid tumour model decreases to 23% at the bottom of the tumour 
compared to that on top of the tumour. Treatment of this tumour will therefore result in a 
range of fluence rates and fluences over the whole of the tumour. That this may have 
important consequences for the efficacy of the treatment is shown by the thickness effect 
found in that study; tumours thinner than 4 mm responded significantly better than thicker 
tumours. Also human skin lesions are usually thicker than mouse skin. In mouse skin PpIX 
is predominantly accumulated in the epidermis that is only ≈ 30 µm thick and the green light 
used for treatment is homogeneously distributed over this region. For this reason the 
optimised treatment parameters found for mouse skin (i.e. 5+95 J cm-2 at 50 mW cm-2 at 
4+6 hours after topical ALA) were translated to a clinical light fractionation scheme using red 
light and a first light fraction of 20 J cm-2 delivered at 50 mW cm-2 followed by a dark interval 
of 2 hours and a second light fraction of 80 J cm-2 at 50 mW cm-2. The initial CR of this 
translated light fractionation scheme are significantly improved 12 which illustrates the 
importance of the illumination parameters for the efficacy of light fractionated ALA-PDT. 
Increasing the fluence used for the second light fraction results in a more effective light 
fractionation scheme. A second light fraction of 95 J cm-2 is more effective than 45 J cm-2. 
This is different from what is found for single illumination schemes where a fluence of 50 J 
cm-2 is equally effective as a fluence of 100 J cm-2. The efficacy of a single illumination is 
limited by the photobleaching of PpIX. This seems logical since continuing an illumination 
once PpIX is photobleached is not likely to lead to more PDT induced damage. Apparently 
this is different for light fractionated ALA-PDT. Here the PpIX fluorescence during the 
second light fraction is almost photobleached after 45 J cm-2, but continuing the illumination 
still results in an increased efficacy. The data described in Chapter 3 also show that the rate 
of photobleaching is reduced during a second light fraction compared to that during the first 
light fraction. This may be due to either a reduced availability of oxygen at the time of the 
second illumination or possibly the differential cellular or tissue localisation of PpIX. The 
PDT damage induced by the first light fraction may result in a locally reduced availability of 
oxygen that will lead to a reduced rate of photobleaching. The results described in Chapter 6 
suggest that there is no difference in tissue localisation of PpIX as all tissues investigated in 
the skin-fold chamber model (tumour, normal and vascular tissue) showed a similar increase 
of PpIX fluorescence after the first light fraction. This is supported by a clinical study 13 in 
which the spatial distribution of PpXI in biopsies of superficial BCC was investigated. Here 
the distribution of PpIX in skin lesions collected two hours after a first light fraction was not 
different from that observed in un-illuminated control lesions. The intracellular localisation of 
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PpIX after illumination was not investigated in this thesis. In normal cells PpIX is 
accumulated in the mitochondria but this may be different for sub-lethally damaged cells 
where the enzymes involved in haem synthesis may be localised differently.  
 
The original hypothesis for the increased damage after light fractionated ALA-PDT was 
the utilisation of the resynthesised PpIX in the second illumination. The results obtained in 
the various studies described in this thesis show, however, that the efficacy of light 
fractionated ALA-PDT is not directly correlated with the amount of resynthesised PpIX as 
estimated from fluorescence. This is clearest for the results described in Chapter 6 where 
significantly more PpIX was available for a single illumination compared to the light 
fractionated PDT and still light fractionated PDT was significantly more effective. The results 
obtained in the hairless mouse model support this conclusion. The most effective light 
fractionation scheme utilised only 10% more PpIX compared to a much less effective 
fractionation scheme. This shows that other factors than just the amount of photosensitiser 
play a role in the mechanism of action.  
The pharmacokinetics of PpIX fluorescence after PDT shows a correlation with the PDT 
dose delivered. While the results of Chapter 6 show that the PpIX fluorescence after PDT is 
due to local re-synthesis this might be expected. PpIX is synthesised from ALA by cells. A 
higher PDT dose results in more PDT induced damage and may therefore cause more 
cellular damage resulting in fewer cells that are capable of PpIX re-synthesis. The 
importance of the PDT induced damage by the first light fraction, i.e., the PDT dose, led us 
to the hypothesis that sub-lethal damage might be an important factor. The PDT dose of the 
first light fraction is relatively small. In normal mouse skin illumination with only the first light 
fraction results in minimal visual skin damage. PpIX fluorescence is bleached to 40% of its 
initial intensity suggesting that considerable damage is induced. That only minimal damage 
is observed in time after PDT might suggest that the damage was repairable. This, 
combined with the importance of timing the second light fraction suggests that cellular 
processes initiated by the first light fraction influence the susceptibility of cells to a second 
light fraction. The results described in Chapter 9 show that the increased efficacy of light 
fractionated ALA-PDT is absent in-vitro. This suggests that the mechanism involved is more 
complicated than the cellular mechanism that was proposed. 
 
While light fractionation resulted in a significant increased efficacy in ALA-PDT, this type 
of illumination was also investigated for MAL-PDT (Chapter 7). Contrary to our expectations 
light fractionation does not increase the efficacy of MAL-PDT. Apparently there are 
differences in the response to MAL and ALA PDT that play a role in the mechanism. 
Although MAL and ALA are both PpIX precursors there are significant differences that may 
be involved in the difference in response. The two molecules are very different in their 
biochemical and biophysical characteristics that potentially could lead in a different spatial 
distribution. The PpIX fluorescence photobleaching data show a small but significant 
difference in rate of photobleaching. While the rate of photobleaching depends on the 
microenvironment of the PpIX molecule this supports the hypothesis of a different 
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distribution. Fluorescence microscopy on skin samples obtained 4 hours after topical 
application of either MAL or ALA, however, seems to show no difference in local spatial 
distribution. PpIX fluorescence is observed in epidermal and dermal cells throughout the full 
skin thickness. This result seems to contradict Moan et al. 14, who showed a difference in the 
systemic distribution of MAL and ALA suggesting a difference in localisation. It seems that 
the difference in systemic distribution is not accompanied by a difference in local distribution. 
The border between systemic distribution and local distribution is formed by the endothelial 
cells that form the lining of blood vessels. If and how the distribution of MAL or ALA is 
different in the endothelial cells could not be investigated in this study. The CD31 and CD34 
markers used to stain them in these mouse samples showed either too much background or 
failed to stain the endothelial cells. It is interesting that the histological samples obtained 2.5 
hours after PDT show a distinct difference in the severity of the oedema formation; more 
oedema is found after ALA-PDT compared to MAL-PDT. The severity of oedema is usually 
not used to score PDT induced damage while oedema is considered to be an indirect result 
of a complex of reactions that deals with an imbalance between the osmotic and hydrostatic 
pressure acting across the semi-permeable capillary walls. Inflammation has a significant 
influence on this as it changes the permeability of capillary walls and increases the pressure 
in and outside vessels. The difference in oedema formation observed was not accompanied 
by a difference in inflammatory response suggesting that this is a difference in vascular 
leakage. ALA-PDT is known to result in vascular leakage 3,15. The results suggest that the 
difference in oedema is due to a difference in the response of endothelial cells to ALA or 
MAL-PDT. How this is involved in the mechanism behind the increased efficacy of light 
fractioned ALA-PDT is unknown and warrants further investigation.  
 
Light fractionated ALA-PDT in clinical practice 
The results of the first pre-clinical studies showing an increased efficacy of light 
fractionated ALA-PDT led to a first clinical study 16 investigating light fractionation in which 
the illumination was split in two equal fractions of 45 J cm-2. The five year follow-up results 
were published in 2006 and showed a significantly increased response compared to the 
results published in the literature for single light treatments. Light fractionated ALA-PDT of 
superficial BCC results in 84% CR compared to 56% for standard ALA-PDT treatment. After 
determining the optimum illumination parameters a second clinical study was initiated 
comparing a single illumination with the translated optimised light fractionation scheme 12. 
Already after one-year follow-up the response of superficial BCC to the optimised 
fractionation schemes was significantly better than to a single illumination scheme (97% 
versus 89% p=0.002). Encouragingly, this significant difference in clinical response is 
maintained 24 months after therapy (96% versus 86%). The importance of the illumination 
parameters is also shown in these studies as the response to the optimised illumination 
scheme is significantly better compared to the non-optimised scheme. Currently, light 
fractionated ALA-PDT using the optimised illumination scheme is daily practice for AK, 
sBCC, thin nodular BCC and Bowens disease in the Department of Dermatology, Erasmus 
Medical Center Rotterdam.  
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Light fractionated ALA-PDT: future perspectives 
The mechanism involved in the increased effectiveness of light fractionated ALA-PDT is 
still unknown but the studies described in this thesis reveal details that warrant further 
investigation. Although light fractionated ALA-PDT was shown to increase the CR of 
superficial BCC, understanding of the mechanism might reveal new and unforeseen 
applications for this type of treatment.  
The results described in Chapter 9 show that light fractionation does not lead to more cell 
death in-vitro. However so far the responses of only two cell lines have been investigated. 
The intention is to extend this study to include a range of cells of different origins. While the 
results described in Chapter 7 and 8 imply that endothelial cells might be involved these will 
be studied first. In-vitro studies are useful for investigating individual cellular responses but it 
is possible that the mechanism involved is more complicated than in vitro studies of a single 
cell line may reveal. Therefore the response of cells in co-culture or even in tissue should be 
investigated. 
Over the last 10 years light fractionated ALA-PDT has evolved from a promising research 
subject to a successful clinical treatment scheme. The clinical responses to light fractionated 
ALA-PDT are excellent but pain is (still) the main side effect of topical ALA-PDT. For 
standard ALA-PDT this can be reduced by using a lower fluence rate. Pre-clinical 
experiments are planned to investigate if a lower fluence rate can be used for light 
fractionation without loss of effectiveness. While illumination parameters are known to be 
important for the efficacy this should be considered carefully. Illumination with a lower 
fluence rate is more effective therefore this should be compensated by a lower fluence so 
that the PDT induced damage by the first fraction remains the same.  
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Summary  
In Chapter 2 the effect of different illumination schemes was determined using the delay 
in growth of a tumour after treatment. Rhabdomyosarcoma, an experimental tumour model, 
was subcutaneously transplanted on the thigh of a rat and treated when its volume reached 
50 mm3. ALA was administered i.v. to a dose of 200 mg kg-1 and the tumours were 
transdermally illuminated using 630 nm red light. The growth of the tumour after treatment 
was assessed daily and the delay in growth was defined as the time the tumour needs to 
double its treatment volume. A single illumination (100 J cm-2 at 100 mW cm-2, 2.5 h after 
ALA administration) yielded a doubling time of 6.6 ± 1.2 days. This was significantly different 
from the untreated control (doubling time 1.7 ± 0.1 days). Illumination earlier (1 hr after ALA 
administration), using a lower fluence rate (25 mW cm-2), a higher fluence (200 J cm-2) or 
even light fractionation with short dark intervals did not result in a significant longer volume 
doubling time. Only light fractionated ALA-PDT (illumination at both 1h and 2.5 h after ALA-
administration with 100 J cm-2 at 100 mW cm-2) resulted in a significant increased tumour 
volume doubling time of 18.9 ± 2.9 days.  
 
In Chapters 3 and 4 the illumination parameters of the two light fractions were varied in 
an attempt to find the optimal illumination scheme in the hairless mouse model. Following 
topical ALA application, PpIX fluorescence and photobleaching kinetics were measured pre-, 
during and after PDT. The results showed that the PpIX fluorescence kinetics after a single 
light fraction depend on the fluence delivered; PDT using a high fluence resulted in more 
PpIX photobleaching and a smaller increase in PpIX fluorescence in time after PDT. The 
skin response was scored daily according to a visual skin damage table and these results 
seemed to correlate with the increase of PpIX fluorescence in time after PDT.  
The effect of various light fractionation schemes was investigated and compared with 
single light fraction PDT. The light parameters used for the first and second light fraction 
have a significant effect on response. PDT induced damage in the first fraction seems a 
determining factor in this while different light fractionation schemes with the same 
cumulative fluence were equally effective when the PDT induced damage by the first fraction 
was the same. The optimal illumination scheme for fractionated ALA-PDT on normal mouse 
skin involves a first light fraction of 5 J cm-2 delivered at 50 mW cm-2 followed by a dark 
interval of 2 hours and a second light fraction of 95 J cm-2 at 50 mW cm-2 using an ALA 
application time of 4 hours.  
 
In Chapter 5 the contribution of neutrophils to the PDT induced damage was investigated 
in the solid tumour model with i.v. ALA administration. PDT was performed on 
subcutaneously growing tumours using either a single light fraction or two light fractions 
under either immunologically normal or neutropenic conditions. The neutropenic condition 
was achieved by treating the animals with anti-granulocyte serum. PpIX fluorescence was 
determined in tumour and normal tissue at different time points before and after PDT. The 
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number of neutrophils in tumour and the circulation was determined as a function of time 
after treatment and compared to growth delay of each scheme. The PpIX fluorescence 
kinetics showed a peak fluorescence intensity at 2.5 hours after ALA administration. The 
amount of photobleaching and the fluorescence kinetics after PDT showed a correlation with 
the fluence of the illumination similar to what was observed in chapter 3 in the hairless 
mouse model using topical ALA. The number of neutrophils within the illuminated tumour 
and in the circulation increased significantly following therapy. This increase was associated 
with an increase in the efficacy of therapy: the more effective the therapy, the greater the 
increase of tumour and blood neutrophils. Administration of anti granulocyte serum 
treatment prevented the influx of neutrophils after ALA-PDT, but did not lead to a significant 
decrease in the efficacy of the PDT treatment on the growth of the tumour for any 
illumination scheme investigated. These results showed that the magnitude of damage 
inflicted on the tumour by ALA-PDT does not depend on the presence of neutrophils in the 
tumour or circulation. This indicates that neutrophils only play a bystander role in ALA-PDT.  
 
In Chapter 6 the increase in PpIX fluorescence after PDT was investigated to determine 
if this is the result of re-distribution or local re-synthesis. The skin-fold observation chamber 
was used to determine the spatial distribution of PpIX fluorescence after PDT. The results 
showed no correlation between the fluorescence increase and the distance from a blood 
vessel. In a separate group the tissue was cooled for one hour after PDT to a temperature of 
10-12°C. At this temperature enzymatic activity and the accumulation of PpIX after ALA 
administration is inhibited. The results showed a significant lower fluorescence increase 
compared to that normally observed after PDT. This study shows that the PpIX fluorescence 
increase after PDT is locally re-synthesised.  
 
In Chapters 7 and 8 the effect of light fractionation is investigated using methyl 
aminolevulinate (MAL) mediated PDT. MAL-PDT is more and more used clinically and since 
light fractionation significantly increased the effectiveness of ALA-PDT, it might have the 
same influence on MAL-PDT. This was investigated in the hairless mouse model using the 
light parameters defined for ALA-PDT single and light fractionated illumination. ALA and 
MAL showed similar PpIX fluorescence kinetics as determined by surface fluorescence 
measurements either during topical application, during PDT and in the dark interval. 
Contrary to the results obtained using ALA-PDT, the visual skin damage after MAL-PDT was 
not different after a single illumination compared to light fractionation. The initial rate of 
photobleaching was slightly greater during ALA-PDT but the difference is small and can not 
explain the different response. While ALA and not MAL-induced PpIX has shown to be 
systemically distributed after topical application on mouse skin, the local distribution of PpIX 
after MAL and ALA might also be different and may be involved in this. However, 
fluorescence microscopy showed no clear difference in the PpIX distribution after either MAL 
or ALA application. Also the histological response after MAL and ALA-PDT seemed not 
different, at first. The amount of oedema formation observed 2.5 hours after PDT was 
different; more oedema was formed after ALA compared to MAL-PDT independent of the 
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illumination scheme used. This suggests that endothelial cells respond differently to ALA 
and MAL-PDT and further investigation is needed to determine the role of endothelial cells in 
the response to light fractionated ALA-PDT.  
 
In Chapter 9 the effect of different illumination schemes was investigated on different cell 
lines in-vitro. Cells were exposed to ALA and illuminated with one or two light fractions 
delivered at 2, 3 and/or 5 hours. In the case of light fractionation the cells remained to be 
exposed to ALA during the dark interval. The fluences used for the light fractions in this 
study were chosen so that the PDT induced damage was expected to be similar to that 
found in in-vivo studies. The cell survival after PDT was determined by the mitochondrial 
activity using the MTT assay. The results showed a strong correlation between cell survival 
and with the duration of ALA exposure; PDT delivered at 5 hours was more effective 
compared to 2 or 3 hours. None of the investigated light fractionation schemes was more 
effective than a single light fraction delivered at 5 hours. The increased effectiveness of light 
fractionated ALA-PDT found in-vivo in the clinic or in pre-clinical models is not observed in-
vitro. 
 
In Chapter 10 the results obtained in these studies are discussed in the context of the 
current concepts in the literature and future perspectives are presented.  
 
Samenvatting  
In hoofdstuk 2 is het effect van verschillende belichtingschema’s onderzocht in een 
solide tumormodel. Een experimentele rat tumor, het rhabdomyosarcoom, werd onderhuids 
op de dij van de rat getransplanteerd en behandeld wanneer het tumorvolume ongeveer 50 
mm3 was. ALA werd intra veneus toegediend in een dosis van 200 mg/kg en de tumoren 
werden transdermaal belicht met rood licht. Het tumorvolume werd dagelijks gemeten om de 
uitstel van de groei, gedefinieerd als de tijd die de tumor nodig had om het dubbele van zijn 
behandelvolume te bereiken, te berekenen. Een onbehandelde controle tumor had een 
verdubbelingtijd van 1.7 ± 0.1 dagen. De groei werd significant vertraagd na een ALA-PDT 
behandeling met een enkele belichting (100 J cm-2 bij 100 mW cm-2, 2.5 uur na ALA 
toediening) tot 6.6 ± 1.2 dagen. Belichting eerder na ALA toediening (na 1 uur), een lagere 
licht intensiteit (25 mW cm-2), een hogere lichtdosis (200 J cm-2) of zelfs gefractioneerd 
belichten met korte donker intervallen had geen significant effect of deze groeivertraging. 
Alleen de gefractioneerde ALA-PDT behandeling waarbij twee licht fracties gegeven werden 
op 1 en op 2.5 uur na ALA toediening (met 100 J cm-2 bij 100 mW cm-2) resulteerde in een 
significante groeivertraging van 18.9 ± 2.9 dagen.  
 
In hoofdstuk 3 en 4 zijn de belichting parameters van de twee licht fracties gevarieerd in 
een poging om het meest optimale belichtingsschema te bepalen met topicale toediening 
van ALA. Dit onderzoek werd uitgevoerd op het haarloze muizen model. De PpIX 
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fluorescentie en fotoblekingskinetiek is gemeten voor, tijdens en na PDT. De reactie van de 
huid werd dagelijks gescoord volgens een huid schade score tabel. De resultaten laten zien 
dat de PpIX fluorescentie kinetiek na een enkele belichting afhankelijk is van de gebruikte 
lichtdosis; belichting met een hoge licht fluentie resulteerde in meer PpIX fotobleking 
gevolgd door een lagere PpIX fluorescentie toename in de tijd na PDT. Dit resultaat 
correleerde met de visueel gescoorde huidschade na PDT. Het effect van de verschillende 
gefractioneerde belichtingschema’s werd vergeleken met het effect van een enkele 
belichting. De lichtparameters die gebruikt worden voor de eerste en tweede lichtfractie 
hebben een significante invloed op de effectiviteit van de behandeling. Hierbij lijkt de schade 
die door de eerste belichting wordt veroorzaakt een bepalende factor aangezien 
verschillende belichtingsschema’s met een gelijke cumulatieve licht dosis even effectief zijn 
wanneer de PDT schade van de eerste fractie gelijk is. Voor de haarloze muizen huid is het 
optimale gefractioneerde belichtingschema alsvolgt: topicaal ALA voor 4 uur, een eerste 
lichtfractie van 5 J cm-2 bij 50 mW cm-2 gevolgd door een donker interval van 2 uur en een 
tweede lichtfractie van 95 J cm-2 bij 50 mW cm-2.  
 
In hoofdstuk 5 is onderzocht of neutrofielen een rol spelen in de effectiviteit van ALA-
PDT. Subcutaan groeiende tumoren werden behandeld met systemische ALA-PDT onder 
normale en neutropene condities. Neutropenie werd bereikt door de dieren te behandelen 
met anti-granulocyten-serum. Op verschillende tijdstippen na ALA toediening en na PDT 
werd de PpIX fluorescentie bepaald in tumor en normaal weefsel. Voor de twee 
verschillende behandelschema’s die zijn onderzocht (de enkele en de dubbele belichting) 
werd als functie van de tijd na behandeling het aantal neutrofielen in het bloed en in de 
tumor bepaald. Dit werd gecorreleerd aan de effectiviteit van de behandeling. De 
fluorescentie intensiteit van PpIX gaf een piek op 2.5 uur na ALA toediening in de tumor. 
Vergelijkbaar met de resultaten behaald in de muizen studie met topicaal ALA (hoofdstuk 3) 
was de mate van bleking tijdens en fluorescentie toename na PDT afhankelijk van de licht 
dosis van de behandeling. Het aantal neutrofielen in de behandelde tumor en in circulatie 
nam significant toe na PDT en was afhankelijk van de effectiviteit van de behandeling: 
hogere toename van het aantal neutrofielen na een effectievere behandeling. Behandeling 
met anti-granulocyten-serum voorkwam dat het aantal neutrofielen toenam na PDT maar dit 
leidde niet tot een verlaging van de effectiviteit. Deze resultaten geven aan dat de schade 
die ALA-PDT veroorzaakt niet afhankelijk is van de aanwezigheid van neutrofielen in het 
behandelvolume dan wel in het bloed. Neutrofielen lijken niet bij te dragen aan de 
effectiviteit van ALA-PDT.  
 
In hoofdstuk 6 is onderzocht of de terugkeer in fluorescentie die waargenomen wordt na 
PDT het gevolg is van locale re-synthese, dan wel een herverdeling in PpIX elders 
gesynthetiseerd, is. Voor dit onderzoek werd gebruik gemaakt van het zogenaamde 
kamertjes model (skin-fold observation chamber) waarin de PpIX fluorescentie als functie 
van de ruimtelijke locatie in het weefsel werd onderzocht. Er werd geen correlatie gevonden 
tussen de mate waarin PpIX fluorescentie terugkeerde ten opzichte van de afstand van een 
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bloedvat. In een andere groep werd het weefsel gedurende 1 uur na PDT gekoeld tot 10-
12°C. Het is bekend dat bij deze temperatuur de enzym activiteit en de ophoping van PpIX 
na ALA toediening geremd is. De terugkeer in fluorescentie na PDT bleek significant lager in 
deze groep. Uit deze resultaten blijkt dat de PpIX fluorescentie toename na PDT 
behandeling het gevolg is van lokale re-synthese.  
 
In hoofdstuk 7 en 8 is het effect van een gefractioneerde belichting bij MAL-PDT 
beschreven. MAL, een ALA ester, wordt steeds meer toegepast in de kliniek en aangezien 
de effectiviteit van ALA-PDT beter is na een gefractioneerde belichting is onderzocht of dit 
ook het geval is bij MAL-PDT. Voor dit onderzoek werd gebruik gemaakt van het haarloze 
muizen model en de gevonden licht parameters voor ALA-PDT voor een enkele en een 
gefractioneerde belichting. De fluorescentie kinetiek van PpIX na toediening van MAL bleek 
niet anders dan die na ALA, zowel tijdens de topicale applicatie als tijdens PDT en in de 
donkere periode tussen de twee licht fracties in. Anders dan bij ALA was er bij MAL geen 
verschil in de visueel gescoorde huidschade na een enkele of een gefractioneerde 
belichting. Omdat is aangetoond dat ALA in de circulatie komt na topicale toediening en 
MAL niet, kan ook de locale distributie van MAL en ALA anders zijn. Dit gegeven zou een rol 
kunnen spelen bij de gevonden verschillen. Fluorescentie microscopie liet echter geen 
duidelijk verschil zien in de PpIX distributie in de huid na MAL of na ALA. Ook de 
histologische response leek in eerste instantie niet te verschillen. Het enige verschil is de 
hoeveelheid oedeem beoordeeld op 2.5 uur na PDT; ALA-PDT leidt tot meer oedeem dan 
MAL-PDT. Hieruit zou afgeleid kunnen worden dat endotheel cellen anders reageren op een 
ALA behandeling dan op een MAL behandeling. Meer onderzoek is nodig om de rol van 
endotheel cellen in de effectiviteit van ALA-PDT te onderzoeken.  
 
In hoofdstuk 9 is het effect van gefractioneerd belichten op verschillende cellijnen in-vitro 
onderzocht. Cellen werden met ALA geïncubeerd en één of twee keer belicht op 2, 3 en/of 5 
uur. In het geval van een gefractioneerde belichting bleven de cellen geïncubeerd met ALA 
in het donkere interval tussen de twee belichtingen. De lichtdosis en lichtintensiteit die 
gebruikt werden voor de in-vitro belichtingen werden zodanig gekozen dat de door PDT 
geïnduceerde schade vermoedelijk vergelijkbaar was met de in-vivo gevonden schade. Cel 
overleving na PDT werd bepaald door de mitochondriale activiteit te meten met behulp van 
de MTT-test. Er werd een sterke correlatie gevonden tussen de ALA incubatie periode en de 
effectiviteit; PDT op 5 uur geeft meer cel dood dan PDT op 2 uur. Geen van de onderzochte 
gefractioneerde belichtingen was effectiever dan een enkele belichting op 5 uur. De 
verbeterde effectiviteit van gefractioneerde ALA-PDT die in-vivo gevonden werd in pre-
klinische modellen en in de kliniek, werd in-vitro niet gevonden. 
  
In hoofdstuk 10 worden de resultaten van dit proefschrift besproken in het licht van de 
huidige opvattingen beschreven in de literatuur en worden toekomstige perspectieven 
genoemd.  
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jaar koos ze de medisch biologische richting en in 1992 studeerde ze af. Sindsdien is ze in 
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Dankwoord 
Het is zover, ik mag na al het zware denk- en schrijfwerk iedereen bedanken voor de alle 
hulp die ik heb gekregen. Gelukkig kan ik zeggen dat ik heel veel hulp heb gehad en daar 
ben ik dan ook erg dankbaar voor.  
 
Allereerst noem ik Dominic Robinson. Dom, your unconditional support (you can do it!) 
has always been heart-warming. I have to switch to Dutch to say what I want to say but you 
will be able to understand. Het leidt dan ook geen twijfel dat jouw bijdrage aan dit boekje 
enorm is. In mijn persoonlijke ontwikkeling van analiste naar onderzoeker heb je me altijd 
gesteund en vooral uitgedaagd om dat beetje extra (waarvan ik niet wist dat het er in zit) ook 
werkelijk te geven. Ik prijs me gelukkig met jou als copromotor en hoop dat we nog lang 
mogen samenwerken. Wellicht is er nu weer wat meer tijd om met onze beide gezinnen op 
te trekken. 
Mijn andere copromotor, Dick Sterenborg, vanaf het moment dat je Willem Star opvolgde 
als afdelingshoofd heb je me gevraagd of promoveren niet wat voor mij was. Toen je zag dat 
ik daar nog niet helemaal over uit was heb je me met rust gelaten maar ben je me blijven 
steunen. Je frisse blik op mijn schrijfwerk heb ik altijd gewaardeerd. Prof. Levendag, ik ken u 
nog uit de tijd dat ik stagiaire was bij Radiobiologie. En nu sta ik hier samen met die andere 
stagiaire, Yvonne mijn paranimf. Ook u heeft me gesteund en geholpen in dit hele proces 
dat promoveren heet. Ik verheug me erop om dit boekje bij u langs te mogen komen 
brengen.  
 
De leden van de kleine commissie, Prof. Neumann, Prof. Roodenburg en Prof. Wilson, u 
allen hartelijk bedankt voor het lezen en beoordelen van dit boekje. Prof. Neumann, de vaart 
waarmee u uw taak als secretaris heeft volbracht was grandioos. Prof. Roodenburg, zolang 
als ik bij PDT zit werken we al samen met “Groningen” en ik ben dan ook vereerd met uw 
bijdrage. Prof. Wilson, zelfs in uw vakantie was u bereid om mijn tekst te lezen. Hartelijk 
bedankt daarvoor.  
 
Willem Star, in 1993 was jij het die me aannam op het eerste ALA project. Hoewel je nu 
al lang met pensioen bent blijf je op de hoogte van de dingen die in het vakgebied spelen. 
Je grootste succes ligt misschien meer op het terrein van de lichtdosimetrie toch ben je ook 
voor het wetenschappelijke onderzoek naar ALA-PDT en de gefractioneerde belichting van 
onschatbare waarde geweest. Ik ben dan ook blij en vereert dat je plaats wilde nemen in de 
grote commissie. Ook de andere leden van de grote commissie, Prof. Kanaar, Prof. Tan en 
Prof. Heimen, wil ik bij deze bedanken voor hun tijd en inzet.  
 
In de afgelopen jaren heb ik met veel collega’s samengewerkt. Nynke, jij was de eerste 
waarbij ik persoonlijk zag dat iemand van de HBO ook kon promoveren. Je was een 
voorbeeld voor mij. Ik heb met veel plezier met je samengewerkt en draag warme 
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herinneringen aan onze gesprekken achter de gordijnen. Lique, we zien elkaar veel minder 
dan toen we nog full time werkten. We kijken dan ook allebei uit naar de maandag waarop 
we elkaar weer zien en even kunnen bijpraten. Het bedenken van nieuwe opstellingen 
waarmee we de experimenten wilden uitvoeren was altijd een feest. Gekscherend zeggen 
we dan ook altijd dat PDT nergens zou zijn als er geen plakband bestond. Het was altijd 
prettig om met jou samen te werken en ik hoop dat dat nog lang zo blijft. Ik ben dan ook blij 
dat je me bijstaat op 12 juni als mijn paranimf. Arjen (zie je de e!), mijn andere kamergenoot 
bedankt voor je heldere scherpe blik op de wetenschappelijke wereld. Van jou heb ik 
geleerd, en ben ik nog aan het leren, om mijn (vrouwelijke) twijfel-kant wat meer los te laten 
(niet twijfelen, gewoon doen!). Robert, hier is tie dan, eindelijk is ook mijn boekje klaar en ja 
ik heb nu ook een datum. Jij bedankt voor alle hulp, de frisse blik en het andere perspectief 
op het leven. En natuurlijk voor de mooie grafiek in de general introduction. Bastiaan, de 
fanatieke sporter van onze afdeling. Hij hoopt nog steeds dat wij (de andere minder 
fanatieke collega’s) mee gaan doen aan de marathon. In de toekomst hoop ik een keer jouw 
boekje op mijn bureau te vinden met misschien zelfs wel mooie confocale platen erin? 
Slavka, you are the latest member of our group. I have enjoyed our lunches and meetings. I 
can always count on a friendly supporting remark from you. I promise you that we will soon 
meet to see the small houses in Madurodam. Ook de andere oud collega’s, Hans, Lars, 
Otto, Hugo, Arjen, Hanneke en Diana (dank je wel voor je Nederlandse taal correcties op de 
samenvatting!) wil ik bedanken voor alle steun die ik in de loop der jaren op verschillende 
vlakken gehad heb.  
 
Dan zijn er nog een aantal coauteurs die een plekje in dit dankwoord verdient hebben. 
Wim Sluiter, onze samenwerking en ons contact was altijd prettig. Het begon met het werk 
van Wil de Vree en photofrin-PDT en ging over naar ons werk, ALA-PDT, met als (tijdelijke?) 
afsluiting het manuscript in 2006. Konnie Hebeda, jouw blik op PDT en de schade die 
daardoor in het weefsel veroorzaakt wordt heb ik altijd gewaardeerd. Samen met jou achter 
de microscoop zitten was altijd weer een waardevol leermoment en interessant en dus nooit 
saai! Carel Meijers, ook met jou heb ik altijd met plezier achter de microscoop gezeten. Ellen 
de Haas, jouw klinische blik op ons preklinisch onderzoek heb ik gewaardeerd. Met jouw 
daadkracht en drive is een grote klinische studie tot stand gekomen waarmee je mooie 
resultaten hebt bereikt (er waren er meer maar vooral die ene waarin gefractioneerd 
belichten beter bleek te werken dan de standaard behandeling is van enorm belang). Ik 
verheug me op de toekomst met misschien wel nog meer van die leuke studies ook samen 
met Tom en Hanke. I also to thank Adriana Casas and her colleagues. Although we always 
“speak” via email, I value our collaboration on the in-vitro study investigating the response to 
light fractionated ALA-PDT. Hopefully we will be able to meet somewhere, on a conference, 
to speak in person.  
Ook de collega’s van het EDC, de pathologie DDHK en centrumlocatie en KCL wil ik 
bedanken voor alle faciliteiten, kennis en hulp die ik heb mogen gebruiken en ontvangen.  
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Omdat mijn carpoolmaten er altijd voor gezorgd hebben dat we veilig op het werk 
aankwamen en na het werk weer veilig thuiskwamen, moet ik ook een groot dank je wel 
richten aan hen. Toen we nog op de Daniel zaten waren dat Marcel en Erna, later kwam 
Margreet erbij en soms Johanna. Eenmaal na de verhuizing naar de centrumlokatie was het 
niet handig om samen te blijven rijden en scheidde onze wegen. Het was altijd erg gezellig 
en als we elkaar, hier in het dorp, tegen het lijf lopen, is het net of we weer in de auto zitten. 
Gelukkig voor mij en m’n auto waren er weer snel nieuwe kandidaten om te poolen. 
Maureen, ik leerde je kennen als de vriendin van Martin maar ik kan nu oprecht zeggen dat 
jij een vriendin van mij bent geworden. In de auto hebben we lief en leed gedeeld en 
besproken. Later kwam ook Margret erbij en met ons drieën praten we de 45 minuten dat 
we onderweg zijn lekker vol en soms is zelfs dat niet lang genoeg.  
 
En dan zijn daar nog de vrienden en familie. De  onvergetelijke soosavonden, sjerriklen 
avondjes, de om de twee maanden op de eerste dinsdag in de maand etentjes, de avondjes 
naar de lokale toneelvereniging, met zijn allen weer eens ouderwets naar de kroeg  
enzovoorts waren een welkome afwisseling. Lisette, je hebt een heel mooi ontwerp gemaakt 
voor de omslag, hartstikke bedankt daarvoor. Christine, vriendin sinds de derde klas van de 
lagere school, worden schieten te kort. Yvonne, mijn steun op congres in Zuid-Korea en nu 
naast me als paranimf. Pap en Mam, zoals ik ook al in mijn CV schreef hebben jullie het 
altijd leuk gevonden dat ik ging leren. En zie, dit komt er nou van ;-). Nu moeten er nieuwe 
kleren gekocht worden voor een feestje. Schoonma, ook u heeft me altijd gesteund en op 
Marit gepast als het nodig was, bedankt daarvoor. Dankzij u weet heel Zevenbergen van 
deze promotie.  
 
Cock, mijn steun en toeverlaat, ik weet zeker dat dit alles niet had kunnen gebeuren 
zonder jouw inzet. Ik leerde je kennen toen ik stage liep en ondertussen sta ik hier. Toen ik 
eenmaal op de trein die promoveren heet sprong zorgde jij ervoor dat ik tot het eindpunt kon 
blijven zitten. Jouw geloof in mij maar ook jouw praktische hulp in het huishouden en het 
opvoeden en opvangen van Marit is van onschatbare waarde. Dit is emancipatie ten top! 
Lieverd, ik had het niet beter kunnen treffen. Marit, lieve schat, moeder zijn van zo’n lieve 
dochter is niet moeilijk. En met je 2,5 jaar is jouw bijdrage aan dit proefschrift het eerste wat 
iedereen ziet, dank je wel voor je mooie tekening op de voorkant van dit boekje! 
 
Zo, en nu gaan we het vieren………… 
 
 
 
